Perrigo (PRGO) 10-K 13 Aug 15 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Jun. 27, 2015	Aug. 07, 2015	Dec. 27, 2013
Entity Information [Line Items]
Entity Registrant Name	PERRIGO CO PLC
Entity Central Index Key	1,585,364
Current Fiscal Year End Date	--06-27
Entity Filer Category	Large Accelerated Filer
Document Type	10-K
Document Period End Date	Jun. 27, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		146,279,437
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 23,365,172,165

Consolidated Statements of Inco

Consolidated Statements of Income - Income Statement Location [Domain] - USD ($) shares in Millions, $ in Millions		12 Months Ended
		Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Net sales		$ 4,603.9	$ 4,060.8	$ 3,539.8
Cost of sales		2,891.4	2,613.1	2,259.8
Gross profit		1,712.5	1,447.7	1,280
Operating expenses
Distribution		67.7	55.3	47.5
Research and development		187.8	152.5	115.2
Selling		319	208.6	186.1
Administration		385.2	411.3	240.2
Write-off of in-process research and development		0	6	9
Restructuring		5.1	47	2.9
Total operating expenses		964.8	880.7	600.9
Operating income	[1]	747.7	567	679.1
Interest expense, Net		146	103.5	65.8
Other expenses, net		343.2	25.1	5.6
Loss on extinguishment of debt		10.5	165.8	0
Income (Loss) from Continuing Operations before Income Taxes, Domestic		248	272.6	607.7
Income tax expense		120	67.3	165.8
Net income		$ (128)	$ (205.3)	$ (441.9)
Basic
Earnings Per Share, Basic		$ 0.92	$ 1.78	$ 4.71
Diluted
Earnings Per Share, Diluted		$ 0.92	$ 1.77	$ 4.68
Weighted average shares outstanding
Basic		139.3	115.1	93.9
Diluted		139.8	115.6	94.5
Dividends declared per share		$ 0.4600	$ 0.3900	$ 0.3500
[1]	Amounts may not cross-foot due to rounding.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Net income	$ (128)	$ (205.3)	$ (441.9)
Other comprehensive income (loss)
Foreign currency translation adjustments	(33.5)	83.8	26.9
Change in fair value of derivative financial instruments, net of tax	(0.2)	(11.6)	6
Change in fair value of investment securities, net of tax	(5.4)	2.4	4.4
Post-retirement liability adjustments, net of tax	1.9	(12)	0.3
Other Comprehensive Income	(37.2)	62.6	37.6
Comprehensive Income	90.8	267.9	479.6
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax, Portion Attributable to Parent	(5.7)	(1.2)	3.2
Other Comprehensive Income (Loss), Available for Sale Securities, Tax	(2.7)	1.2	0
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax	$ 0.6	$ 0	$ 0.2

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) shares in Millions, $ in Millions		Jun. 27, 2015	Jun. 28, 2014
Current assets
Cash and cash equivalents		$ 785.6	$ 799.5
Investment securities		12.7	5.9
Accounts receivable, net		1,282.1	935.1
Inventories		838.9	631.6
Current deferred income taxes		122.3	62.8
Prepaid expenses and other current assets		141.3	116
Total current assets		3,182.9	2,550.9
Non-current assets
Property and equipment, net	[1]	932.4	779.9
Goodwill and other indefinite-lived intangible assets		7,235	3,543.8
Other intangible assets, net		8,105.6	6,787
Non-current deferred income taxes		39.6	23.6
Other non-current assets		225.1	167.6
Total non-current assets		16,537.7	11,301.9
Total assets	[1]	19,720.6	13,852.8
Current liabilities
Accounts payable		747.5	364.3
Short-term debt		6.4	2.1
Payroll and related taxes		133.9	112.3
Accrued customer programs		368.1	256.5
Accrued liabilities		246.4	179.4
Accrued income taxes		52.6	17.4
Current deferred income taxes		80.6	1.1
Current portion of long-term debt		58.2	141.6
Total current liabilities		1,693.7	1,074.7
Non-current liabilities
Long-term debt, less current portion		5,246.9	3,063.1
Non-current deferred income taxes		1,745.1	727.9
Other non-current liabilities		372.1	293.4
Total non-current liabilities		7,364.1	4,084.4
Total liabilities		9,057.8	5,159.1
Controlling interest:
Preferred stock, without par value, 10 million shares authorized		0	0
Ordinary shares, without par value, 200 million shares authorized		8,621.9	6,678.2
Accumulated other comprehensive income		102.4	139.6
Retained earnings		1,938.3	1,875.1
Total controlling interest		10,662.6	8,692.9
Noncontrolling interest		0.2	0.8
Total shareholders' equity		10,662.8	8,693.7
Total liabilities and shareholders' equity		$ 19,720.6	$ 13,852.8
Supplemental Disclosures of Balance Sheet Information
Preferred shares, issued and outstanding		0	0
Ordinary shares, issued and outstanding		146.3	133.8
[1]	Amounts may not cross-foot due to rounding.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) shares in Millions, $ in Millions	Jun. 27, 2015€ / shares	Jun. 27, 2015USD ($)$ / sharesshares	Jun. 28, 2014€ / shares	Jun. 28, 2014USD ($)$ / sharesshares
Allowance for Doubtful Accounts Receivable | $		$ 2.4		$ 2.7
Commitments and Contingencies | $		$ 0		$ 0
Shareholders' Equity
Preferred shares, par value | $ / shares		$ 0.0001		$ 0.0001
Preferred shares, shares authorized		10		10
Ordinary shares, par value | € / shares	€ 0.001		€ 0.001
Ordinary shares, shares authorized		10,000		10,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Cash Flows From (For) Operating Activities
Net income	$ 128	$ 205.3	$ 441.9
Adjustments to derive cash flows
Depreciation and amortization	548.8	358.9	160.2
Loss on acquisition-related foreign currency derivatives	326.4	0	0
Share-based compensation	31.6	24.6	18.4
Total loss on extinguishment of debt	10.5	165.8	0
Non-cash restructuring charges	5.1	47	2.9
Deferred income taxes	(16.4)	(53.8)	5.7
Other Operating Activities, Cash Flow Statement	17	10.5	(3.4)
Subtotal	1,051	758.3	625.6
Changes in operating assets and liabilities, net of asset and business acquisitions and disposition
Accounts receivable	(81.7)	(226.7)	(37)
Inventories	10.7	83	(94.6)
Accounts payable	140.6	(24.9)	6.5
Payroll and related taxes	(30.2)	(55.5)	(11.9)
Accrued customer programs	69.9	113.1	12.6
Accrued liabilities	37.3	23	8.4
Accrued income taxes	17.5	(10.7)	28.9
Other	(16.8)	33.9	15.3
Subtotal	147.3	(64.8)	(71.8)
Net cash from operating activities	1,198.3	693.5	553.8
Cash Flows (For) From Investing Activities
Acquisitions of businesses, net of cash acquired	(2,181.8)	(1,605.8)	(852.3)
Payments for Derivative Instrument, Investing Activities	(329.9)	0	0
Proceeds from sale of securities	0	81.4	8.6
Additions to property and equipment	(137)	(171.6)	(104.1)
Other investing	1.8	(8.8)	0
Net cash for investing activities	(2,646.9)	(1,704.8)	(947.8)
Cash Flows (For) From Financing Activities
Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less	(52.5)	(3)	5
Proceeds from issuance of debt	2,504.3	3,293.6	637.3
Repayments of long-term debt	(1,823.5)	(2,035)	(40)
Payments of Debt Extinguishment Costs	0	(133.5)	0
Deferred financing fees	(28.1)	(48.8)	(6)
Issuance of common stock	1,043.4	9.8	10.7
Repurchase of common stock	(35.7)	0	0
Cash dividends	(64.8)	(46.1)	(33)
Other financing	(19.2)	(9)	3.3
Net cash from (for) financing activities	1,523.9	1,028	577.2
Effect of exchange rate changes on cash	(89.2)	2.9	(5.8)
Net increase in cash and cash equivalents	(13.9)	19.6	177.4
Cash and cash equivalents, beginning of period	799.5	779.9	602.5
Cash paid/received during the year for:
Interest paid	143.2	98.4	58.5
Interest received	1.1	2.4	3.9
Income taxes paid	131	93.2	133.2
Income taxes refunded	$ 9.6	$ 4.3	$ 1.3

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock Issued [Member]	Accumulated Other Comprehensive Income (loss) [Member]	Retained Earnings [Member]
Balance, shares at Jun. 30, 2012		93,500
Balance at Jun. 30, 2012	$ 1,851,000	$ 504,700	$ 39,400	$ 1,306,900
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	441,900	0	0	441,900
Other comprehensive income (loss), net of tax	37,600	$ 0	37,600	0
Issuance of Common Stock Under
Stock options, shares		400
Stock options, value	10,700	$ 10,700	0	0
Restricted stock plan, shares		400
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	0	$ 0	0	0
Compensation for stock options	6,100	6,100	0	0
Compensation for resticted stock	12,300	12,300	0	0
Cash dividends	(33,000)	0	0	(33,000)
Tax Effect from Stock Transactions	17,100	$ 17,100	0	0
Repurchases of common stock, shares		(112)
Repurchases of common stock, value	(12,400)	$ (12,400)	0	0
Balance, shares at Jun. 29, 2013		94,100
Balance at Jun. 29, 2013	2,331,400	$ 538,500	77,000	1,715,900
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	205,300	0	0	205,300
Other comprehensive income (loss), net of tax	62,600	$ 0	62,600	0
Issuance of Common Stock Under
Stock Issued During Period, Shares, Acquisitions		39,400
Stock Issued During Period, Value, Acquisitions	6,117,200	$ 6,117,200	0	0
Stock options, shares		200
Stock options, value	9,800	$ 9,800	0	0
Restricted stock plan, shares		200
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	0		0	0
Compensation for stock options	6,500	$ 6,500	0	0
Compensation for resticted stock	18,100	18,100	0	0
Cash dividends	(46,100)	0	0	(46,100)
Tax Effect from Stock Transactions	8,200	$ 8,200	0	0
Repurchases of common stock, shares		(60)
Repurchases of common stock, value	(7,500)	$ (7,500)	0	0
Equity issuance costs	(5,400)	(5,400)	0	0
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests	(7,200)	$ (7,200)	0	0
Balance, shares at Jun. 28, 2014		133,800
Balance at Jun. 28, 2014	8,692,900	$ 6,678,200	139,600	1,875,100
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	128,000	0	0	128,000
Other comprehensive income (loss), net of tax	(37,200)	$ 0	(37,200)	0
Issuance of Common Stock Under
Stock Issued During Period, Shares, New Issues		6,800
Stock Issued During Period, Value, New Issues	1,035,000	$ 1,035,000
Stock Issued During Period, Shares, Acquisitions		5,400
Stock Issued During Period, Value, Acquisitions	$ 904,900	$ 904,900	0	0
Stock options, shares	170	200
Stock options, value	$ 8,500	$ 8,500	0	0
Restricted stock plan, shares		200
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures	0	$ 0	0	0
Compensation for stock options	6,900	6,900	0	0
Compensation for resticted stock	24,700	24,700	0	0
Cash dividends	(64,800)	0	0	(64,800)
Tax Effect from Stock Transactions	7,000	$ 7,000	0	0
Repurchases of common stock, shares		(100)
Repurchases of common stock, value	(7,600)	$ (7,600)	0	0
Equity issuance costs	(35,700)	$ (35,700)	0	0
Balance, shares at Jun. 27, 2015		146,300
Balance at Jun. 27, 2015	$ 10,662,600	$ 8,621,900	$ 102,400	$ 1,938,300

Consolidated Statements of Sha8

Consolidated Statements of Shareholders' Equity (Parenthetical) - $ / shares	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Dividends declared per share	$ 0.4600	$ 0.3900	$ 0.3500

Summary of Signifcant Accountin

Summary of Signifcant Accounting Policies	12 Months Ended
	Jun. 27, 2015
Summary of Significant Accounting Policies [Abstract]
Summary of significant accounting policies	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES a. General Information The Company Perrigo Company plc was incorporated under the laws of Ireland on June 28, 2013. We became the successor registrant of Perrigo Company, a Michigan corporation, on December 18, 2013 in connection with the acquisition of Elan Corporation, plc ("Elan"), which is discussed further in Note 2 . Unless the context requires otherwise, the terms "Perrigo", the "Company", "we," "our," "us," and similar pronouns used herein refer to Perrigo Company plc, its subsidiaries, and all predecessors of Perrigo Company plc and its subsidiaries. With the acquisition of Omega Pharma Invest N.V. ("Omega"), we are an over-the-counter ("OTC") consumer goods and leading specialty pharmaceutical company, offering patients and customers high-quality products at affordable prices. From our beginning in 1887 as a packager of home remedies, we have grown to become the world's largest manufacturer of OTC healthcare products and supplier of infant formulas for the store brand market. We are also a leading provider of generic extended topical prescription products, and we receive royalties from sales of the multiple sclerosis drug Tysabri ® . We provide “Quality Affordable Healthcare Products ® ” across a wide variety of product categories and geographies, primarily in North America, Europe and Australia, as well as in other markets, including Israel and China. Basis of Presentation Our current fiscal year is a 52 or 53 week period, which ends the Saturday on or about June 30. Fiscal years 2015 , 2014 , and 2013 were comprised of 52 weeks and ended on June 27, 2015 , June 28, 2014 , and June 29, 2013 , respectively. In fiscal year 2015, we announced that our fiscal year-end will begin on January 1 and end on December 31 of each year, starting on January 1, 2016. Fiscal year 2015, which ended on June 27, 2015, will be followed by a transition period from June 28, 2015 to December 31, 2015. We plan to disclose the results of the transition period on a Form 10-KT transition report. Subsequent to June 27, 2015, we will continue to close our books on the Saturday closest to end of the quarter, with the last quarter ending on December 31. This practice will only affect the quarterly reporting periods and not the annual reporting periods. Segment Reporting Change In conjunction with the Omega acquisition, we changed our reporting segments to better align with our new organizational structure. These organizational changes were made to optimize our structure to better serve our customers and to reflect the way in which our chief operating decision maker reviews our operating results and allocates resources. The changes in our reporting segments are as follows: • Consumer Healthcare ( "CHC" ), which includes our former Consumer Healthcare segment, former Nutritionals segment, and our former Israel Pharmaceuticals and Diagnostics business, which was previously reported in our “Other” segment; • Branded Consumer Healthcare ( "BCH" ), which consists of the newly acquired Omega business; • Prescription Pharmaceuticals ( " Rx Pharmaceuticals " ), which continues to include the Rx Pharmaceuticals business; • Specialty Sciences , which is comprised primarily of assets focused on the treatment of multiple sclerosis(Tysabri ® ). In addition, we have an Other reporting segment that consists of our Active Pharmaceutical Ingredients ("API") business, which does not meet the quantitative threshold required to be a separately reportable segment. All historical segment information has been reclassified to conform to this new reporting segment presentation. Financial information related to our business segments and geographic locations can be found in Item 8. Note 17 . Principles of Consolidation The consolidated financial statements include our accounts and accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation. Unconsolidated Variable Interest Entities We have R&D arrangements with certain biotechnology companies that we determined to be variable interest entities ("VIEs"). We did not consolidate the VIEs in our financial statements because we lack the power to direct the activities that most significantly impact their economic performance and thus are not considered the primary beneficiaries of these entities. These arrangements provide us with certain rights and obligations to purchase product candidates from the VIEs, dependent upon the outcome of the development activities. Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions, which affect the reported earnings, financial position and various disclosures. Although the estimates are considered reasonable, actual results could differ from the estimates. Non-U.S. Operations We translate our non-U.S. dollar-denominated operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in the cumulative translation account, a component of Accumulated Other Comprehensive Income ("AOCI"). Gains or losses from foreign currency transactions are included in Other expense, net. b. Revenues We generally record revenues from product sales when the goods are shipped to the customer. For customers with Free on Board ("FOB") destination terms, a provision is recorded to exclude shipments estimated to be in-transit to these customers at the end of the reporting period. A sales allowance is recorded and accounts receivable are reduced as revenues are recognized for estimated losses on credit sales due to customer claims for discounts, price discrepancies, returned goods and other items. Revenue is also reduced for any contractual customer program arrangements and related liabilities are recorded concurrently. We maintain customer-related accruals and allowances that consist primarily of chargebacks, rebates, sales returns, shelf stock allowances, administrative fees and other incentive programs. Some of these adjustments relate specifically to the Rx Pharmaceuticals segment while others relate only to the CHC and BCH segments. Certain of these accruals and allowances are recorded in the balance sheet as current liabilities and others are recorded as a reduction in accounts receivable. Changes in these estimates and assumptions related to customer programs may result in additional accruals or allowances. Customer-related accruals and allowances were $434.9 million at June 27, 2015 and $318.0 million at June 28, 2014 . Revenues from service and royalty arrangements, including revenues from collaborative agreements, consist primarily of royalty payments, payments for research and development services, up-front fees and milestone payments. If an arrangement requires the delivery or performance of multiple deliverables or service elements, we determine whether the individual elements represent separate units of accounting. If the separate elements represent separate units of accounting, we recognize the revenue associated with each element separately and revenue is allocated among elements based on their relative selling prices. If the elements within a multiple deliverable arrangement are not considered separate units of accounting, the delivery of an individual element is considered not to have occurred if there are undelivered elements that are considered essential to the arrangement. To the extent such arrangements contain refund clauses triggered by non-performance or other adverse circumstances, revenue is not recognized until all contractual obligations are satisfied. Non-refundable up-front fees are deferred and amortized to revenue over the related performance period. We estimate the performance period based on the specific terms of each collaborative agreement. Revenue associated with research and development services is recognized on a proportional performance basis over the period that we perform the related activities under the terms of the agreement. Revenue resulting from the achievement of contingent milestone events stipulated in the agreements is recognized when the milestone is achieved. Milestones are based upon the occurrence of a substantive element specified in the contract. Tysabri ® represented 96% of our fiscal year 2015 royalty revenue. Shipping and handling costs billed to customers are included in net sales. Conversely, shipping and handling expenses we incur are included in cost of sales. c. Cash and Cash Equivalents Cash and cash equivalents consist primarily of demand deposits and other short-term investments with maturities of three months or less at the date of purchase. The carrying amount of cash and cash equivalents approximates its fair value. d. Investments Available for Sale Investments We determine the appropriate classification of securities as held-to-maturity, available-for-sale, or trading. The classification depends on the purpose for which the financial assets were acquired. Marketable equity securities are classified as available-for-sale. These securities are carried at fair value with unrealized gains and losses included in AOCI. The assessment for impairment of marketable securities classified as available-for-sale is based on established financial methodologies, including quoted market prices for publicly traded securities. If we determine that a loss in the value of an investment is other than temporary, the investment is written down to its estimated fair value. Any such losses are recorded in Other expense, net. See Note 6 for more information on our available for sale investments. Cost Method Investments Non-marketable equity securities are carried at cost, less any write down for impairments, and are adjusted for impairment based on methodologies, an assessment of the impact of general private equity market conditions, and discounted projected future cash flows. Non-marketable equity securities are recorded in Other non-current assets on the Consolidated Balance Sheets. See Note 6 for more information on our cost method investments. Equity Method Investments The equity method of accounting is used for unconsolidated entities over which we have significant influence; generally this represents ownership interests of at least 20% and not more than 50%. Under the equity method of accounting, we record the investments at carrying value and adjust for a proportionate share of the profits and losses of these entities each period. We evaluate our equity method investments for recoverability. If we determine that a loss in the value of an investment is other than temporary, the investment is written down to its estimated fair value. Any such losses are recorded in Other expense, net. Evaluations of recoverability are based primarily on projected cash flows. Due to uncertainties in the estimation process, actual results could differ from such estimates. Equity method investments are recorded in Other non-current assets on the Consolidated Balance Sheets. See Note 6 for more information on our equity method investments. e. Derivative Instruments We record derivative instruments (including certain derivative instruments embedded in other contracts) on the balance sheet on a gross basis as either an asset or liability measured at fair value. See Note 7 for a table indicating where each component is recorded on the Consolidated Balance Sheets. Additionally, changes in a derivative's fair value, which are measured at the end of each period, is recognized in earnings unless specific hedge accounting criteria are met. If hedge accounting criteria are met for cash flow hedges, the changes in a derivative’s fair value are recorded in shareholders’ equity as a component of other comprehensive income ("OCI"), net of tax. These deferred gains and losses are recognized in income in the period in which the hedged item and hedging instrument affect earnings. Any ineffective portion of the change in fair value is immediately recognized in earnings. We are exposed to credit loss in the event of nonperformance by the counterparties on derivative contracts. It is our policy to manage our credit risk on these transactions by dealing only with financial institutions having a long-term credit rating of "A" or better and by distributing the contracts among several financial institutions to diversify credit concentration risk. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of the forward currency exchange contracts at June 27, 2015 and June 28, 2014 was 15 months. f. Accounts Receivable and Factoring We maintain an allowance for doubtful accounts that reduces our receivables to amounts that are expected to be collected. In estimating the allowance, management considers factors such as current overall and industry-specific economic conditions, statutory requirements, historical and anticipated customer performance, historical experience with write-offs and the level of past-due amounts. Changes in these conditions may result in additional allowances. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. As a result of the Omega acquisition, we assumed multiple accounts receivable factoring arrangements with non-related third-party financial institutions (the “Factors”). Pursuant to the terms of the arrangements, we sell to the Factors certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. An administrative fee ranging from 0.14% to 0.15% per diem is charged on the gross amount of accounts receivables assigned to the Factors, plus interest is calculated at the applicable EUR LIBOR rate plus 70 basis points. The total amount factored and excluded from accounts receivable on our Consolidated Balance Sheets was $171.6 million at June 27, 2015 , a $23.9 million increase since we acquired Omega. g. Inventories Inventories are stated at the lower of cost or market. Cost is determined using the first-in first-out ("FIFO") method. Inventory related to research and development is expensed at the point when it is determined the materials have no alternative future use. We maintain reserves for estimated obsolete or unmarketable inventory based on the difference between the cost of the inventory and its estimated net realizable value. In estimating the reserves, management considers factors such as excess or slow-moving inventories, product expiration dating, products on quality hold, current and future customer demand and market conditions. Changes in these conditions may result in additional reserves. See Note 4 for additional information on our inventory. h. Property, Plant and Equipment, net Property, plant and equipment, net are recorded at cost and are depreciated using the straight-line method. Useful lives for financial reporting range from 2 to 15 years for machinery and equipment and 10 to 45 years for buildings. Maintenance and repair costs are charged to earnings, while expenditures that increase asset lives are capitalized. Depreciation expense was $84.3 million , $77.9 million , and $66.2 million for fiscal years 2015 , 2014 , and 2013 , respectively, and includes amortization of assets recorded under capital leases. We held the following property, plant and equipment, net at June 27, 2015 and June 28, 2014 (in millions): June 27, June 28, Land $ 48.7 $ 36.1 Buildings 528.3 430.3 Machinery and equipment 1,094.0 1,001.4 Gross property and equipment 1,671.0 1,467.8 Less accumulated depreciation (738.6 ) (687.9 ) Property and equipment, net $ 932.4 $ 779.9 i. Goodwill and Intangible Assets Goodwill represents amounts paid for an acquisition in excess of the fair value of net assets received. Goodwill is tested for impairment annually in our fourth quarter, or more frequently if changes in circumstances or the occurrence of events suggest impairment exists. The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows and market valuation multiples. The estimates associated with the goodwill impairment tests are considered critical due to the judgments required in determining fair value amounts, including projected discounted future cash flows. Changes in these estimates may result in the recognition of an impairment loss. We have intangible assets that we have acquired through various business acquisitions and that include trademarks, trade names and brands, in-process research and development ("IPR&D"), developed product technology/formulation and product rights, distribution and license agreements, customer relationships and distribution networks, and non-compete agreements. The assets are typically initially valued using either the: • Relief from royalty method : This method assumes that if the acquired company did not own the intangible asset or intellectual property, it would be willing to pay a royalty for its use. The benefit of ownership of the intellectual property is valued as the relief from the royalty expense that would otherwise be incurred. We typically use this method for valuing readily transferable intangible assets that have licensing appeal, such as trade names and trademarks and certain technology assets. • Multi-period excess earnings method : This method starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. We typically use this method for valuing intangible assets such as developed product technology, customer relationships, product formulations and IPR&D. Indefinite-lived intangible assets include IPR&D and certain trademarks, trade names and brands. IPR&D assets are recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. If the associated research and development is completed, the IPR&D asset becomes a definite-lived intangible asset and is amortized over the asset's assigned useful life. If it is abandoned, an impairment loss is recorded. Indefinite-lived trademarks, trade names and brands are tested for impairment annually during our fourth quarter, or more frequently if changes in circumstances or the occurrence of events suggest impairment exists, by comparing the carrying value of the assets to their estimated fair values. An impairment loss is recognized if the carrying amount of the asset is not recoverable and its carrying amount exceeds its fair value. Definite-lived intangible assets consist of a portfolio of developed product technology/formulation and product rights, distribution and license agreements, customer relationships, non-compete agreements, and certain trademarks and trade names. The assets are amortized on either a straight-line basis or proportionately to the benefits derived from those relationships or agreements. Useful lives vary by asset type and are determined based on the period over which the intangible asset is expected to contribute directly or indirectly to our future cash flows. We also review all other long-lived assets that have finite lives and that are not held for sale for impairment when indicators of impairment are evident by comparing the carrying value of the assets to their estimated future undiscounted cash flows. See Note 3 for further information on our goodwill and intangible assets. j. Debt We elected to early adopt new accounting guidance related to deferred financing fees (as further described below under "Recent Accounting Standard Pronouncements") as of June 27, 2015. As a result, we changed our accounting policy to record deferred financing fees as a reduction of Long-term debt rather than as a Non-current asset. The balance sheet has been adjusted to reflect this change for all years presented. k. Share-Based Awards We measure and record compensation expense for all share-based awards based on estimated grant date fair values, and net of any estimated forfeitures over the vesting period of the awards. Forfeiture rates are estimated at the grant date based on historical experience and adjusted in subsequent periods for any differences in actual forfeitures from those estimates. We estimate the fair value of stock option awards granted based on the Black-Scholes option pricing model, which requires the use of subjective and complex assumptions. These assumptions include estimating the expected term that awards granted are expected to be outstanding, the expected volatility of our stock price for a period commensurate with the expected term of the related options, and the risk-free rate with a maturity closest to the expected term of the related awards. Restricted stock and restricted stock units are valued based on our stock price on the day the awards are granted. See Note 10 for further information on our share-based awards. l. Income Taxes Deferred income tax assets and liabilities are recorded based upon the difference between the financial reporting and the tax reporting basis of assets and liabilities using the enacted tax rates. To the extent that available evidence raises doubt about the realization of a deferred income tax asset, a valuation allowance is established. We have not made a provision for U.S. or additional non-U.S. taxes on undistributed post-acquisition earnings of non-U.S. subsidiaries because those earnings are considered permanently reinvested in the operations of those subsidiaries. We record reserves for uncertain tax positions to the extent it is more likely than not that the tax position will be sustained on audit, based on the technical merits of the position. Periodic changes in reserves for uncertain tax positions are reflected in the provision for income taxes. We include interest and penalties attributable to uncertain tax positions and income taxes as a component of our income tax provision. m. Legal Contingencies We are involved in product liability, patent, commercial, regulatory and other legal proceedings that arise in the normal course of business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range and no amount within that range is a better estimate, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. We have established reserves for certain of our legal matters, as described in Note 14 . We also separately record any insurance recoveries that are probable of occurring. n. Research and Development All research and development costs, including payments related to products under development and research consulting agreements, are expensed as incurred. We may continue to make non-refundable payments to third parties for new technologies and for research and development work that has been completed. These payments may be expensed at the time of payment depending on the nature of the payment made. Research and development spending was $187.8 million , $152.5 million , and $115.2 million for fiscal years 2015 , 2014 , and 2013 , respectively. Fiscal year 2015 included incremental research and development expenses related to the collaboration agreement entered into as a result of the Omega acquisition. Fiscal year 2014 included incremental research and development expenses due to the Sergeant's, Velcera, and Aspen acquisitions, as well as research and development expenses related to the novel therapeutic agent for Alzheimer's disease ("ELND005") Phase 2 clinical program in collaboration with Transition Therapeutics Inc. ("Transition") that we acquired in the Elan acquisition. We ended our collaboration with Transition during the third quarter of fiscal 2014 and are no longer responsible for ongoing development activities and costs associated with ELND005. See Note 15 for additional information on collaboration agreements. Fiscal year 2013 included incremental research and development expenses attributable to the acquisitions of Sergeant's, Rosemont, and Velcera acquisitions. We actively collaborate with other pharmaceutical companies to develop, manufacture and market certain products or groups of products. We may choose to enter into these types of agreements to, among other things, leverage our or others’ scientific research and development expertise or utilize our extensive marketing and distribution resources. Our policy on accounting for costs of strategic collaborations determines the timing of the recognition of certain development costs. In addition, this policy determines whether the cost is classified as development expense or capitalized as an asset. Management is required to form judgments with respect to the commercial status of such products in determining whether development costs meet the criteria for immediate expense or capitalization. For example, when we acquire certain products for which there is already an Abbreviated New Drug Application ("ANDA") or New Drug Application ("NDA") approval directly related to the product, and there is net realizable value based on projected sales for these products, we capitalize the amount paid as an intangible asset. If we acquire product rights that are in the development phase and as to which we have no assurance that the third-party will successfully complete its development milestones, we expense the amount paid. See Note 15 for more information on our current collaboration agreements. o. Advertising Costs We expense advertising costs as incurred. Advertising costs were $55.7 million , $41.4 million , and $26.1 million in fiscal years 2015 , 2014 , and 2013 , respectively. Advertising costs relate primarily to print advertising, direct mail, on-line advertising and social media communications primarily in our CHC and BCH segments. p. Earnings per Share ("EPS") Basic EPS is calculated using the weighted-average number of ordinary shares outstanding during each period. It excludes both the dilutive effects of additional common shares that would have been outstanding if the shares issued under stock incentive plans had been exercised and the dilutive effect of restricted shares and restricted share units, to the extent those shares and units have not vested. Diluted EPS is calculated including the effects of shares and potential shares issued under stock incentive plans, following the treasury stock method. q. Defined Benefit Plans As part of the Omega acquisition in fiscal year 2015, we assumed the liabilities under a number of defined benefit plans for employees based primarily in the Netherlands, Germany, France and Norway. Omega companies operate various pension plans across each country. As part of the Elan acquisition in fiscal year 2014, we assumed responsibility for the funding of two Irish defined benefit plans, which subsequently have been combined. Two significant assumptions, the discount rate and the expected rate of return on plan assets, are important elements of expense and liability measurement. We evaluate these assumptions annually. Other assumptions involve employee demographic factors, such as retirement patterns, mortality, turnover, and the rate of compensation increase. The liability recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The defined benefit obligation is calculated periodically by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid and that have terms to maturity approximating the terms of the related pension liability. Actuarial gains and losses are recognized using the corridor method. Under the corridor method, to the extent that any cumulative unrecognized net actuarial gain or loss exceeds 10% of the greater of the present value of the defined benefit obligation and the fair value of the plan assets, that portion is recognized over the expected average remaining working lives of the plan participants. Otherwise, the net actuarial gain or loss is recorded in OCI. We recognize the funded status of benefit plans on the Consolidated Balance Sheets. In addition, we recognize the gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic pension cost of the period as a component of OCI. See Note 13 for further information on our defined benefit plans. r. Recent Accounting Standard Pronouncements Recently Adopted Accounting Standards Accounting Standard Update Description Date of Adoption Effect on the Financial Statements or Other Significant Matters Interest- Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs These amendments require debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. June 27, 2015 As of June 27, 2015 and June 28, 2014 we reclassified $40.5 million and $27.4 million, respectively, of deferred financing fees from Other non-current assets to Long-term debt. Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists These amendments provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. July 1, 2014 In first quarter fiscal year 2015 we presented $90.2 million as a reclassification from Non-current deferred income taxes to Other non-current liabilities upon adoption. Recently Issued Accounting Standards Not Yet Adopted Standard Description Effective Date Effect on the Financial Statements or Other Significant Matters Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity These amendments raise the threshold for a disposal to qualify as a discontinued operation and require new disclosures of both discontinued operations and certain other disposals that do not currently meet the definition of a discontinued operation. Additional disclosures will include an entity's continuing involvement with a discontinued operation following the disposal date and retained equity method investments in a discontinued operation. July 1, 2015 Adoption of this guidance will not have a material effect on our Consolidated Results of Operations or financial condition. Revenue from Contracts with Customers The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: identify the contract(s) with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) the entity satisfies a performance obligation. This guidance allows for two adoption methods, full retrospective approach or modified retrospective approach. January 1, 2018 We are currently evaluating the possible adoption methodologies and the implications of adoption on our consolidated financial statements.

Acquisitions

Acquisitions	12 Months Ended
	Jun. 27, 2015
Business Combinations [Abstract]
Acquisitions	ACQUISITIONS All of the below acquisitions, with the exception of the Vedants equity transaction, have been accounted for under the acquisition method of accounting, and the related assets acquired and liabilities assumed were recorded at fair value as of the acquisition date. The effects of all of the acquisitions described below were included in the Consolidated Financial Statements prospectively from the date of acquisition. Unless otherwise indicated, acquisition costs incurred were immaterial and were recorded in administration expense. Pending Acquisitions Naturwohl Pharma GmbH On July 22, 2015, we announced that we agreed to acquire Naturwohl Pharma, GmbH with its leading German dietary supplement brand, Yokebe. Our acquisition of the brand continues to build on our BCH segment's leading OTC product portfolio and European commercial infrastructure. The transaction has been unanimously approved by the Boards of Directors of Perrigo and Naturwohl Pharma and is expected to close in the third calendar quarter, pending German regulatory approval and the satisfaction of customary closing conditions. These assets will be purchased through an all-cash transaction valued at €130.0 million ( $145.2 million ). GlaxoSmithKline Consumer Healthcare On June 2, 2015, we announced that we had entered into an agreement to acquire a portfolio of well-established OTC brands from GlaxoSmithKline Consumer Healthcare (“GSK”), in connection with GSK’s commitments to the European Commission and other regulators to divest these businesses in the context of the formation of a consumer health joint venture between GSK and Novartis International AG (“Novartis”). The acquisition of this portfolio builds upon the global platform we established through the Omega acquisition to help us expand our share in the European OTC market. These assets will be purchased through an all-cash transaction valued at €200.0 million ( $223.4 million ). The transaction is expected to close in the third calendar quarter. Fiscal Year 2015 Acquisitions Gelcaps Exportadora de Mexico, S.A. de C.V. On May 12, 2015 , we acquired 100% of Gelcaps Exportadora de Mexico, S.A. de C.V. ("Gelcaps"), the Mexican operations of Durham, North Carolina-based Patheon Inc. for $35.8 million in cash. The acquisition adds softgel manufacturing technology to our supply chain capabilities and broadens our presence, product portfolio and customer network in Mexico. Operating results attributable to Gelcaps are included in the CHC segment. The intangible assets acquired included a trademark with a 25 year useful life and customer relationships with a 20 year useful life. We utilized the relief from royalty method for valuing the trademark and the multi-period excess earnings method for valuing the customer relationships. Based on valuation estimates utilizing the comparative sales method, a step-up in the value of inventory of $0.6 million was recorded in the opening balance sheet, which will be charged to cost of goods sold by the end of next quarter. In addition, property, plant and equipment were written up by $0.9 million to their estimated fair market value based on a valuation method that included both the cost and market approaches. This additional step-up in value is being depreciated over the estimated remaining useful lives of the assets. The goodwill recorded is not deductible for tax purposes. Omega Pharma Invest N.V. On March 30, 2015 , we completed our acquisition of Omega, a limited liability company incorporated under the laws of Belgium. Omega was a leading European OTC company, and we expect it to provide us several key benefits, including advancing our growth strategy outside the U.S. by providing access across a larger global platform with critical mass in key European countries, establishing commercial infrastructure in the high-barrier to entry European OTC marketplace, strengthening our product portfolio while enhancing scale and distribution, enhancing our financial profile, and expanding our international management capabilities. We purchased 95.77% of the issued and outstanding share capital of Omega ( 685,348,257 shares) from Alychlo N.V. (“Alychlo”) and Holdco I BE N.V. (“Holdco” and, together with Alychlo, the “Sellers”), limited liability companies incorporated under the laws of Belgium under the terms of the Share Purchase Agreement dated November 6, 2014 (the "Share Purchase Agreement"). Omega holds the remaining 30,243,983 shares as treasury shares. The acquisition was a cash and stock transaction made up of the following consideration (in millions except per share data): Perrigo ordinary shares issued 5.4 Perrigo share price at transaction close on March 30, 2015 $ 167.64 Total value of Perrigo ordinary shares issued $ 904.9 Cash consideration 2,078.3 Total consideration $ 2,983.2 The cash consideration shown in the above table was financed by a combination of debt and equity. We issued $1.6 billion of debt as described in Note 8 , and issued 6.8 million ordinary shares, which raised $999.3 million net of issuance costs. The Sellers have agreed to indemnify us for certain potential future losses. The Sellers’ indemnification and other obligations to us under the Share Purchase Agreement are secured up to €248.0 million ( $277.0 million ). Under the terms of the Share Purchase Agreement, Alychlo and its affiliates are subject to a three -year non-compete in Europe, and the Sellers are subject to a two -year non-solicit, in each case subject to certain exceptions. The Share Purchase Agreement contains other customary representations, warranties, and covenants of the parties thereto. The operating results attributable to Omega are included in the BCH segment. We incurred costs in connection with the Omega acquisition related to general transaction costs (legal, banking and other professional fees), financing fees, and debt extinguishment. The amounts recorded were not allocated to a reporting segment. The table below details the acquisition costs, as well as losses on hedging activities associated with the acquisition purchase price, and where they were recorded (in millions): Fiscal Year Line item 2015 Administration $ 29.7 Interest expense, net 23.7 Other expense, net 324.0 Loss on extinguishment of debt 9.6 Total acquisition-related costs $ 387.0 See Note 7 for further details on losses on Omega-related hedging activities shown above in Other expense, net, and Note 8 for details on the loss on extinguishment of debt. We acquired the following intangible assets: indefinite-lived trademarks and brands; definite-lived trademarks and trade names with useful lives ranging from 8 to 20 years; customer relationships and distribution networks with useful lives ranging from 7 to 21 years; and developed product technology with useful lives ranging from 4 to 13 years. We also recorded goodwill, which is not deductible for tax purposes and represents the value we assigned to the expected synergies described above. We utilized the multi-period excess earnings method for the indefinite-lived trademarks and brands, the definite-lived brands, and customer relationships and distribution networks. We utilized the relief from royalty method for the developed product technology and definite-lived trade names. Based on valuation estimates utilizing the comparative sales method, a step-up in the value of inventory of $15.1 million was recorded in the opening balance sheet and was charged to cost of goods sold during the fourth quarter of fiscal year 2015. In addition, property, plant and equipment were written up $41.5 million to their estimated fair market value based on a valuation method that included both the cost and market approaches. This additional step-up in value is being depreciated over the estimated remaining useful lives of the assets. Additionally, the fair value of the debt assumed on the date of acquisition exceeded par value by $101.9 million , which was recorded as part of the carrying value of the underlying debt and will be amortized as a reduction of interest expense over the remaining terms of the respective debt instruments. For more information on the debt we assumed from Omega and our subsequent payments on the debt, see Note 8 . Lumara Health, Inc. On October 31, 2014 , we acquired a portfolio of women's healthcare products from Lumara Health, Inc., ("Lumara") a privately-held, Chesterfield, Missouri-based specialty pharmaceutical company, for cash consideration of $83.0 million . The acquisition of this portfolio further expanded our women's healthcare product offerings. Operating results attributable to the acquired Lumara products are included in the Rx Pharmaceuticals segment. The intangible assets acquired consisted of three product formulations with useful lives ranging from 8 to 12 years. The assets were valued utilizing the multi-period excess earnings method. Purchase Price Allocation of Fiscal Year 2015 Acquisitions The measurement period related to the Lumara acquisition is now closed. As a result, the Lumara opening balance sheet is final. The Omega and Gelcaps opening balance sheets are still preliminary and are based on valuation information, estimates and assumptions available at June 27, 2015 . As we finalize the fair value estimates of assets acquired and liabilities assumed, additional purchase price adjustments may be recorded during the measurement period. Tax accounts as well as certain tangible and intangible assets have not yet been finalized. Fair value estimates are based on a complex series of judgments about future events and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets and liabilities assumed, as well as asset lives, can materially impact our results of operations. As we continue to arrange and obtain the information to finalize our purchase accounting assessment. We expect that there will be changes in the valuation of assets acquired and liabilities assumed, that may have a material impact on our results of operations and financial position. The below table indicates the purchase price allocation for our fiscal year 2015 acquisitions (in millions): Omega * All Other (1)* Total purchase consideration $ 2,983.2 $ 118.8 Assets acquired: Cash and cash equivalents $ 14.7 $ 4.6 Accounts receivable 264.7 11.4 Inventories 214.4 8.7 Current net deferred tax assets 6.4 0.6 Prepaid expenses and other current assets 39.2 2.7 Property and equipment 121.2 6.1 Goodwill 1,513.1 4.8 Intangible assets: Trademarks, trade names and brands 2,427.2 4.4 Customer relationships and distribution networks 1,342.7 6.6 Formulations — 82.0 Developed product technology 32.7 — Other intangible assets 3,802.6 93.0 Other non-current assets 2.4 0.4 Total assets 5,978.7 132.3 Liabilities assumed: Accounts payable 243.1 4.6 Short-term debt 24.6 — Accrued liabilities 44.5 5.5 Payroll and related taxes 51.3 — Accrued customer programs 39.8 — Long-term debt 1,471.0 — Non-current net deferred income tax liabilities 1,038.7 3.3 Other non-current liabilities 82.5 0.1 Total liabilities 2,995.5 13.5 Net assets acquired $ 2,983.2 $ 118.8 (1) Includes opening balance sheets for the Gelcaps acquisition and Lumara product acquisition. * Omega and Gelcaps opening balance sheets are preliminary. Fiscal Year 2014 Acquisitions Aspen Global Inc. On February 28, 2014 , we acquired a basket of value-brand OTC products sold in Australia and New Zealand from Aspen Global Inc. ("Aspen"). The acquisition of this product portfolio broadened our product offering in Australia and New Zealand and furthered our strategy to expand the CHC portfolio internationally. Operating results attributable to the acquired Aspen products are included in the CHC segment. The intangible assets acquired consisted of trademarks and trade names, customer relationships, and non-compete agreements. Customer relationships were assigned a 15 -year useful life. Trademarks and trade names were assigned a 25 -year useful life and non-compete agreements were assigned a 5 -year useful life. Goodwill is deductible for tax purposes. Fera Pharmaceuticals, LLC On February 18, 2014 , we acquired a distribution and license agreement for the marketing and sale of Methazolomide from Fera Pharmaceuticals, LLC ("Fera"), a privately-held specialty pharmaceutical company. The acquisition of this agreement further expanded our ophthalmic offerings. Operating results attributable to this agreement are included in the Rx Pharmaceuticals segment. The intangible asset acquired was assigned a 15 -year useful life. Elan Corporation, plc On December 18, 2013 , we acquired Elan, which led to our new corporate structure headquartered in Dublin, Ireland. We have utilized this new structure to continue to grow in our core markets and further expand outside of the U.S. The acquisition also provided us with our Tysabri ® royalty stream, enhancing our operating cash flows and diversifying our revenues, and recurring annual operational synergies, related cost reductions, and tax savings. Certain of these synergies resulted from the elimination of redundant public company costs while optimizing back-office support. The jurisdictional mix of income and the new corporate structure are expected to provide tax benefits to the worldwide structure. The acquisition was a cash and stock transaction as follows (in millions except per share data): Elan shares outstanding as of December 18, 2013 515.7 Exchange ratio per share 0.07636 Total Perrigo shares issued to Elan shareholders 39.4 Perrigo per share value at transaction close on December 18, 2013 $ 155.34 Total value of Perrigo shares issued to Elan shareholders $ 6,117.2 Cash consideration paid at $6.25 per Elan share 3,223.2 Cash consideration paid for vested Elan stock options and share awards 111.5 Total consideration $ 9,451.9 In addition, we paid cash consideration of $16.1 million to the Elan stock option and share award holders for the unvested portion of their awards. This amount was charged to earnings during fiscal year 2014. At the completion of the transaction, the holder of each Elan ordinary share and each Elan American Depositary Share received $6.25 in cash and 0.07636 of a Perrigo ordinary share. As a result of the transaction, based on the number of outstanding shares of Perrigo and Elan as of December 18, 2013 , former Perrigo and Elan shareholders held approximately 71% and 29% , respectively, of Perrigo's ordinary shares immediately after giving effect to the acquisition. The operating results for Elan are included in the Specialty Sciences segment. During fiscal year 2014, we incurred and expensed acquisition-related costs, which were not allocated to a reporting segment. The costs related primarily to general transaction costs (legal, banking and other professional fees), financing fees, and debt extinguishment. See Note 8 for further details on the loss on extinguishment of debt. The table below details these transaction costs and where they were recorded (in millions): Fiscal Year Line item 2014 Administration expense $ 108.9 Interest, net 10.0 Other expense, net 0.2 Loss on extinguishment of debt 165.8 Total acquisition-related costs $ 284.9 We acquired two definite-lived intangible assets in the acquisition, both of which are exclusive technology agreements: Tysabri ® : We are entitled to royalty payments from Biogen Idec Inc. ("Biogen") based on its Tysabri ® revenues in all indications and geographies. The royalty was 12% for the 12-month period ended May 1, 2014. Subsequent to May 1, 2014, we are entitled to 18% royalty payments on annual sales up to $2.0 billion and 25% royalty payments on annual sales above $2.0 billion . The asset was assigned a value of $5.8 billion and a useful life of 20 years. Prialt ® : We are also entitled to royalty payments based on Prialt ® revenues. The royalty rates range from 7% to 17.5% based on specific levels of annual U.S. sales. The asset was assigned a value of $11.0 million and a useful life of 10 years. Additionally, we recorded $2.3 billion of goodwill which represents the expected synergies of the combined company, as described above. The goodwill is not deductible for tax purposes. The following table reflects the allocation by reportable segment (in millions): Segment Goodwill CHC $ 1,287.4 Rx Pharmaceuticals 845.1 Specialty Sciences 200.6 Total $ 2,333.1 Purchase Price Allocation of Fiscal Year 2014 Acquisitions The purchase price allocations for all fiscal year 2014 acquisitions are now final. We finalized the purchase price allocation for Elan during fiscal year 2015. Since June 28, 2014, revisions included a $13.0 million decrease in net tax-related liabilities, resulting in a corresponding decrease in goodwill. The below table indicates the purchase price allocation for our fiscal year 2014 acquisitions (in millions): Elan All Other (1) Purchase price paid $ 9,451.9 $ 71.0 Contingent consideration — 0.8 Total purchase consideration $ 9,451.9 $ 71.8 Assets acquired: Cash and cash equivalents $ 1,807.3 $ — Investment securities 100.0 — Accounts receivable 44.2 — Inventories — 3.0 Prepaid expenses and other current assets 27.1 — Property and equipment 9.2 — Goodwill 2,333.1 4.6 Intangible assets: Trademarks, trade names and brands — 34.8 Customer relationships — 9.8 Non-competition agreements — 1.8 Distribution and license agreements 5,811.0 17.8 Other intangible assets, net 5,811.0 64.2 Other non-current assets 93.4 — Total assets 10,225.3 71.8 Liabilities assumed: Accounts payable 2.0 — Accrued liabilities 120.8 — Deferred tax liabilities 631.8 — Other non-current liabilities 18.8 — Total liabilities 773.4 — Net assets acquired $ 9,451.9 $ 71.8 (1) Includes opening balance sheet of the Aspen and Fera (Methazolomide) product acquisitions. Vedants Drug & Fine Chemicals Private Limited To further improve the long-term cost position of its API business, on August 6, 2009 , we acquired an 85% stake in Vedants Drug & Fine Chemicals Private Limited ("Vedants"), an API manufacturing facility in India, for $11.5 million in cash. We purchased the remaining 15% stake in Vedants during fiscal year 2014 for $7.2 million in cash. The transaction was accounted for as an equity transaction and resulted in the elimination of the noncontrolling interest. Actual and Pro Forma Impact of Fiscal Year 2015 and 2014 Acquisitions Our Consolidated Financial Statements include operating results from the Omega, Gelcaps, and Elan acquisitions, and the Lumara, Aspen, and Fera (Methazolomide) product acquisitions, from the date of each acquisition through June 27, 2015 . Net sales and operating income attributable to the Omega, Gelcaps, and Lumara acquisitions included in our fiscal year 2015 financial statements totaled $418.2 million and $18.9 million , respectively. Net sales and operating loss attributable to the Elan, Aspen, and Fera (Methazolomide) acquisitions included in our fiscal 2014 financial statements totaled $168.5 million and $53.9 million , respectively. The following unaudited pro forma information gives effect to the Omega, Gelcaps, and Elan acquisitions, and Lumara, Aspen, and Fera (Methazolomide) product acquisitions, as if the acquisitions had occurred on June 30, 2013 and had been included in our Results of Operations for fiscal years 2015 and 2014 (in millions): (Unaudited) Fiscal 2015 Fiscal 2014 Net sales $ 5,671.3 $ 5,816.3 Net income $ 122.5 $ 212.8 The historical consolidated financial information of Perrigo, Omega, Gelcaps, and Elan, and the acquired Lumara, Aspen, and Fera assets, has been adjusted in the pro forma information to give effect to pro forma events that are (1) directly attributable to the transactions, (2) factually supportable and (3) expected to have a continuing impact on combined results. In order to reflect the occurrence of the acquisitions on June 30, 2013 as required, the unaudited pro forma results include adjustments to reflect the incremental amortization expense to be incurred based on the current preliminary values of each acquisition's identifiable intangible and tangible assets, along with the reclassification of acquisition-related costs from the period ended June 27, 2015 to the period ended June 28, 2014. The unaudited pro forma results do not reflect future events that have occurred or may occur after the acquisitions, including but not limited to, the anticipated realization of ongoing savings from operating synergies and tax savings in subsequent periods. The decline in the Euro relative to the U.S. dollar negatively impacted fiscal year 2015 pro forma net sales attributed to Omega. If the Euro to U.S. dollar exchange rate had remained constant from fiscal year 2014 to fiscal year 2015, pro forma net sales attributed to Omega would have increased in fiscal year 2015 by an estimated $189.3 million . Fiscal Year 2013 Acquisitions Fera Pharmaceuticals, LLC On June 17, 2013 , we acquired an ophthalmic sterile ointment and solution product portfolio from Fera. The acquisition of this product portfolio expanded our ophthalmic offerings and position within the Rx extended topical space. Operating results attributable to this agreement are included in the Rx Pharmaceuticals segment. The intangible assets were assigned a 15 -year useful life. Goodwill is deductible for tax purposes. Velcera, Inc. On April 1, 2013 , we completed the acquisition of 100% of the shares of privately-held Velcera, Inc. ("Velcera"). Velcera, through its FidoPharm subsidiary, was a leading companion pet health product company committed to providing consumers with best-in-class companion pet health products that contain the same active ingredients as branded veterinary products, but at a significantly lower cost. FidoPharm products, including the PetArmor ® flea and tick products, are available at major retailers nationwide, offering consumers the benefits of convenience and cost savings to ensure the highest quality care for their pets. The acquisition helped establish our animal health category as described below. The operating results for Velcera are included in the CHC segment. The intangible assets acquired consisted of a distribution and license agreement, customer relationships, trade name and trademarks, and non-compete agreements. The distribution and license agreement was assigned a 10 -year useful life. The customer relationships were assigned a 20 -year useful life, the trademarks and trade names were assigned a 25 -year useful life, and the non-compete agreements were assigned a 3 -year useful life. Goodwill is not deductible for tax purposes. Rosemont Pharmaceuticals Ltd. On February 11, 2013 , we acquired 100% of the shares of privately-held Rosemont Pharmaceuticals Ltd. ("Rosemont"). Based in Leeds, U.K., Rosemont was a specialty and generic prescription pharmaceutical company focused on the manufacturing and marketing of oral liquid formulations. The acquisition expanded our Rx product offering into the U.K. and Europe. The operating results for Rosemont are included in the Rx Pharmaceuticals segment. The intangible assets acquired consisted of developed product technology, IPR&D, trademarks and trade names, distribution and license agreements, and non-compete agreements. The developed product technology has a useful life of 7 years. IPR&D is considered to have an indefinite life until such time as the research is completed (at which time it becomes a definite-lived intangible asset) or is determined to have no future use (at which time it is impaired). The distribution and license agreements were assigned a 14 -year useful life and the non-compete agreements were assigned a 3 -year useful life. Goodwill is not deductible for tax purposes. Cobrek Pharmaceuticals, Inc. On December 28, 2012 , we acquired the remaining 81.5% interest of Cobrek Pharmaceuticals, Inc. ("Cobrek"), a privately-held drug development company, for $42.0 million in cash. In May 2008, we acquired the initial 18.5% minority stake in Cobrek for $12.6 million in conjunction with entering into a product development collaborative agreement focused on generic pharmaceutical foam dosage form products. As of the acquisition date, the partnership had successfully yielded two commercialized foam-based products and had an additional two U.S. Food and Drug Administration ("FDA") approved foam-based products, both of which were launched during fiscal year 2013. Cobrek derived its earnings stream primarily from exclusive technology agreements, which were assigned useful lives of 12 years. The Cobrek acquisition further strengthened our position in foam-based technologies for existing and future U.S. Rx products. Goodwill is not deductible for tax purposes. Sergeant's Pet Care Products, Inc. On October 1, 2012 , we completed the acquisition of substantially all of the assets of privately-held Sergeant's. Sergeant's was a leading supplier of animal health products, including flea and tick remedies, health and well-being products, natural and formulated treats, and consumable products. The acquisition expanded our CHC product portfolio into the animal health category. The intangible assets acquired include developed product technology, trademarks and trade names, favorable supply agreements, customer relationships, and non-compete agreements. The developed product technology was assigned a 10 -year useful life; trademarks and trade names have an indefinite useful life; the favorable supply agreements were assigned a 7 -year useful life; customer relationships were assigned a 20 -year useful life; and non-compete agreements were assigned useful lives ranging from one to three years. Goodwill is not deductible for tax purposes. At the time of the acquisition, a step-up in the value of inventory of $7.7 million was recorded in the opening balance sheet as assets acquired based on valuation estimates and was charged to cost of sales during fiscal year 2013 as the acquired inventory was sold. In addition, property, plant and equipment were written up by $6.1 million to their estimated fair market value based on a valuation method that included both the cost and market approaches. This additional step-up in value is being depreciated over the estimated remaining useful lives of the assets. Purchase Price Allocation of Fiscal Year 2013 Acquisitions The purchase price allocations for all of our fiscal year 2013 acquisitions are final. The below table indicates the final purchase price allocation for fiscal year 2013 acquisitions (in millions): Sergeant's Rosemont Velcera All Other (1) Purchase price paid $ 285.0 $ 282.9 $ 175.1 $ 139.9 Contingent consideration — — — 22.2 Total purchase consideration $ 285.0 $ 282.9 $ 175.1 $ 162.1 Assets acquired: Cash and cash equivalents $ — $ 2.1 $ 18.9 $ — Accounts receivable 19.7 10.6 6.3 — Inventories 37.7 9.6 9.7 1.3 Property and equipment 25.4 13.1 0.6 — Goodwill 80.2 147.0 62.5 18.1 Intangible assets: Developed product technology 66.1 114.6 — 158.1 Distribution and license agreements 1.3 3.6 116.0 — Customer relationships 10.0 — 8.7 — Trademarks, trade names and brands 33.0 17.3 7.6 — Non-competition agreements — 1.5 3.0 — IPR&D — 11.2 — — Favorable supply agreement 25.0 — — — Intangible assets 135.4 148.2 135.3 158.1 Deferred tax assets 1.5 0.2 7.9 3.6 Other non-current assets 3.0 0.8 0.4 0.3 Total assets 302.9 331.6 241.6 181.4 Liabilities assumed: Accounts payable 13.7 2.6 6.5 — Accrued liabilities 4.2 7.6 4.8 0.5 Deferred tax liabilities — 36.0 48.2 18.8 Other non-current liabilities — 2.5 7.0 — Total liabilities 17.9 48.7 66.5 19.3 Net assets acquired $ 285.0 $ 282.9 $ 175.1 $ 162.1 (1) Includes opening balance sheet of the Cobrek acquisition and Fera product acquisition. We have completed our obligation under the contingent portion of the Fera purchase price shown above as of June 27, 2015 . Payments towards the contingent consideration totaled $18.3 million in fiscal year 2015 and $6.7 million in fiscal year 2014. The difference between the initial contingent consideration recorded as part of the purchase price and the payments represents the change in the fair value of the contingent consideration, which was recorded to Other expense, net each quarter.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	12 Months Ended
	Jun. 27, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions): CHC BCH Rx Pharma- Specialty Sciences Other Total Balance at June 29, 2013 $ 611.6 $ — $ 385.4 $ — $ 92.2 $ 1,089.2 Business acquisitions 1,297.2 — 851.0 201.8 — 2,350.0 Currency translation adjustment 7.6 — 21.9 — 5.4 34.9 Balance at June 28, 2014 1,916.4 — 1,258.3 201.8 97.6 3,474.1 Business acquisitions 4.8 1,513.1 — — — 1,517.9 Impairments (6.8 ) — — — — (6.8 ) Currency translation adjustment (9.7 ) 38.8 (20.0 ) — (9.4 ) (0.3 ) Purchase accounting adjustments (7.2 ) — (4.7 ) (1.1 ) — (13.0 ) Balance at June 27, 2015 $ 1,897.5 $ 1,551.9 $ 1,233.6 $ 200.7 $ 88.2 $ 4,971.9 The increase in goodwill in fiscal year 2015 was due primarily to the Omega acquisition. Additionally we recorded $4.8 million of goodwill in the CHC segment due to the Gelcaps acquisition. The increase in goodwill in fiscal year 2014 was due primarily to the acquisition of Elan, which contributed $2.3 billion of goodwill. We allocated $2.1 billion of goodwill to the reporting units that are expected to benefit from the synergies related to the Elan transaction. See Note 2 for additional information. We also recorded $4.6 million of goodwill to the CHC segment due to the acquisition of the Aspen product portfolio. Step one of our fiscal year 2015 annual goodwill impairment testing indicated that our CHC Mexico reporting unit's goodwill fair value was below its net book value as of March 28, 2015. As a result, we initiated the second step of the goodwill impairment test to measure the amount of impairment. Refer to Note 1 for our impairment process. We concluded that the goodwill was fully impaired and recorded an impairment of $6.8 million in our CHC segment during the quarter ended June 27, 2015 in Other expense, net. No other segments were affected by this impairment charges. No impairment charge was recorded as a result of the annual goodwill impairment testing during fiscal years 2014 or 2013 . During the third quarter we identified indicators of potential impairment of our Animal Health reporting unit's intangible assets, which include goodwill, indefinite-lived intangible assets, and definite-lived intangible assets. We performed impairment testing for all of our Animal Health intangible assets as of March 29, 2015, and none were determined to be impaired. Additionally, goodwill and indefinite-lived intangible assets were tested again in conjunction with our annual fourth quarter testing and resulted in no impairment. We will continue to monitor and assess our Animal Health intangible assets for potential impairment should further impairment indicators arise and test at least annually as applicable. Intangible Assets Other intangible assets and the related accumulated amortization consisted of the following (in millions): June 27, 2015 June 28, 2014 Gross Accumulated Amortization Gross Accumulated Amortization Amortizable intangibles : Distribution and license agreements $ 6,029.9 $ 502.3 $ 6,027.3 $ 192.1 Developed product technology/formulation and product rights 1,025.3 383.1 931.7 302.5 Customer relationships and distribution networks 1,749.9 146.2 372.0 97.5 Trademarks, trade names and brands 340.8 11.5 47.8 5.6 Non-compete agreements 14.7 11.9 15.3 9.4 Total amortizable intangibles $ 9,160.6 $ 1,055.0 $ 7,394.1 $ 607.1 Non-amortizable intangibles : Trademarks, trade names and brands $ 2,257.3 $ — $ 59.5 $ — In-process research and development 5.8 — 10.2 — Total non-amortizable intangibles 2,263.1 — 69.7 — Total other intangible assets $ 11,423.7 $ 1,055.0 $ 7,463.8 $ 607.1 Certain intangible assets are denominated in currencies other than the U.S. dollars; therefore, their gross and net carrying values are subject to foreign currency movements. The increase in gross amortizable intangible assets during fiscal year 2015 was due primarily to the Omega acquisition, as discussed in Note 2 . No material impairment charges were recorded as a result of the annual intangible asset impairment testing during fiscal years 2015 , 2014 or 2013 . We did record an impairment charge on certain IPR&D assets during fiscal years 2014 and 2013 due to changes in the projected development and regulatory timelines for various projects. These impairments totaled $6.0 million and $9.0 million for fiscal years 2014 and 2013 , respectively. During fiscal year 2014 , the remaining $13.0 million of IPR&D assets acquired as part of the Paddock acquisition was reclassified to a definite-lived developed product technology intangible asset and is being amortized on a proportionate basis consistent with the economic benefits derived therefrom over an estimated useful life of 12 years. The weighted-average useful life for our amortizable intangible assets by asset class at June 27, 2015 was as follows: Amortizable Intangible Asset Category Weighted-Average Useful Life (Years) Distribution and license agreements 20 Developed product technology/formulation and product rights 12 Customer relationships and distribution networks 20 Trademarks, trade names and brands 19 Non-compete agreements 2 We recorded amortization expense of $464.5 million , $281.0 million and $94.0 million during fiscal years 2015 , 2014 , and 2013 , respectively. The increase in amortization expense in fiscal year 2015 was due primarily to the incremental amortization expense incurred on the amortizable intangible assets acquired from Elan as well the inclusion of one quarter of amortization expense related to the intangible assets acquired from Omega. Estimated future amortization expense includes the additional amortization related to recently acquired intangible assets subject to amortization. Our estimated future amortization expense is as follows (in millions): Time Period Amount < 1 year $ 589.1 1-2 years 582.7 2-3 years 569.3 3-4 years 551.8 4-5 years 521.6 > 5 years 5,291.1

Inventories (Notes)

Inventories (Notes)	12 Months Ended
	Jun. 27, 2015
Inventory [Abstract]
Inventory Disclosure [Text Block]	INVENTORIES Major components of inventory at June 27, 2015 , and June 28, 2014 , were as follows (in millions): June 27, June 28, Finished goods $ 468.9 $ 307.0 Work in process 158.2 146.7 Raw materials 211.8 177.9 Total inventories $ 838.9 $ 631.6

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Jun. 27, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS Fair value is the price that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy is used in selecting inputs, with the highest priority given to Level 1, as these are the most transparent or reliable. Level 1: Quoted prices for identical instruments in active markets. Level 2: Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level 3: Valuations derived from valuation techniques in which one or more significant inputs are not observable. The following tables summarize the valuation of our financial instruments carried at fair value by the above pricing categories as of June 27, 2015 and June 28, 2014 (in millions): June 27, 2015 Level 1 Level 2 Level 3 Total Assets: Investment securities $ 12.7 $ — $ — $ 12.7 Foreign currency forward contracts — 12.4 — 12.4 Funds associated with Israeli post-employment benefits — 17.3 — 17.3 Total assets $ 12.7 $ 29.7 $ — $ 42.4 Liabilities: Foreign currency forward contracts — 4.6 — 4.6 Total liabilities $ — $ 4.6 $ — $ 4.6 June 28, 2014 Level 1 Level 2 Level 3 Total Assets: Investment securities $ 20.7 $ — $ — $ 20.7 Foreign currency forward contracts — 3.1 — 3.1 Funds associated with Israeli post-employment benefits — 19.3 — 19.3 Total assets $ 20.7 $ 22.4 $ — $ 43.1 Liabilities: Contingent consideration $ — $ — $ 17.4 $ 17.4 Interest rate swap agreements — 8.3 — 8.3 Foreign currency forward contracts — 0.8 — 0.8 Total liabilities $ — $ 9.1 $ 17.4 $ 26.5 The table below presents a reconciliation for assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for fiscal years 2015 and 2014 (in millions). Fiscal Year 2015 2014 Contingent Consideration Beginning balance: $ 17.4 $ 22.2 Net realized losses 0.9 1.1 Purchases or additions — 0.8 Settlements (18.3 ) (6.7 ) Ending balance: $ — $ 17.4 Net realized gains (losses) in the table above were recorded in Administrative expense. There were no transfers between Level 1, 2, and 3 during the years ended June 27, 2015 and June 28, 2014 . Our policy regarding the recording of transfers between levels is to record any such transfers at the end of the reporting period. See Note 6 for information on our investment securities. See Note 7 for a discussion of derivatives. Israeli post-employment benefits represent amounts we have deposited in funds managed by financial institutions designated by management to cover post-employment benefits for its Israeli employees as required by Israeli law. The funds are recorded in Other non-current assets and values are determined using prices for recently traded financial instruments with similar underlying terms, as well as directly or indirectly observable inputs, such as interest rates and yield curves, that are observable at commonly quoted intervals. Contingent consideration represented milestone payment obligations obtained through product acquisitions and was valued using estimates based on probability-weighted outcomes, sensitivity analysis, and discount rates reflective of the risk involved. The estimates were updated quarterly and the liabilities were adjusted to fair value depending on a number of assumptions, including the competitive landscape and regulatory approvals that may impact the future sales of a product. As of June 27, 2015 , our fixed rate long-term debt consisted of public bonds and retail bonds that were assumed with the Omega acquisition. The public bonds had a carrying value and fair value of $3.9 billion based on quoted market prices (Level 1). The retail bonds had a carrying value of $820.9 million and a fair value of $902.4 million based on interest rates offered for borrowings of a similar nature and remaining maturities (Level 2). As of June 28, 2014 , our fixed rate long-term debt consisted of private placement senior notes with registration rights with a carrying value of $2.3 billion and a fair value of $2.4 billion . The fair value at June 28, 2014 was determined by discounting the future cash flows of the financial instruments to their present value, using interest rates offered for borrowings of a similar nature and remaining maturities (Level 2). The carrying amounts of our other financial instruments, consisting of cash and cash equivalents, accounts receivable, accounts payable, short-term debt and variable rate long-term debt, approximate their fair value.

Investments (Notes)

Investments (Notes)	12 Months Ended
	Jun. 27, 2015
Investments, Debt and Equity Securities, Equity Method Investments and Joint Ventures [Abstract]
Investments	INVESTMENTS Available for Sale Securities Our available for sale securities totaled $12.7 million at June 27, 2015 and were reported in Investment securities . At June 28, 2014 , available for sale securities totaled $20.7 million , of which $5.9 million was reported in Investment securities and $14.8 million was reported in Other non-current assets . Net unrealized investment gains (losses) on available for sale securities were as follows (in millions): Fiscal Year 2015 2014 Net unrealized investment gains (losses): Equity securities, at cost less impairments $ 17.1 $ 17.1 Gross unrealized gains 5.7 3.8 Gross unrealized losses (10.1 ) (0.2 ) Estimated fair value of equity securities $ 12.7 $ 20.7 During fiscal year 2014, we sold one of our investment securities and recorded a loss of $9.9 million . The loss was reclassified out of AOCI and into earnings. The factors affecting the assessment of impairments include both general financial market conditions and factors specific to a particular company. The equity securities in a gross unrealized loss position at June 27, 2015 were in that position for less than 12 months. We have evaluated the near-term prospects of the equity securities in relation to the severity and duration of the unrealized impairments, and based on that evaluation, we have the ability and intent to hold the investments until a recovery of fair value. Cost Method Investments Our cost method investments totaled $6.8 million and $9.0 million at June 27, 2015 and June 28, 2014 , respectively, and were included in Other non-current assets . Equity Method Investments Our equity method investments totaled $48.9 million and $57.4 million at June 27, 2015 and June 28, 2014 , respectively, and are included in Other non-current assets . We recorded net loss es of $9.9 million and $8.7 million during fiscal years 2015 and 2014 , respectively, for our proportionate share of the equity method investment earnings or losses. In addition, during fiscal year 2014 we sold one of our equity method investments and recorded a loss of $2.8 million . All of the losses noted above were recorded in Other expense, net.

Indebtedness

Indebtedness	12 Months Ended
	Jun. 27, 2015
Indebtedness [Abstract]
Indebtedness	5 years 2,950.8 Accounts Receivable Securitization We previously had a $200.0 million accounts receivable securitization program. This program expired June 12, 2015, and we chose not to renew it. There were no borrowings outstanding under the securitization program at June 28, 2014 ." id="sjs-B4">INDEBTEDNESS Debt Total borrowings outstanding at June 27, 2015 and June 28, 2014 are summarized as follows (in millions): June 27, June 28, Short term debt $ 6.4 $ 2.1 Term loans 2013 Term loan due December 18, 2015 — 300.0 2013 Term loan due December 18, 2018 — 630.0 * 2014 Term loan due December 5, 2019 530.5 — Total term loans 530.5 930.0 Public bonds Coupon Due 1.300% November 8, 2016 (2) 500.0 500.0 * 4.500% May 23, 2017 (3) 201.0 — * 5.125% December 12, 2017 (3) 335.0 — 2.300% November 8, 2018 (2) 600.0 600.0 * 5.000% May 23, 2019 (3) 134.1 — 3.500% December 15, 2021 (1) 500.0 — * 5.105% July 19, 2023 (3) 150.8 — 4.000% November 15, 2023 (2) 800.0 800.0 3.900% December 15, 2024 (1) 700.0 — 5.300% November 15, 2043 (2) 400.0 400.0 4.900% December 15, 2044 (1) 400.0 — Total public bonds 4,720.9 2,300.0 Other financing 6.6 8.1 Unamortized premium (discount), net 87.5 (6.0 ) Deferred financing fees (40.5 ) (27.4 ) Total borrowings outstanding 5,311.4 3,206.8 Less short-term debt and current portion of long-term debt (64.6 ) (143.7 ) Total long-term debt less current portion $ 5,246.8 $ 3,063.1 (1) Public bonds issued on December 2, 2014, discussed below collectively as the "2014 Bonds." (2) Private placement unsecured senior notes with registration rights as of June 28, 2014 and public bonds as of October 1, 2014, discussed below collectively as the "2013 Bonds." (3) Debt assumed from Omega. * Debt denominated in euros subject to fluctuations in the euro to U.S. dollar exchange rate. We were in compliance with all covenants under our various debt agreements as of June 27, 2015 and June 28, 2014 . Omega Financing Bridge Agreement In connection with the Omega acquisition, on November 6, 2014 , we entered into a €1.75 billion ( $2.2 billion ) senior unsecured 364 -day bridge loan facility (the "Bridge Loan Facility"). Upon issuance of our permanent debt financing described below, the Bridge Loan Facility was terminated on December 3, 2014. At no time did we draw upon the Bridge Loan Facility. Debt Issuance On December 2, 2014 , Perrigo Finance plc, our 100% owned finance subsidiary ("Perrigo Finance"), issued $500.0 million in aggregate principal amount of 3.50% senior notes due 2021 (the "2021 Notes”), $700.0 million in aggregate principal amount of 3.90% senior notes due 2024 (the “2024 Notes”), and $400.0 million in aggregate principal amount of 4.90% senior notes due 2044 (the “2044 Notes” and, together with the 2021 Notes and the 2024 Notes, the “2014 Bonds”). Interest on the 2014 Bonds is payable semiannually in arrears in June and December of each year, beginning in June 2015. The 2014 Bonds are governed by a base indenture and a first supplemental indenture (collectively the "2014 Indenture"). The 2014 Bonds are fully and unconditionally guaranteed on a senior unsecured basis by Perrigo Company plc, and no other subsidiary of Perrigo Company plc guarantees the 2014 Bonds. There are no restrictions under the 2014 Bonds on our ability to obtain funds from our subsidiaries. Perrigo Finance received net proceeds of approximately $1.6 billion from issuance of the 2014 Bonds after fees and market discount. Perrigo Finance may redeem the 2014 Bonds in whole or in part at any time for cash at the make-whole redemption prices described in the 2014 Indenture. On December 5, 2014 , Perrigo Finance entered into a term loan agreement consisting of a €500.0 million ( $614.3 million ) tranche, with the ability to draw an additional €300.0 million ( $368.6 million ) tranche, maturing December 5, 2019, and a $600.0 million revolving credit agreement which stepped up to $1.0 billion upon the closing of the Omega acquisition (the "2014 Revolver") (together, the "2014 Credit Agreements"), and Perrigo Company plc ("Perrigo Company") entered into a $300.0 million term loan tranche maturing December 18, 2015. There were no borrowings outstanding under the 2014 Revolver as of June 27, 2015 . Debt Extinguishment On December 5, 2014, we repaid the remaining $895.0 million outstanding under our 2013 Term Loan, then terminated both the 2013 Term Loan and 2013 Revolver described below in "Elan Financing." On June 25, 2015, we repaid the $300.0 million 2014 Term Loan. We recorded a $10.5 million loss on extinguishment of debt during fiscal year 2015 , which consisted of the Bridge Loan Facility interest expense and deferred financing fees related to the 2013 Term Loan, 2013 Revolver and 2014 Term Loan. Assumed Debt and Repayment In connection with the Omega acquisition, we assumed $20.0 million in aggregate principal amount of 6.19% senior notes due 2016 ("2016 Notes"), €135.0 million ( $147.0 million ) in aggregate principal amount of 5.1045% senior notes due 2023 ("2023 Notes"), €300.0 million ( $326.7 million ) in aggregate principal amount of 5.125% retail bonds due 2017 , €180.0 million ( $196.0 million ) in aggregate principal amount of 4.500% retail bonds due 2017 , €120.0 million ( $130.7 million ) in aggregate principal amount of 5.000% retail bonds due 2019 (collectively, the "Retail Bonds"), a revolving credit facility with €500.0 million ( $544.5 million ) outstanding, and certain overdraft facilities totaling €51.4 million ( $56.0 million ). The fair value of the 2023 Notes and Retail Bonds exceeded par value by €93.6 million ( $101.9 million ) on the date of the acquisition. As a result, a fair value adjustment was recorded as part of the carrying value of the underlying debt and will be amortized as a reduction of interest expense over the remaining terms of the respective debt instruments. The adjustment does not affect cash interest payments. On April 8, 2015 , we repaid the €500.0 million ( $539.1 million ) outstanding under the assumed Omega's revolving credit facility and terminated the facility. On May 29, 2015, we repaid the $20.0 million 2016 Notes. Elan Financing Bridge Agreement In connection with the Elan acquisition, on July 28, 2013 , we entered into a $2.65 billion debt bridge credit agreement (the "Debt Bridge") and a $1.7 billion cash bridge credit agreement (the "Cash Bridge") (together, the "Bridge Credit Agreements"). The commitments under the Debt Bridge and the Cash Bridge agreements were terminated on November 8, 2013 and December 24, 2013, respectively. At no time did we draw under the Bridge Credit Agreements. Debt Issuance On September 6, 2013 , Perrigo Company entered into a $1.0 billion term loan agreement (the "2013 Term Loan") and a $600.0 million revolving credit agreement (the "2013 Revolver") (together, the "2013 Credit Agreements"). The 2013 Term Loan consisted of a $300.0 million tranche maturing December 18, 2015 and a $700.0 million tranche maturing December 18, 2018. Both tranches were drawn in full on December 18, 2013. Amounts outstanding under the 2013 Credit Agreements bore interest at our option (a) at the alternative base rate or (b) the eurodollar rate plus, in either case, applicable margins as set forth in the 2013 Credit Agreements. Our obligations under the 2013 Credit Agreements were guaranteed by Perrigo Company plc, certain U.S. subsidiaries of Perrigo Company plc, Elan, and certain Irish subsidiaries of Elan until November 21, 2014, at which time the terms of the 2013 Credit Agreements were amended to remove all guarantors. On November 8, 2013, Perrigo Company issued $500.0 million aggregate principal amount of its 1.30% senior notes due 2016 (the "2016 Notes"), $600.0 million aggregate principal amount of its 2.30% senior notes due 2018 (the "2018 Notes"), $800.0 million aggregate principal amount of its 4.00% senior notes due 2023 (the "2023 Notes") and $400.0 million aggregate principal amount of its 5.30% senior notes due 2043 (the "2043 Notes" and, together with the 2016 Notes, the 2018 Notes and the 2023 Notes, the "2013 Bonds") in a private placement with registration rights. Interest on the 2013 Bonds is payable semiannually in arrears in May and November of each year, beginning in May 2014. The 2013 Bonds are governed by a base indenture and a first supplemental indenture (collectively, the "2013 Indenture"). The 2013 Bonds are the Company's unsecured and unsubordinated obligations, ranking equally in right of payment to all of Perrigo Company existing and future unsecured and unsubordinated indebtedness. Perrigo Company received net proceeds of $2.3 billion from issuance of the 2013 Bonds after fees and market discount. The 2013 Bonds are not entitled to mandatory redemption or sinking fund payments. We may redeem the 2013 Bonds in whole or in part at any time for cash at the make-whole redemption prices described in the 2013 Indenture. The 2013 Bonds were guaranteed on an unsubordinated, unsecured basis by the same entities that guaranteed the 2013 Credit Agreement until November 21, 2014, at which time the 2013 Indenture was amended to remove all guarantors. On September 2, 2014, we offered to exchange our private placement senior notes with public bonds (the "Exchange Offer"). The Exchange Offer expired on October 1, 2014, at which time substantially all of the private placement notes had been exchanged for bonds registered with the Securities and Exchange Commission. As a result of the changes in the guarantor structure noted above, we are no longer required to present guarantor financial statements. Debt Extinguishment On December 18, 2013, we repaid the remaining principal balance with accrued interest and fees of $360.0 million outstanding under our credit agreement dated as of October 26, 2011, then terminated the agreement. On November 20, 2013, we priced a tender offer and consent solicitation with regard to our 2.95% Notes, which were issued pursuant to the indenture dated as of May 16, 2013. The total tender consideration was $578.3 million . On December 26, 2013, notice was given to holders that the remaining notes not duly tendered would be redeemed on December 27, 2013 at a redemption price of par plus accrued interest. On December 27, 2013, the redemption was completed for a total payment of $28.5 million . Upon completion of the redemption, the indenture was terminated. On December 23, 2013, we completed the prepayment of all obligations under our Private Placement Notes. All of the Notes were outstanding under the master note purchase agreement dated May 29, 2008 with various institutional investors (the "Note Agreement"). The terms of the Note Agreement provided for prepayment at any time at our option together with applicable make-whole premiums and accrued interest, which totaled $1.1 billion . Upon completion of the prepayment, the Note Agreement was terminated. As a result of the debt retirements, we recorded a loss of $165.8 million during fiscal year 2014 as follows (in millions): Make-whole payments $ 133.5 Write-off of financing fees on Bridge Credit Agreements 19.0 Write-off of deferred financing fees 10.5 Write-off of unamortized discount 2.8 Total loss on extinguishment of debt $ 165.8 Future Maturities The annual future maturities of our short-term and long-term debt, including capitalized leases, are as follows (in millions): Payment Due Amount < 1 year $ 65.0 1-2 years 758.5 2-3 years 399.1 3-4 years 811.3 4-5 years 279.5 > 5 years 2,950.8 Accounts Receivable Securitization We previously had a $200.0 million accounts receivable securitization program. This program expired June 12, 2015, and we chose not to renew it. There were no borrowings outstanding under the securitization program at June 28, 2014 .

Earnings (Loss) Per Share

Earnings (Loss) Per Share	12 Months Ended
	Jun. 27, 2015
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE AND SHAREHOLDERS' EQUITY Earnings per Share A reconciliation of the numerators and denominators used in our basic and diluted EPS calculation is as follows (in millions): Fiscal Year 2015 2014 2013 Numerator: Net income $ 128.0 $ 205.3 $ 441.9 Denominator: Weighted average shares outstanding for basic EPS 139.3 115.1 93.9 Dilutive effect of share-based awards 0.5 0.5 0.6 Weighted average shares outstanding for diluted EPS 139.8 115.6 94.5 Anti-dilutive share-based awards excluded from computation of diluted EPS 0.1 0.1 0.2 Shareholder's Equity On and prior to December 18, 2013, our common stock consisted of common stock of Perrigo Company, a Michigan Corporation, and since December 19, 2013, our common stock has consisted of ordinary shares of Perrigo Company plc, incorporated under the laws of Ireland. Prior to June 6, 2013, our common stock traded on the NASDAQ Global Select Market ("NASDAQ") under the symbol PRGO. Since June 6, 2013, our ordinary shares have traded on the New York Stock Exchange ("NYSE") under the symbol PRGO. In association with the acquisition of Agis Industries (1983) Ltd., our ordinary shares have been trading on the Tel Aviv Stock Exchange ("TASE") since March 16, 2005. In January 2003, the Board of Directors adopted a policy of paying quarterly dividends. We paid dividends of $64.8 million , $46.1 million , and $33.0 million , or $0.46 , $0.39 , and $0.35 per share, during fiscal years 2015 , 2014 , and 2013 , respectively. The declaration and payment of dividends and the amount paid, if any, are subject to the discretion of the Board of Directors and depend on our earnings, financial condition, capital and surplus requirements and other factors the Board of Directors may consider relevant.

Share-based compensation (Notes

Share-based compensation (Notes)	12 Months Ended
	Jun. 27, 2015
Share-based Compensation [Abstract]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]	SHARE-BASED COMPENSATION PLANS All share-based compensation for employees and directors is granted under the 2013 Long-Term Incentive Plan (the "Plan"), as amended. The Plan has been approved by our shareholders and provides for the granting of awards to our employees and directors. As of June 27, 2015 , there were 5.1 million shares available to be granted. The purpose of the Plan is to attract and retain individuals of exceptional managerial talent and encourage these individuals to acquire a vested interest in the Company's success and prosperity. The awards that are granted under this program include non-qualified stock options, restricted shares, and restricted share units. Restricted shares are generally service-based, requiring a certain length of service before vesting occurs, while restricted share units can be either service-based or performance-based. Performance-based restricted share units require a certain length of service until vesting; however, they contain an additional performance feature, which can vary the amount of shares ultimately paid out based on certain performance criteria specified in the Plan. Awards granted under the Plan vest and may be exercised and/or sold from one to ten years after the date of grant based on a vesting schedule. Share-based compensation expense was $31.6 million for fiscal year 2015 , $24.6 million for fiscal year 2014 , and $18.4 million for fiscal year 2013 . As of June 27, 2015 , unrecognized share-based compensation expense was $35.3 million , and the weighted-average period over which the expense is expected to be recognized was approximately 1.7 years. Proceeds from the exercise of stock options and excess income tax benefits attributable to stock options exercised are credited to ordinary shares. Stock Options A summary of activity related to stock options is presented below (options in thousands): Fiscal Year Ended June 27, 2015 Number of Options Weighted-Average Exercise Price Per Share Weighted- Average Remaining Term in Years Aggregate Intrinsic Value Beginning options outstanding 850 $ 77.26 Granted 181 $ 147.75 Exercised (170 ) $ 49.26 Forfeited or expired (4 ) $ 128.76 Ending options outstanding 857 $ 97.49 6.6 $ 79.8 Options exercisable 515 $ 74.16 5.4 $ 59.9 Options expected to vest 334 $ 132.47 8.4 $ 19.4 The aggregate intrinsic value for options exercised during the year was $20.7 million for fiscal year 2015 , $17.8 million for fiscal year 2014 , and $29.5 million for fiscal year 2013 . The weighted-average fair value per share at the grant date for options granted during the year was $39.96 for fiscal year 2015 , $38.28 for fiscal year 2014 , and $34.24 for fiscal year 2013 . The fair values were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions: Fiscal Year 2015 2014 2013 Dividend yield 0.3 % 0.3 % 0.3 % Volatility, as a percent 27.1 % 32.7 % 34.9 % Risk-free interest rate 1.7 % 1.8 % 0.8 % Expected life in years 5.3 5.3 5.4 The valuation model utilizes historical volatility. The risk-free interest rate is based on the yield of U.S. government securities with a maturity date that coincides with the expected term of the option. The expected life in years is estimated based on past exercise behavior of employees. Non-Vested Restricted Shares A summary of activity related to nonvested restricted shares is presented below (shares in thousands): Fiscal Year Ended June 27, 2015 Number of Shares Weighted- Average Grant Date Fair Value Per Share Weighted- Average Remaining Term in Years Aggregate Intrinsic Value Beginning non-vested restricted shares outstanding 9 $ 100.84 Granted — $ — Vested (9 ) $ 100.84 Forfeited — $ — Ending non-vested restricted shares outstanding — $ — 0.0 $ — There were no shares granted in fiscal year 2015 . The weighted-average fair value per share at the date of grant for restricted shares granted during the year was $145.19 for fiscal year 2014 , and $100.84 for fiscal year 2013 . The total fair value of restricted shares that vested during the year was $0.9 million for fiscal year 2015 , $2.3 million for fiscal year 2014 , and $0.6 million for fiscal year 2013 . Non-vested Service-Based Restricted Share Units A summary of activity related to non-vested service-based restricted share units is presented below (units in thousands): Fiscal Year Ended June 27, 2015 Number of Non-vested Service- Based Share Units Weighted- Average Grant Date Fair Value Per Share Weighted- Average Remaining Term in Years Aggregate Intrinsic Value Beginning non-vested service-based share units outstanding 247 $ 112.89 Granted 135 $ 153.99 Vested (91 ) $ 99.54 Forfeited (8 ) $ 126.13 Ending non-vested service-based share units outstanding 283 $ 136.48 1.2 $ 53.9 The weighted average fair value per share at the date of grant for service-based restricted share units granted during the year was $153.99 for fiscal year 2015 , $133.08 for fiscal year 2014 , and $109.20 for fiscal year 2013 . The total fair value of service-based restricted share units that vested during the year was $9.1 million for fiscal year 2015 , $6.8 million for fiscal year 2014 , and $5.7 million for fiscal year 2013 . Non-Vested Performance-Based Restricted Share Units A summary of activity related to non-vested performance-based restricted share units is presented below (units in thousands): Fiscal Year Ended June 27, 2015 Number of Performance- Based Share Units Weighted- Average Grant Date Fair Value Per Share Weighted- Average Remaining Term in Years Aggregate Intrinsic Value Beginning non-vested performance-based share units outstanding 182 $ 109.63 Granted 106 $ 150.14 Vested (56 ) $ 91.14 Forfeited (3 ) $ 126.96 Ending non-vested performance-based share units outstanding 229 $ 129.77 1.38 $ 43.6 The weighted-average fair value per share at the date of grant for performance-based restricted share units granted during the year was $150.14 for fiscal year 2015 , $119.85 for fiscal year 2014 , and $108.6 for fiscal year 2013 . The weighted-average fair value of performance-based restricted share units can fluctuate depending upon the success or failure of the achievement of performance criteria as set forth in the Plan. The total fair value of performance-based restricted share units that vested during the year was $5.1 million for fiscal year 2015 , $4.6 million for fiscal year 2014 , and $5.0 million for fiscal year 2013 .

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	12 Months Ended
	Jun. 27, 2015
Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Changes in our AOCI balances, net of tax, for fiscal years 2015 and 2014 were as follows (in millions): Fair value of derivative financial instruments, net of tax Foreign currency translation adjustments Fair value of investment securities, net of tax Post-retirement and pension liability adjustments, net of tax Total AOCI Balance at June 29, 2013 $ (4.5 ) $ 80.6 $ — $ 0.9 $ 77.0 OCI before reclassifications (18.2 ) 83.8 (4.3 ) (12.0 ) 49.3 Amounts reclassified from AOCI 6.6 — 6.7 — 13.3 Other comprehensive income (loss) (11.6 ) 83.8 2.4 (12.0 ) 62.6 Balance at June 28, 2014 (16.1 ) 164.4 2.4 (11.1 ) 139.6 OCI before reclassifications (15.1 ) (33.5 ) (5.4 ) 1.9 (52.1 ) Amounts reclassified from AOCI 14.9 — — — 14.9 Other comprehensive income (loss) (0.2 ) (33.5 ) (5.4 ) 1.9 (37.2 ) Balance at June 27, 2015 $ (16.3 ) $ 130.9 $ (3.0 ) $ (9.2 ) $ 102.4

Income Taxes

Income Taxes	12 Months Ended
	Jun. 27, 2015
Income Taxes [Abstract]
Income Taxes	INCOME TAXES Pre-tax income and the provision for income taxes from continuing operations are summarized as follows (in millions): Fiscal Year 2015 2014 2013 Pre-tax income (loss): Ireland (821.2 ) (369.3 ) — Other 1,069.2 641.9 607.7 Total 248.0 272.6 607.7 Provision for income taxes: Current: Ireland (2.0 ) 2.2 — United States - Federal 77.0 44.0 125.0 United States - State 6.9 9.3 10.7 Other Foreign 54.1 49.1 24.3 Subtotal 136.0 104.6 160.1 Deferred (credit): Ireland 7.5 (24.2 ) — United States - Federal (17.5 ) 7.8 16.6 United States - State (0.8 ) (5.8 ) — Other Foreign (5.2 ) (15.1 ) (10.9 ) Subtotal (16.0 ) (37.3 ) 5.7 Total 120.0 67.3 165.8 A reconciliation of the provision based on the Federal statutory income tax rate to our effective income tax rate is as follows: Fiscal Year 2015 2014 2013 Provision at statutory rate 12.5 % 12.5 % 35.0 % Ireland tax on non-trading differences (10.3 ) 2.8 — Expenses not deductible for tax purposes/ deductions not expensed for book, net 15.5 12.1 (0.6 ) U.S. Operations: State income taxes, net of federal benefit (1.0 ) (0.2 ) 1.1 Foreign tax credit — 0.2 (0.1 ) Research and development credit (0.8 ) (0.5 ) (0.5 ) Other 5.6 (0.8 ) (1.0 ) Other foreign differences (earnings taxed at other than applicable statutory rate) (16.6 ) (16.0 ) (8.7 ) Worldwide operations: Valuation allowance changes 25.0 2.9 — Audit impacts — — (1.2 ) Change in unrecognized taxes 18.5 15.0 3.3 Rate change impacts — (3.3 ) — Effective income tax rate 48.4 % 24.7 % 27.3 % We have provided a provision for income taxes through opening balance sheet accounting on a portion of pre-acquisition earnings of the Omega group of companies. No further provision has been made for income taxes on remaining undistributed earnings of foreign subsidiaries, of approximately $3.4 billion at June 27, 2015 , since it is our intention to indefinitely reinvest undistributed earnings of our foreign subsidiaries. Due to the number of legal entities and taxing jurisdictions involved and the complexity of the legal entity structure, the complexity of tax laws in the various jurisdictions, including, but not limited to the rules pertaining to the utilization of foreign tax credits in the U.S. and the impact of income projections to calculations, we believe it is not practicable to estimate, within any reasonable range, the additional income taxes may be payable on the remittance of such undistributed earnings. Deferred income taxes arise from temporary differences between the financial reporting and the tax reporting basis of assets and liabilities and operating loss and tax credit carryforwards for tax purposes. The components of our net deferred income tax asset (liability) was as follows: Fiscal Year 2015 2014 Deferred income tax asset (liability): Depreciation and amortization $ (1,889.0 ) $ (982.6 ) Inventory basis differences 30.2 43.9 Accrued liabilities 67.2 84.3 Allowance for doubtful accounts 0.9 0.9 Research and development 62.8 3.7 Loss carryforwards 502.4 300.4 Share-based compensation 14.3 14.3 Foreign tax credit 10.6 10.6 Federal benefit of unrecognized tax positions 26.3 20.7 Other, net 29.7 59.6 Subtotal (1,144.6 ) (444.2 ) Valuation allowance for loss and credit carryforwards (519.2 ) (198.4 ) Net deferred income tax asset (liability): $ (1,663.8 ) $ (642.6 ) The above amounts are classified on the Consolidated Balance Sheets as follows (in millions): June 27, June 28, Assets $ 161.9 $ 86.4 Liabilities (1,825.7 ) (729.0 ) Net deferred income tax (liability) asset $ (1,663.8 ) $ (642.6 ) At June 27, 2015 , we had gross carryforwards as follows: worldwide federal net operating losses, excluding U.S. states, of $2.9 billion , U.S. state net operating losses of $459.0 million , worldwide federal capital losses of $29.4 million , U.S. state credits of $1.5 billion and U.S. federal credits of $269.1 million . At June 27, 2015, gross valuation allowances had been provided for worldwide federal net operating loss carryforwards, excluding U.S. states, in the amount of $2.4 billion , $416.0 million for U.S. state net operating loss carryforwards, $29.4 million for worldwide federal capital loss carryforwards, $1.5 billion for U.S. state credit carryforwards and $198.2 million for U.S. federal credit carryforward as utilization of such carryforwards within the applicable statutory periods is uncertain. The U.S. federal net operating loss carryforwards expire through 2035, U.S. capital loss carryforward expires through 2017 and U.S. federal credit carryforwards of $37.2 million and $167.8 million expire through 2025 and through 2027, respectively, with the remaining U.S. credits having no expiration. U.S. state net operating loss carryforwards expire through 2035, and U.S. state credit carryforwards expire through 2030. Of the non-U.S. net operating loss carryforwards, $4.4 million , $32.0 million , $0.1 million , $1.2 million and $4.5 million expire through 2017, 2020, 2022, 2023, and 2025, respectively, while the remaining amounts of non U.S. net operating loss carryforwards and non-U.S. capital loss carryforwards have no expiration. The valuation allowances for these net operating loss carryforwards are adjusted annually, as necessary. After application of the valuation allowances described above, we anticipate no limitations will apply with respect to the realization of our net deferred income tax assets. The following table summarizes the activity related to amounts recorded for uncertain tax positions, excluding interest and penalties, for the years ended June 27, 2015 and June 28, 2014 (in millions): Unrecognized Tax Benefits Balance at June 29, 2013 $ 110.1 Additions: Positions related to the current year 28.8 Positions related to prior years 22.7 Reductions: Positions related to the current year — Positions related to prior years — Settlements with taxing authorities — Lapse of statutes of limitation (1.5 ) Balance at June 28, 2014 160.1 Additions: Positions related to the current year 38.9 Positions related to prior years 122.7 Reductions: Positions related to the current year — Positions related to prior years — Settlements with taxing authorities (1.4 ) Lapse of statutes of limitation (1.7 ) Balance at June 27, 2015 $ 318.6 We recognize interest and penalties related to uncertain tax positions as a component of income tax expense. The total amount accrued for interest and penalties in the liability for uncertain tax positions was $65.7 million and $45.3 million as of June 27, 2015 and June 28, 2014 , respectively. The total liability for uncertain tax positions was $384.3 million and $205.4 million as of June 27, 2015 and June 28, 2014 , respectively, after considering the federal tax benefit of certain state and local items, of which $217.6 million and $170.2 million , respectively, would impact the effective tax rate in future periods, if recognized. This increase is due primarily to acquisitions and the current year impact related to prior year positions. We file income tax returns in numerous jurisdictions and are therefore subject to audits by tax authorities. Our primary income tax jurisdictions are Ireland, the U.S., Israel, Belgium, France, and the United Kingdom. Although we believe that our tax estimates are reasonable and that we prepare our tax filings in accordance with all applicable tax laws, the final determination with respect to any tax audit and any related litigation could be materially different from our estimates or from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on operating results and/or cash flows in the periods for which that determination is made. In addition, future period earnings may be adversely impacted by litigation costs, settlements, penalties, and/or interest assessments. The IRS audit of fiscal years 2009 and 2010 had previously concluded with the issuance of a statutory notice of deficiency on August 27, 2014. While we had previously agreed on certain adjustments and made associated payments of $8.0 million , inclusive of interest in November, 2014, the statutory notice of deficiency asserted various additional positions, including transfer pricing, relative to the same fiscal 2009 and 2010 audit. The statutory notice asserted an incremental tax obligation of approximately $68.9 million , inclusive of interest and penalties. We disagree with the IRS’s positions asserted in the notice of deficiency. In January 2015, we paid this amount, a prerequisite to being able to contest the IRS’s positions in U.S. Federal court, and in June 2015, we filed a request for a refund. In the event that the IRS denies our request for a refund, we intend to contest the IRS’s asserted positions in U.S. Federal court. The payment was recorded in the third fiscal quarter as a deferred charge on the balance sheet given our anticipated action to recover this amount. An unfavorable resolution of this matter could have a material impact on our consolidated financial statements in future periods. There are numerous other income tax jurisdictions for which tax returns are not yet settled, none of which are individually significant. At this time, we cannot predict the outcome of any audit or related litigation. Based on the final resolution of tax examinations, judicial or administrative proceedings, changes in facts or law, expirations of statute of limitations in specific jurisdictions or other resolutions of, or changes in, tax positions, it is reasonably possible that unrecognized tax benefits for certain tax positions taken on previously filed tax returns may change materially from those represented on the financial statements as of June 27, 2015 . During the next 12 months, it is reasonably possible that such circumstances may occur that would have a material effect on previously unrecognized tax benefits. As a result, the total net amount of unrecognized tax benefits may decrease, which would reduce the provision for taxes on earnings by a range estimated at $2.0 million to $15.0 million . Tax Rate Changes and Exemptions in Israel Prior to fiscal year 2011, certain of our Israel subsidiaries had been granted Privileged Enterprise status under the Law for the Encouragement of Capital Investments (1959). Income derived from such entities was entitled to various tax benefits beginning in the year the subsidiary first generated taxable income. These benefits applied to an entity depending on certain elections. These benefits were generally granted with the understanding that cash dividends would not be distributed from the affected income. Should dividends be distributed out of tax exempt income, the subsidiary would be required to pay a 10% to 25% tax on the distribution. We do not currently intend to cause distribution of a dividend, which would involve additional tax liability in the foreseeable future; therefore, no provision has been made for such tax on post-acquisition earnings. In fiscal year 2011, Israel enacted new tax legislation that reduced the effective tax rate to 10% for 2011 and 2012, 7% for 2013 and 2014, and 6% thereafter for certain qualifying entities that elect to be taxed under the new legislation. This legislation was rescinded as announced in the Official Gazette on August 5, 2013. The new legislation enacted a 9% rate for certain qualifying entities that elect to be taxed under the new legislation. We have two entities that had previously elected the new tax legislation for years after fiscal 2011. For all other entities that do not qualify for this reduced rate, the tax rate has been increased from 25% to 26.5% . These rates were applicable to us as of June 30, 2013. In addition to the above benefits, we periodically apply for grants from the Office of the Chief Scientist in Israel's Ministry of Industry and Trade to assist us with development projects. The receipt of these grants subjects us to certain restrictions and pre-approval requirements, which may be conditioned by additional royalty payments with rights to transfer intellectual property and/or production abroad. All affected subsidiaries are currently in compliance with these conditions.

Post Employment Plans

Post Employment Plans	12 Months Ended
	Jun. 27, 2015
Postemployment Benefits [Abstract]
Post Employment Plans	POST EMPLOYMENT PLANS Defined Contribution Plans We have a qualified profit-sharing and investment plan under Section 401(k) of the IRS, which covers substantially all U.S. employees. Our contributions to the plan include an annual nondiscretionary contribution of 3% of an employee's eligible compensation and a discretionary contribution at the option of the Board of Directors. Additionally, we match a portion of employees' contributions. Our contributions to the plan were $24.6 million , $25.6 million , and $23.0 million in fiscal years 2015 , 2014 , and 2013 , respectively. We also have a defined contribution plan that covers Ireland employees. We contribute up to 18% of each participating employee’s annual eligible salary on a monthly basis. In connection with matching contributions under the Irish defined contribution plan, we recorded $0.7 million and $0.5 million of expense in fiscal year 2015 and from December 18, 2013 to June 28, 2014, respectively. For the defined contribution plans associated with the Omega acquisition, we pay contributions to pension insurance plans. From March 30, 2015 to June 27, 2015, we recorded $0.6 million in connection with matching contributions to the defined contribution plans. Pension and Postretirement Healthcare Benefit Plans We assumed the liability of two defined benefit plans (staff and executive plan) for employees based in Ireland with the Elan acquisition in 2013. These plans were closed to new entrants from March 31, 2009, and a defined contribution plan was established for employees in Ireland hired after this date. In January 2013, Elan ceased the future accrual of benefits to the active members of the defined benefit pension plans. Active members became deferred members of the defined benefit plans on January 31, 2013 and became members of the defined contribution plan on February 1, 2013. As of March 11, 2015, both plans (staff and executive plan) were merged and all plan assets and liabilities were transferred from the executive scheme to the staff scheme as a result of a plan combination. The value of plan assets and liabilities transferred were derived by reference to market conditions and assumptions as at March 11, 2015. In general, upon retirement, eligible Ireland employees in the staff plan are entitled to a pension calculated at 1/60 th (1/52 nd for the executive plan) of their final salary for each year of service, subject to a maximum of 40 years. The investments of the plans at June 27, 2015 consisted of units held in independently administered funds. In connection with the Omega acquisition, we also assumed the liability of a number of defined benefit plans as well as a postretirement healthcare plan. The defined benefit plans cover employees based primarily in the Netherlands, Germany, France, and Norway. Omega companies operate various pension plans across each country. Finally, we provide certain healthcare benefits to eligible U.S. employees and their dependents who meet certain age and service requirements when they retire. Generally, benefits are provided to eligible retirees after age 65 and to their dependents. Increases in our contribution for benefits are limited to increases in the Consumer Price Index. Additional healthcare cost increases are paid through participant contributions. We accrue the expected costs of such benefits during a portion of the employees’ years of service. The plan is not funded. Under current plan provisions, the plan is not eligible for any U.S. federal subsidy related to the Medicare Modernization Act of 2003 Part D Subsidy. The change in the projected benefit obligation and plan assets at June 27, 2015 and June 28, 2014 consisted of the following (in millions): Pension Benefits Other Benefits Fiscal Year 2015 * 2014 ** 2015 * 2014 Projected benefit obligation at beginning of period $ 89.0 $ — $ 4.6 $ 3.9 Acquisitions 70.4 84.4 1.0 — Service costs 0.9 — 0.3 0.5 Interest cost 2.4 1.4 0.2 0.3 Actuarial loss (6.8 ) 12.1 — — Benefits paid (0.9 ) (0.2 ) (0.1 ) (0.1 ) Settlements — (8.0 ) — — Foreign currency translation (14.7 ) (0.7 ) — — Benefit obligation at end of period $ 140.3 $ 89.0 $ 6.0 $ 4.6 Fair value of plan assets at beginning of period 99.6 — — — Acquisitions 49.9 107.3 — — Actual return on plan assets (1.0 ) 5.4 — — Benefits paid (0.1 ) (0.2 ) — — Settlements — (12.1 ) — — Employer contributions 2.4 — — — Foreign currency translation (17.5 ) (0.8 ) — — Fair value of plan assets at end of period $ 133.3 $ 99.6 $ — $ — Funded (unfunded) status recognized in other assets $ (7.0 ) $ 10.6 $ (6.0 ) $ (4.6 ) * Includes Omega activity from March 30, 2015 to June 27, 2015 . ** Includes Elan activity from December 18, 2013 to June 28, 2014 . Total defined benefit pension asset of $12.8 million is recorded in Other Assets and total defined benefit pension liability of $19.8 million is recorded in Other long term liabilities. The total accumulated benefit obligation for the defined benefit pension plans was $136.6 million and $89.0 million at June 27, 2015 and June 28, 2014 , respectively. As of June 27, 2015 and June 28, 2014, the unamortized net actuarial loss in AOCI for defined benefit pension was $9.2 million and $11.9 million , respectively. The estimated amount to be recognized from AOCI into net periodic cost during the next twelve months is $0.8 million . Total other benefits liability of $6.0 million is recorded in Other long term liabilities. The unfunded accumulated projected benefit obligation related to other benefits was $6.0 million and $4.6 million at June 27, 2015 and June 28, 2014 , respectively. As of June 27, 2015 and June 28, 2014 , an unrecognized actuarial gain of $0.1 million was included in OCI, net of tax. At June 27, 2015 , the total estimated future benefit payments to be paid by the plans for the next five years was approximately $6.5 million for pension benefits and $1.0 million for other benefits as follows (in millions): Payment Due Pension Benefits Other Benefits < 1 year $ 0.8 $ 0.1 1 - 2 years 1.1 0.2 3 - 4 years 1.2 0.2 4 - 5 years 1.5 0.2 5 - 6 years 1.9 0.3 > 6 years 13.4 1.8 The expected benefits to be paid are based on the same assumptions used to measure our benefit obligation at June 27, 2015 , including the expected future employee service. We expect to contribute $2.0 million to the defined benefit plans within the next year. Net periodic pension cost for fiscal years 2015 and 2014 consisted of the following (in millions): Pension Benefits Other Benefits Fiscal Year 2015 * 2014 ** 2015 * 2014 Service cost $ 0.9 $ — $ 0.3 $ 0.5 Interest cost 2.4 1.4 0.2 0.3 Expected return on plan assets (2.7 ) (1.9 ) — 0.6 Net actuarial loss 1.0 0.7 0.1 Net periodic pension cost $ 1.6 $ 0.2 $ 0.6 $ 1.4 * Includes Omega activity from March 30, 2015 to June 27, 2015 . ** Includes Elan activity from December 18, 2013 to June 28, 2014 . The weighted-average assumptions used to determine net periodic pension cost and benefit obligation as of June 27, 2015 and June 28, 2014 were: Pension Benefits Other Benefits Fiscal Year 2015 * 2014 ** 2015 * 2014 Discount rate 2.11 % 2.90 % 4.25 % 4.25 % Inflation 1.93 % 2.00 % Expected return on assets 2.85 % 2.92 % * Includes Omega activity from March 30, 2015 to June 27, 2015 . ** Includes Elan activity from December 18, 2013 to June 28, 2014 . The discount rate is based on market yields at the valuation date and chosen with reference to the yields available on high-quality corporate bonds, having regard to the duration of the plan's liabilities. As of June 27, 2015 , the expected weighted-average long-term rate of return on assets of 2.85% was calculated based on the assumptions of the following returns for each asset class: Equities 5.8 % Bonds 1.2 % Absolute return fund 3.5 % Insurance contracts 2.3 % Property 4.8 % The investment mix of the pension plans' assets is a blended asset allocation, with a diversified portfolio of shares listed and traded on recognized exchanges. As of June 27, 2015 , the current long-term asset allocation ranges of the trusts are as follows: Equities 10% - 20% Bonds 30% - 40% Absolute return 20% - 30% Insurance contracts 20% - 30% Property 0% - 10% Other 0% - 10% The purpose of the pension funds is to provide a flow of income for members in retirement. A flow of income delivered through fixed interest bonds provides a costly but close match to this objective. Equities are held within the portfolio as a means of reducing this cost, but holding equities creates a strategic risk because they give a very different pattern of return. Property investments are held to help diversify the portfolio. Investment risk is measured and monitored on an ongoing basis through annual liability measurements, periodic asset/liability studies, and investment portfolio reviews. The following table sets forth the fair value of the pension plan assets, as of June 27, 2015 (in millions): Quoted Prices in Active Markets Other Observable Inputs Unobservable Inputs (Level 1) (Level 2) (Level 3) Total Equities $ 16.7 $ — $ — $ 16.7 Bonds 49.7 — — 49.7 Absolute return fund 34.8 — — 34.8 Insurance contracts — — 31.5 31.5 Property — — 0.4 0.4 Other 0.2 — — 0.2 Total $ 101.4 $ — $ 31.9 $ 133.3 The following table sets forth the fair value of the pension plan assets, as of June 28, 2014 (in millions): Quoted Prices in Active Markets Other Observable Inputs Unobservable Inputs (Level 1) (Level 2) (Level 3) Total Equities $ 20.8 $ — $ — $ 20.8 Bonds 48.3 — — 48.3 Property — — 0.8 0.8 Other 0.1 — — 0.1 Absolute return fund 29.6 — — 29.6 Total $ 98.8 $ — $ 0.8 $ 99.6 For a discussion of the fair value levels and the valuation methodologies used to measure equities, bonds, and the absolute return fund, see Note 5 . The following table sets forth a summary of the changes in the fair value of the Level 3 pension plan assets, which were measured at fair value on a recurring basis for fiscal years 2015 and 2014 (in millions): Fiscal Year 2015 * 2014 ** Level 3 assets held at beginning of year $ 0.8 $ — Acquisitions 31.5 0.7 Unrealized gains (0.4 ) 0.1 Level 3 assets held at end of year $ 31.9 $ 0.8 * Includes Omega activity from March 30, 2015 to June 27, 2015 . ** Includes Elan activity from December 18, 2013 to June 28, 2014 . All properties in the fund are valued by independent valuation experts by forecasting the returns of the market at regular intervals. The inputs to the forecasts include gross national product growth, interest rates and inflation. The fair value of the insurance contracts is an estimate of the amount that would be received in an orderly sale to a market participant at the measurement date. The amount the plan would receive from the contract holder if the contracts were terminated is the primary input and is unobservable. The insurance contracts are therefore classified as Level 3 investments. Deferred Compensation Plans We have non-qualified plans related to deferred compensation and executive retention that allow certain employees and directors to defer compensation subject to specific requirements. Although the plans are not formally funded, we own insurance policies that had a cash surrender value of $32.7 million and $28.0 million at June 27, 2015 and June 28, 2014 , respectively, that are intended as a long-term funding source for these plans. The assets, which are recorded in Other non-current assets, are not a committed funding source and may, under certain circumstances, be subject to claims from creditors. The deferred compensation liability of $32.3 million and $28.1 million at June 27, 2015 and June 28, 2014 , respectively, was recorded in Other non-current liabilities. Israeli Post Employment Benefits Israeli labor laws and agreements require us to pay benefits to employees dismissed or retiring under certain circumstances. Severance pay is calculated on the basis of the most recent employee salary levels and the length of employee service. Our Israeli subsidiaries also provide retirement bonuses to certain managerial employees. We make regular deposits to retirement funds and purchase insurance policies to partially fund these liabilities. The deposited funds may be withdrawn only upon the fulfillment of requirements pursuant to Israeli labor laws. The liability related to these post employment benefits, which is recorded in Other non-current liabilities, was $21.3 million and $24.0 million at June 27, 2015 and June 28, 2014 , respectively. We funded $17.3 million and $19.3 million of this amount, which is recorded in Other non-current assets, as of June 27, 2015 and June 28, 2014 , respectively. Our contributions to the above plans were $1.0 million , $0.4 million , and $0.9 million for fiscal years 2015 , 2014 , and 2013 , respectively.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 27, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES We lease certain assets, principally warehouse facilities and computer equipment, under agreements that expire at various dates through calendar 2024. Certain leases contain provisions for renewal and purchase options and require us to pay various related expenses. Future non-cancelable minimum operating lease commitments are as follows (in millions): Due Amount < 1 year $ 45.6 1-2 years 37.7 2-3 years 32.3 3-4 years 21.2 5-6 years 15.4 > 6 years 20.3 Rent expense under all leases was $39.2 million , $34.5 million , and $27.6 million for fiscal years 2015 , 2014 , and 2013 , respectively. At June 27, 2015 we had non-cancelable purchase obligations totaling $429.9 million consisting of contractual commitments to purchase materials and services to support operations. The obligations are expected to be paid within one year. In addition to the discussions below, we have pending certain other legal actions and claims incurred in the normal course of business. We record accruals for such contingencies when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of June 27, 2015 , we have determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. We have accrued for these matters and will continue to monitor each related legal issue and adjust accruals for new information and further development. Other than what is disclosed below, we consider the litigation matters to be immaterial individually and in the aggregate. Texas Medicaid In June 2013, we received notices from the Office of the Attorney General for the State of Texas, of civil investigative demands to two of our affiliates, Perrigo Pharmaceuticals Company and Paddock Laboratories, LLC, for information under the Texas Medicaid Fraud Prevention Act relating to the submission of prices to Texas Medicaid in claims for reimbursement for drugs. We have cooperated with requests for information and are in the process of evaluating this and other information. While we do not know the full extent of our potential liability at this time and intend to vigorously defend against any claims, we could be subject to material penalties and damages. We established a contingency loss accrual of $15.0 million to cover potential settlement or other outcomes. Due to changes in circumstances, during the third quarter of fiscal year 2015, we accrued an additional $9.0 million . In addition, we recorded a receivable of $7.0 million representing the amount we expect to collect from the previous owners of Paddock Laboratories, LLC. We cannot predict whether we will obtain a settlement on terms we deem acceptable, or whether a settlement or potential liability for these claims will be higher than the amount recorded. Eltroxin During October and November 2011, nine applications to certify a class action lawsuit were filed in various courts in Israel related to Eltroxin, a prescription thyroid medication manufactured by a third party and distributed in Israel by Perrigo Israel Agencies Ltd. The respondents include Perrigo Israel Pharmaceuticals Ltd. and/or Perrigo Israel Agencies Ltd., the manufacturers of the product, and various healthcare providers who provide healthcare services as part of the compulsory healthcare system in Israel. One of the applications was dismissed and the remaining eight applications were consolidated into one application. The applications arose from the 2011 launch of a reformulated version of Eltroxin in Israel. The consolidated application generally alleges that the respondents (a) failed to timely inform patients, pharmacists and physicians about the change in the formulation; and (b) failed to inform physicians about the need to monitor patients taking the new formulation in order to confirm patients were receiving the appropriate dose of the drug. As a result, claimants allege they incurred the following damages: (a) purchases of product that otherwise would not have been made by patients had they been aware of the reformulation; (b) adverse events to some patients resulting from an imbalance of thyroid functions that could have been avoided; and (c) harm resulting from the patients' lack of informed consent prior to the use of the reformulation. Several hearings on whether or not to certify the consolidated application took place in December 2013 and January 2014. On May 17, 2015, the District Court certified the motion against Perrigo Israel Agencies Ltd. and dismissed it against the remaining respondents, including Perrigo Israel Pharmaceuticals Ltd. On June 16, 2015, Perrigo submitted a motion for permission to appeal the decision to certify to the Israeli Supreme Court together with a motion to stay the proceedings of the class action until the motion for permission to appeal is adjudicated. The decision whether to allow Perrigo to file an appeal has been transferred to a panel of three justices. Other than requiring Perrigo to file its statement of defense to the underlying proceedings, the underlying proceedings have been stayed pending a decision on the motion to appeal. At this stage, we cannot reasonably predict the outcome or the liability, if any, associated with these claims. Neot Hovav In March and June of 2007, lawsuits were filed by three separate groups against both the State of Israel and the Council of Neot Hovav in connection with waste disposal and pollution from several companies, including ours, that have operations in the Neot Hovav region of Israel. These lawsuits were subsequently consolidated into a single proceeding in the District Court of Beer-Sheva. The Council of Neot Hovav, in June 2008, and the State of Israel, in November 2008, asserted third-party claims against several companies, including ours. The pleadings allege a variety of personal injuries arising out of the alleged environmental pollution. Neither the plaintiffs nor the third-party claimants were required to specify a maximum amount of damages, but the pleadings alleged damages in excess of $72.5 million , subject to foreign currency fluctuations between the Israeli shekel and the U.S. dollar. On January 9, 2013, the District Court of Beer-Sheva ruled in our favor. On September 29, 2014, the Supreme Court of Israel affirmed the ruling of the District Court in our favor and as a result, the matter is now closed. Tysabri ® Product Liability Lawsuits Perrigo Company plc and collaborator Biogen Idec are co-defendants in product liability lawsuits arising out of the occurrence of Progressive Multifocal Leukoencephalopathy ("PML"), a serious brain infection, and serious adverse events, including deaths, which occurred in patients taking Tysabri ® . Perrigo Company plc and Biogen Idec will each be responsible for 50% of losses and expenses arising out of any Tysabri ® product liability claims. While these lawsuits will be vigorously defended, management cannot predict how these cases will be resolved. Adverse results in one or more of these lawsuits could result in substantial judgments against us.

Collaboration Agreements

Collaboration Agreements	12 Months Ended
	Jun. 27, 2015
Collaboration Agreements [Abstract]
Collaboration Agreements [Text Block]	We actively collaborate with other pharmaceutical companies to develop, manufacture and market certain products or groups of products. These types of agreements are common in the pharmaceutical industry. We may choose to enter into these types of agreements to, among other things, leverage our or others’ scientific research and development expertise or utilize our extensive marketing and distribution resources. Terms of the various collaboration agreements may require us to make or receive milestone payments upon the achievement of certain product research and development objectives and pay or receive royalties on the future sale, if any, of commercial products resulting from the collaboration. Milestone and up-front payments made are generally recorded in research and development expense if the payments relate to drug candidates that have not yet received regulatory approval. Milestone and up-front payments made related to approved drugs will generally be capitalized and amortized to cost of goods sold over the economic life of the product. Royalties received are generally reflected as revenues, and royalties paid are generally reflected as cost of goods sold. We enter into a number of collaboration agreements in the ordinary course of business. Although we do not consider these arrangements to be material, the following is a brief description of notable agreements entered into during fiscal years 2015 , 2014 , and 2013 . Fiscal Year 2015 In May 2015, we entered into a development agreement wherein we transferred the ownership rights to two pharmaceutical products to a clinical stage development company to fund and conduct development activities for the products. We do not expect to incur any expense related to the development of either product. If the products are approved by the FDA, we will execute a buy-back agreement to purchase each product for a multiple of the development costs incurred. Based on the initial development budget for each product, the estimated purchase price for both products is approximately $78.0 million . If development costs exceed the initial budgeted amounts, the purchase price will increase but will not exceed approximately $105.0 million . If the products are approved by the FDA and we purchase the products, we estimate the acquisitions will occur in 2019 and 2020. In May 2015, we entered into an agreement with a clinical stage biotechnology company for the development of two specialty pharmaceutical products. We paid $18.0 million for an option to acquire the two products after the completion of Phase 3 clinical trials for one of the products. The $18.0 million fee is reported in research and development expense. If we exercise the purchase option to acquire both products, we would expect to make contingent payments if we obtain regulatory approval and achieve certain sales milestones. The contingent milestone payments could total $30.0 million in aggregate. If we do not exercise the purchase option for the first product, we may elect to acquire only the second product and would be subject to potential milestone payments up to $17.5 million . We will also be obligated to make certain royalty payments over periods ranging from seven to ten years from the launch of each product. In December 2014, we entered into a collaboration agreement with a clinical stage biotechnology company, pursuant to which the parties will collaborate in the ongoing development of a topical OTC drug product. We will provide assistance including non-clinical, clinical, and manufacturing activities in support of an NDA submission to the FDA. As part of the agreement, we paid $10.0 million for an exclusive option to purchase and license certain assets as specified in separate asset purchase and license agreements. The $10.0 million fee is reported in Research and development expense. If the product is successful in Phase 3 clinical trials, we are required to make an additional option payment of $5.0 million . If we exercise our purchase option, we will be required to pay a purchase price of $10.0 million as well as certain contingent milestone payments, which could total $50.0 million in aggregate. Fiscal Year 2014 As a result of the Elan acquisition, we acquired a collaborative arrangement with Transition related to the joint development and commercialization of ELND005 (Scyllo-inositol). During the third quarter of fiscal year 2014, we announced that we had entered into an agreement with Transition to progress the clinical development of ELND005 in a number of important indications including Alzheimer's disease, bipolar disorder and Down syndrome. As part of the agreement, Transition acquired all of the shares of a wholly owned, indirect Irish subsidiary of Perrigo Company plc, which had previously been responsible for carrying out all development activities associated with ELND005. Upon closing on February 28, 2014, Transition is solely responsible for all ongoing development activities and costs associated with ELND005. We are eligible to receive milestone payments ranging from $10.0 million to $15.0 million should ELND005 achieve approval of the ANDA as well as specific worldwide net sales hurdles. If a product were to be commercialized, we would be entitled to receive a royalty of 6.5% of net sales for the life of the product. Fiscal Year 2013 In November 2012, we entered into a joint development agreement with another generic pharmaceutical company pursuant to which we are to provide research and development and future manufacturing services for a generic version of a specified prescription pharmaceutical. We are entitled to receive various milestone payments throughout the development period, which will be recognized in accordance with the milestone method. During fiscal year 2013, we recognized revenue of $0.8 million upon completion of a milestone under this agreement. We are entitled to receive additional individual milestone payments ranging from $0.5 million to $2.0 million for achieving other specified milestones, including but not limited to completion of bioequivalence studies, FDA acceptance of the ANDA, and FDA approval of the ANDA. If the product is approved, we may receive combined total milestone payments ranging from $3.8 million to $5.5 million depending upon various market conditions at the time of generic market formation. Also in accordance with the agreement, the parties will share in development costs and future profits associated with the manufacture and sale of the generic prescription pharmaceutical product. Additional future milestone payments and receipts related to agreements not specifically discussed above are not material.

Restructuring Charges

Restructuring Charges	12 Months Ended
	Jun. 27, 2015
Restructuring Charges [Abstract]
Restructuring Charges	RESTRUCTURING CHARGES We periodically take action to reduce redundant expenses and improve operating efficiencies, typically in connection with business acquisitions. The following reflects our restructuring activity for fiscal years 2015 , 2014 , and 2013 (in millions): Balance at June 30, 2012 $ 1.7 Additional charges 2.9 Payments (1.7 ) Balance at June 29, 2013 2.9 Additional charges 47.0 Payments (28.7 ) Non-cash adjustments (4.8 ) Balance at June 28, 2014 16.4 Additional charges 5.1 Payments (18.5 ) Non-cash adjustments (1.4 ) Balance at June 27, 2015 $ 1.6 Restructuring activity includes severance, lease exit costs, and asset impairments. The charges during fiscal year 2014 were due primarily to Elan. There were no other material restructuring programs in any of the years presented, and the remaining charges did not materially impact any one reportable segment. All charges are shown in restructuring expense on our Consolidated Statements of Operations. All of the remaining liability for employee severance benefits will be paid within the next year, while cash expenditures related to the remaining liability for lease exit costs will be incurred over the remaining terms of the applicable leases. Asset impairments are non-cash charges recorded when the carrying amount of a discontinued fixed asset exceeds its fair value.

Segment and Geographic Informat

Segment and Geographic Information	12 Months Ended
	Jun. 27, 2015
Segments and Geographic Information [Abstract]
Segment and Geographic Information	SEGMENT AND GEOGRAPHIC INFORMATION As discussed in Note 1 , in conjunction with the Omega acquisition, we changed our reporting segments to better align with our new organizational structure. This structure is consistent with the way our chief operating decision maker makes operating decisions, allocates resources and manages the growth and profitability of the business. Operating segments with similar economic characteristics, including long-term profitability, nature of the products sold and production processes, distribution methods, and classes of customers, are aggregated as reportable segments. We generated third-party net sales in the following geographic locations (1) during each of the fiscal years presented (in millions): 2015 2014 2013 Ireland $ 344.0 $ 146.7 $ — U.S. 3,303.6 3,291.6 2,978.1 Europe 613.6 217.2 164.0 All other countries (2) 342.7 405.3 397.7 $ 4,603.9 $ 4,060.8 $ 3,539.8 (1) We attribute net sales to countries based on sales location. (2) Includes sales generated primarily in Israel, Mexico, Australia, and Canada. The net book value of property and equipment at June 27, 2015 and June 28, 2014 was as follows (in millions): June 27, June 28, Ireland $ 1.4 $ 2.0 U.S. 558.6 530.7 Europe 153.8 31.7 Israel 119.8 119.6 All other countries 98.8 95.9 $ 932.4 $ 779.9 Sales to Walmart accounted for 15% of consolidated net sales in fiscal year 2015 and 19% in both fiscal year 2014 and fiscal year 2013 . Sales to Walmart are reported primarily in our CHC segment. Below is a summary of our results by reporting segment for fiscal years 2015 , 2014 , and 2013 . Prior periods have been restated to conform to our new reporting segments (in millions). CHC BCH (1) Rx Pharmaceut-icals Specialty Sciences (2) Other Unallocated expenses Total (3) Fiscal Year 2015 Net sales $ 2,750.0 $ 401.1 $ 1,001.1 $ 344.0 $ 107.7 $ — $ 4,603.9 Operating income (loss) $ 405.6 $ 26.6 $ 373.9 $ 36.3 $ 26.8 $ (121.5 ) $ 747.7 Operating income % 14.7 % 6.6 % 37.3 % 10.6 % 24.9 % — % 16.2 % Total assets $ 4,381.6 $ 6,441.1 $ 2,667.9 $ 5,979.0 $ 251.0 $ — $ 19,720.6 Capital expenditures $ 80.5 $ 3.6 $ 42.9 $ 0.5 $ 6.4 $ 3.1 $ 137.0 Property and equip, net $ 600.0 $ 122.5 $ 124.1 $ — $ 85.8 $ — $ 932.4 Depreciation/amortization $ 123.2 $ 38.3 $ 85.1 $ 291.6 $ 10.6 $ — $ 548.8 Fiscal Year 2014 Net sales $ 2,849.4 $ — $ 927.1 $ 146.7 $ 137.6 $ — $ 4,060.8 Operating income (loss) $ 413.1 $ — $ 349.8 $ (68.6 ) $ 46.1 $ (173.4 ) $ 567.0 Operating income (loss) % 14.5 % — % 37.7 % (46.7 )% 33.5 % — % 14.0 % Total assets $ 4,931.0 $ — $ 2,537.2 $ 6,096.6 $ 288.0 $ — $ 13,852.8 Capital expenditures $ 128.3 $ — $ 32.9 $ — $ 10.4 $ — $ 171.6 Property and equip, net $ 577.3 $ — $ 104.8 $ 2.1 $ 95.7 $ — $ 779.9 Depreciation/amortization $ 106.6 $ — $ 86.5 154.4 $ 11.4 $ — $ 358.9 Fiscal Year 2013 Net sales $ 2,671.0 $ — $ 709.5 — $ 159.3 $ — $ 3,539.8 Operating income (loss) $ 401.8 $ — $ 263.2 — $ 48.9 $ (34.7 ) $ 679.1 Operating income % 15.0 % — % 37.1 % — % 30.7 % — % 19.2 % Total assets $ 3,447.5 $ — $ 1,604.9 — $ 284.5 $ — $ 5,336.9 Capital expenditures $ 97.1 $ — $ 17.7 — $ 17.3 $ — $ 132.2 Property and equip, net $ 508.0 $ — $ 80.8 — $ 92.7 $ — $ 681.4 Depreciation/amortization $ 96.1 $ — $ 54.9 — $ 9.1 $ — $ 160.2 (1) BCH only includes activity from March 30, 2015 to June 27, 2015. (2) Specialty Sciences only includes activity from December 18, 2013 to June 28, 2014 for fiscal year 2014. (3) Amounts may not cross-foot due to rounding. The following is a summary of our net sales by category by fiscal year (in millions): 2015 2014 2013 CHC Cough/Cold/Allergy/Sinus (1) $ 486.2 $ 510.1 $ 500.6 Analgesics (1) 441.7 504.0 536.0 Gastrointestinal (1) 395.3 400.1 388.8 Infant nutritionals 383.9 374.8 350.1 Smoking cessation 299.4 236.8 193.2 Vitamins, minerals and dietary supplements 185.6 176.9 158.3 Animal health 156.9 178.0 123.2 Other CHC (1) , (2) 335.9 468.7 420.9 Total CHC 2,684.9 2,849.4 2,671.1 BCH branded OTC products 401.2 — — Generic prescription drugs 1,066.1 927.1 709.5 Tysabri ® royalties 344.0 146.7 — Active pharmaceutical ingredients 107.7 137.6 159.3 Total net sales $ 4,603.9 $ 4,060.8 $ 3,539.8 (1) Includes sales from our OTC contract manufacturing business. (2) Consists primarily of feminine hygiene, diabetes care, dermatological care, diagnostic products, and other miscellaneous or otherwise uncategorized product lines and markets none of which is greater than 10% of the CHC segment.

Quarterly Financial Data

Quarterly Financial Data	12 Months Ended
	Jun. 27, 2015
Quarterly Financial Data [Abstract]
Quarterly Financial Data (unaudited) [Text Block]	QUARTERLY FINANCIAL DATA (unaudited) The following table presents unaudited quarterly consolidated operating results for each of our last eight fiscal quarters. The information below has been prepared on a basis consistent with our audited consolidated financial statements (in millions, except per share amounts). Fiscal Year 2015 First Quarter (2) Second Quarter (3) Third Quarter (4) Fourth Quarter (5) Net sales $ 951.5 $ 1,071.7 $ 1,049.1 $ 1,531.6 Gross profit $ 321.8 $ 383.8 $ 378.8 $ 628.1 Net income (loss) $ 96.3 $ 70.2 $ (94.9 ) $ 56.4 Earnings (loss) per share (1) : Basic $ 0.72 $ 0.52 $ (0.67 ) $ 0.39 Diluted $ 0.72 $ 0.51 $ (0.67 ) $ 0.38 Weighted average shares outstanding Basic 133.9 136.3 140.8 146.3 Diluted 134.4 136.8 140.8 146.8 (1) The sum of individual per share amounts may not equal due to rounding. (2) Includes acquisition costs of $1.1 million , restructuring charges of $1.7 million , equity method investment losses of $3.1 million , and a $1.2 million investment distribution . (3) Includes restructuring charges of $2.4 million , an R&D payment made in connection with a collaborative agreement of $10.0 million , Omega transaction expenses of $17.8 million , losses on derivatives associated with the Omega acquisition of $64.7 million , equity method investment losses of $3.0 million , income from transfer of rights agreement of $12.5 million , and $9.6 million loss on extinguishment of debt. (4) Includes acquisition costs totaling $2.0 million , an increase in litigation accrual of $2.0 million , restructuring charges of $1.1 million , Omega financing fees of $18.6 million , and losses on derivatives associated with the Omega acquisition of $258.2 million . (5) Includes legal and consulting fees related to our defense against Mylan N.V. of $13.4 million , acquisition costs of $18.5 million , goodwill impairment of $6.8 million , losses on derivatives terminated with extinguishment of associated debt and associated with hedging the pending GSK acquisition of $5.5 million , losses on equity method investments of $3.5 million , an inventory step up related to the Omega acquisition totaling $15.6 million , and an initial payment made in connection with an R&D agreement of $18.0 million . Fiscal Year 2014 First Quarter (2) Second Quarter (3) Third Quarter (4) Fourth Quarter (5) Net sales $ 933.4 $ 979.0 $ 1,004.2 $ 1,144.2 Gross profit $ 356.3 $ 360.7 $ 315.0 $ 415.7 Net income (loss) $ 111.4 $ (86.0 ) $ 48.1 $ 131.7 Earnings (loss) per share (1) : Basic $ 1.18 $ (0.87 ) $ 0.36 $ 0.98 Diluted $ 1.18 $ (0.87 ) $ 0.36 $ 0.98 Weighted average shares outstanding Basic 94.2 98.7 133.7 133.8 Diluted 94.7 98.7 134.3 134.3 (1) The sum of individual per share amounts may not equal due to rounding. (2) Includes Elan transactions costs of $12.0 million , litigation settlement of $2.5 million , and acquisition costs of $1.9 million . (3) Includes loss on extinguishment of debt of $165.8 million , Elan transaction costs of $103.2 million , restructuring charges totaling $14.9 million , write-off of contingent consideration of $4.9 million related to Fera, and write-off of IPR&D totaling $6.0 million related to Paddock and Rosemont. (4) Includes restructuring charges totaling $19.5 million , write-up of contingent consideration of $5.8 million related to Fera, and $3.2 million of Elan transaction costs . (5) Includes restructuring charges totaling $10.5 million and a loss contingency of $15.0 million related to Texas Medicaid.

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Jun. 27, 2015
Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	VALUATION AND QUALIFYING ACCOUNTS PERRIGO COMPANY PLC (in millions) Fiscal Year 2015 2014 2013 Balance at beginning of period $ 2.7 $ 2.1 $ 2.6 Net bad debt expenses 0.6 (0.5 ) — Additions/(deductions) (1) (0.9 ) 1.1 (0.4 ) Balance at end of period $ 2.4 $ 2.7 $ 2.1 (1) Uncollectible accounts written off, net of recoveries. Also includes effects of changes in foreign exchange rates.

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	12 Months Ended
	Jun. 27, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments and Hedging Activities Disclosure [Text Block]	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows: Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing. Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses. All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes. All of our designated derivatives were classified as cash flow hedges as of June 27, 2015 and June 28, 2014 . Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. Any ineffective portion of the change in fair value of the derivative is immediately recognized in earnings, recorded in Other expense, net. All of our designated derivatives are assessed for hedge effectiveness quarterly. We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item. Interest Rate Swaps and Treasury Locks Interest rate swap agreements are contracts to exchange floating rate for fixed rate payments (or vice versa) over the life of the agreement without the exchange of the underlying notional amounts. The notional amounts of the interest rate swap agreements are used to measure interest to be paid or received and do not represent the amount of exposure to credit loss. The differential paid or received on the interest rate swap agreements is recognized as an adjustment to interest expense. All of our interest rate swaps qualify for hedge accounting treatment. We had a $300.0 million term loan with floating interest rates priced off the LIBOR yield curve, which was repaid during fiscal year 2015, as described in Note 8 . As a result of the term loan repayment on June 24, 2015, the forward interest rate swap agreements with a notional amount totaling $240.0 million that were in place to hedge the change in the LIBOR rate were terminated as well. We recorded a loss of $3.6 million in Other expense, net for the amount remaining in AOCI when the hedge was terminated. In connection with the Omega acquisition, we assumed a $20.0 million private placement note. We also assumed an interest rate swap agreement with a notional amount totaling $20.0 million that was in place to hedge the cross currency exchange differences between the U.S. dollar and the euro on the above-mentioned debt. On May 29, 2015, we repaid the loan and the interest rate swap. Because the interest rate swap was recorded at fair market value on the date of termination, no gain or loss was recorded. For more information on the acquired debt and termination, see Note 8 . Also in connection with the Omega acquisition, we assumed €500.0 million ( $544.5 million ) of debt under Omega's revolving credit facility, as well as an interest rate swap agreement with a notional amount totaling €135.0 million ( $147.0 million ) that was in place to hedge the change in the floating rate on that credit facility. On April 8, 2015, we repaid the loan and terminated the interest rate swap. Because the interest rate swap was recorded at fair market value on the date of termination, no gain or loss was recorded. For more information on the acquired debt and termination, see Note 8 . During the second quarter of fiscal year 2015, we entered into forward interest rate swaps and treasury locks (together "Rate Locks") to hedge against changes in the interest rates between the date the Rate Locks were entered into and the date of the issuance of our 2014 Bonds, discussed in Note 8 . These Rate Locks were designated as cash flow hedges of expected future debt issuances with a notional amount totaling $750.0 million . The Rate Locks were settled upon the issuance of an aggregate $1.6 billion principal amount of our 2014 Bonds on December 2, 2014 for a cumulative after-tax loss of $5.8 million in OCI after recording $1.1 million of ineffectiveness to Other Expense, net. During the first quarter of fiscal year 2014, we entered into forward interest rate swap agreements to hedge against changes in the benchmark interest rate between the date the swap agreements were entered into and the date of the issuance of our 2013 Bonds, discussed in Note 8 . These swaps were designated as cash flow hedges of expected future debt issuances with a notional amount totaling $725.0 million . The interest rate swaps were settled upon the issuance of an aggregate $2.3 billion principal amount of our 2013 Bonds on December 18, 2013 for a cumulative after-tax loss of $12.8 million in OCI after recording $0.5 million of ineffectiveness to Other Expense, net. In addition, due to the retirement of the underlying private placement senior notes (described in Note 8 as "the Private Placement Notes") on December 23, 2013, we wrote off the amounts remaining in AOCI associated with the cash flow hedges related to the Private Placement Notes, resulting in an after-tax loss of $2.6 million recorded to Other expense, net. Foreign Currency Derivatives We enter into foreign currency forward contracts, both designated and non-designated, in order to manage the impact of foreign exchange fluctuations on expected future purchases and related payables denominated in a foreign currency, as well as to hedge the impact of foreign exchange fluctuations on expected future sales and related receivables denominated in a foreign currency. Both types of forward contracts have a maximum maturity date of 15 months. The total notional amount for these contracts was $452.3 million and $228.5 million as of June 27, 2015 and June 28, 2014 , respectively. In June 2015, in order to economically hedge the foreign currency exposure associated with the planned payment of the euro-denominated purchase price of the GSK product acquisition discussed in Note 2 , we entered into a non-designated option contract to protect against a strengthening of the euro relative to the U.S. dollar. We recorded losses of $1.9 million for the change in fair value of the option contract during fiscal year 2015 in Other expense, net. Because these derivatives were economically hedging a future acquisition, the cash outflow associated with their settlement is shown as an investing activity on the Consolidated Statements of Cash Flows. In November 2014, in order to economically hedge the foreign currency exposure associated with the planned payment of the euro-denominated purchase price of Omega, we entered into non-designated option contracts with a total notional amount of €2.0 billion . The option contracts settled in December 2014, resulting in a loss of $26.4 million . The option contracts were replaced with non-designated forward contracts that matured during the third quarter of fiscal year 2015. We recorded losses of $298.1 million during fiscal year 2015 related to the settlement of the forward contracts. Both losses were recorded primarily in Other expense, net. The losses on the derivatives due to changes in the euro to U.S. dollar exchange rates were economically offset at closing in the final settlement of the euro-denominated Omega purchase price. Because these derivatives were economically hedging a future acquisition, the cash outflow associated with their settlement is shown as an investing activity on the Consolidated Statements of Cash Flows. Fair Value Hedges During the first quarter of fiscal year 2014, we entered into three pay-floating interest rate swaps with a total notional amount of $425.0 million to hedge changes in the fair value of our Private Placement Notes from fluctuations in interest rates. These swaps were designated and qualified as fair value hedges of our fixed rate debt. Accordingly, the gain or loss recorded on the pay-floating interest rate swaps was directly offset by the change in fair value of the underlying debt. Both the derivative instrument and the underlying debt were adjusted to market value at the end of each period with any resulting gain or loss recorded in Other expense, net . The hedge was terminated in the second quarter of fiscal year 2014 due to the retirement of the underlying notes. Effects of Derivatives on the Financial Statements The below tables indicate the effects of all of our derivative instruments on our consolidated financial statements at June 27, 2015 and June 28, 2014 . All amounts exclude income tax effects and are presented in millions. The balance sheet location and gross fair value of our outstanding derivative instruments were as follows: Asset Derivatives Fair Value Balance Sheet Location June 27, June 28, Designated derivatives: Foreign currency forward contracts Other current assets $ 3.3 $ 2.8 Total designated derivatives $ 3.3 $ 2.8 Non-designated derivatives: Foreign currency forward contracts Other current assets $ 9.1 $ 0.3 Total non-designated derivatives $ 9.1 $ 0.3 Liability Derivatives Fair Value Balance Sheet Location June 27, June 28, Designated derivatives: Foreign currency forward contracts Accrued liabilities $ 2.0 $ 0.7 Interest rate swap agreements Other non-current liabilities — 8.3 Total designated derivatives $ 2.0 $ 9.0 Non-designated derivatives: Foreign currency forward contracts Accrued liabilities $ 2.6 $ 0.1 Total non-designated derivatives $ 2.6 $ 0.1 The gains (losses) recognized in OCI for the effective portion of our designated cash flow hedges were as follows: Amount of Gain/(Loss) Recorded in OCI Designated Cash Flow Hedges June 27, June 28, Treasury locks $ (2.7 ) $ — Interest rate swap agreements (10.1 ) 7.2 Foreign currency forward contracts (7.7 ) 15.1 $ (20.5 ) $ 22.3 The gains (losses) reclassified from AOCI into earnings for the effective portion of our designated cash flow hedges were as follows: Amount of Gain/(Loss) Reclassified from AOCI to Income Designated Cash Flow Hedges Income Statement Location June 27, June 28, Treasury locks Interest expense, net $ (0.1 ) $ 0.2 Interest rate swap agreements Interest expense, net (16.4 ) 3.9 Foreign currency forward contracts Net sales 2.0 (2.5 ) Cost of sales (4.2 ) (6.3 ) Interest expense, net — (0.2 ) Other expense, net (4.5 ) (2.2 ) $ (23.2 ) $ (7.1 ) We expect to reclassify a $1.2 million loss out of AOCI into earnings during the next 12 months. The gains (losses) recognized against earnings for the ineffective portion of our designated cash flow hedges were as follows: Amount of Gain/(Loss) Recognized in Income Designated Cash Flow Hedges Income Statement Location June 27, June 28, Treasury locks Other expense, net $ (0.4 ) $ 2.3 Interest rate swap agreements Other expense, net (0.7 ) (5.4 ) Foreign currency forward contracts Net sales (0.1 ) (0.1 ) Cost of sales 0.2 0.3 Total $ (1.0 ) $ (2.9 ) The effects of our fair value hedges on the Consolidated Statements of Operations were as follows: Amount of Gain/(Loss) Recognized in Income Designated Fair Value Hedges Income Statement Location June 27, June 28, Interest rate swap agreements Other expense, net $ — $ 0.9 Fixed-rate debt Other expense, net — (4.1 ) Net hedge $ — $ (3.2 ) The effects of our non-designated derivatives on the Consolidated Statements of Operations were as follows: Amount of Gain/(Loss) Recognized in Income Non-Designated Derivatives Income Statement Location June 27, June 28, Foreign currency forward contracts Other expense, net $ (295.4 ) $ (0.1 ) Interest expense, net (3.4 ) — Foreign exchange option contracts Other expense, net (26.4 ) — Total $ (325.2 ) $ (0.1 )
Derivatives, Policy [Policy Text Block]	Derivative Instruments We record derivative instruments (including certain derivative instruments embedded in other contracts) on the balance sheet on a gross basis as either an asset or liability measured at fair value. See Note 7 for a table indicating where each component is recorded on the Consolidated Balance Sheets. Additionally, changes in a derivative's fair value, which are measured at the end of each period, is recognized in earnings unless specific hedge accounting criteria are met. If hedge accounting criteria are met for cash flow hedges, the changes in a derivative’s fair value are recorded in shareholders’ equity as a component of other comprehensive income ("OCI"), net of tax. These deferred gains and losses are recognized in income in the period in which the hedged item and hedging instrument affect earnings. Any ineffective portion of the change in fair value is immediately recognized in earnings. We are exposed to credit loss in the event of nonperformance by the counterparties on derivative contracts. It is our policy to manage our credit risk on these transactions by dealing only with financial institutions having a long-term credit rating of "A" or better and by distributing the contracts among several financial institutions to diversify credit concentration risk. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of the forward currency exchange contracts at June 27, 2015 and June 28, 2014 was 15 months. We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows: Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing. Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses. All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes. All of our designated derivatives were classified as cash flow hedges as of June 27, 2015 and June 28, 2014 . Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. Any ineffective portion of the change in fair value of the derivative is immediately recognized in earnings, recorded in Other expense, net. All of our designated derivatives are assessed for hedge effectiveness quarterly. We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.

Summary of Signifcant Account28

Summary of Signifcant Accounting Policies (Policies)	12 Months Ended
	Jun. 27, 2015
Summary of Significant Accounting Policies [Abstract]
Basis of Presentation [Policy Text Block]	Basis of Presentation Our current fiscal year is a 52 or 53 week period, which ends the Saturday on or about June 30. Fiscal years 2015 , 2014 , and 2013 were comprised of 52 weeks and ended on June 27, 2015 , June 28, 2014 , and June 29, 2013 , respectively. In fiscal year 2015, we announced that our fiscal year-end will begin on January 1 and end on December 31 of each year, starting on January 1, 2016. Fiscal year 2015, which ended on June 27, 2015, will be followed by a transition period from June 28, 2015 to December 31, 2015. We plan to disclose the results of the transition period on a Form 10-KT transition report. Subsequent to June 27, 2015, we will continue to close our books on the Saturday closest to end of the quarter, with the last quarter ending on December 31. This practice will only affect the quarterly reporting periods and not the annual reporting periods.
Segment Reporting, Policy [Policy Text Block]	Segment Reporting Change In conjunction with the Omega acquisition, we changed our reporting segments to better align with our new organizational structure. These organizational changes were made to optimize our structure to better serve our customers and to reflect the way in which our chief operating decision maker reviews our operating results and allocates resources. The changes in our reporting segments are as follows: • Consumer Healthcare ( "CHC" ), which includes our former Consumer Healthcare segment, former Nutritionals segment, and our former Israel Pharmaceuticals and Diagnostics business, which was previously reported in our “Other” segment; • Branded Consumer Healthcare ( "BCH" ), which consists of the newly acquired Omega business; • Prescription Pharmaceuticals ( " Rx Pharmaceuticals " ), which continues to include the Rx Pharmaceuticals business; • Specialty Sciences , which is comprised primarily of assets focused on the treatment of multiple sclerosis(Tysabri ® ). In addition, we have an Other reporting segment that consists of our Active Pharmaceutical Ingredients ("API") business, which does not meet the quantitative threshold required to be a separately reportable segment. All historical segment information has been reclassified to conform to this new reporting segment presentation. Financial information related to our business segments and geographic locations can be found in Item 8. Note 17 .
Principles of Consolidation [Policy Text Block]	Principles of Consolidation The consolidated financial statements include our accounts and accounts of all majority-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
Consolidation, Variable Interest Entity, Policy [Policy Text Block]	Unconsolidated Variable Interest Entities We have R&D arrangements with certain biotechnology companies that we determined to be variable interest entities ("VIEs"). We did not consolidate the VIEs in our financial statements because we lack the power to direct the activities that most significantly impact their economic performance and thus are not considered the primary beneficiaries of these entities. These arrangements provide us with certain rights and obligations to purchase product candidates from the VIEs, dependent upon the outcome of the development activities.
Use of Estimates [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with U.S. generally accepted accounting principles ("GAAP") requires management to make estimates and assumptions, which affect the reported earnings, financial position and various disclosures. Although the estimates are considered reasonable, actual results could differ from the estimates.
Non-U.S. Operations [Policy Text Block]	Non-U.S. Operations We translate our non-U.S. dollar-denominated operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in the cumulative translation account, a component of Accumulated Other Comprehensive Income ("AOCI"). Gains or losses from foreign currency transactions are included in Other expense, net.
Revenues [Policy Text Block]	Revenues We generally record revenues from product sales when the goods are shipped to the customer. For customers with Free on Board ("FOB") destination terms, a provision is recorded to exclude shipments estimated to be in-transit to these customers at the end of the reporting period. A sales allowance is recorded and accounts receivable are reduced as revenues are recognized for estimated losses on credit sales due to customer claims for discounts, price discrepancies, returned goods and other items. Revenue is also reduced for any contractual customer program arrangements and related liabilities are recorded concurrently. We maintain customer-related accruals and allowances that consist primarily of chargebacks, rebates, sales returns, shelf stock allowances, administrative fees and other incentive programs. Some of these adjustments relate specifically to the Rx Pharmaceuticals segment while others relate only to the CHC and BCH segments. Certain of these accruals and allowances are recorded in the balance sheet as current liabilities and others are recorded as a reduction in accounts receivable. Changes in these estimates and assumptions related to customer programs may result in additional accruals or allowances. Customer-related accruals and allowances were $434.9 million at June 27, 2015 and $318.0 million at June 28, 2014 . Revenues from service and royalty arrangements, including revenues from collaborative agreements, consist primarily of royalty payments, payments for research and development services, up-front fees and milestone payments. If an arrangement requires the delivery or performance of multiple deliverables or service elements, we determine whether the individual elements represent separate units of accounting. If the separate elements represent separate units of accounting, we recognize the revenue associated with each element separately and revenue is allocated among elements based on their relative selling prices. If the elements within a multiple deliverable arrangement are not considered separate units of accounting, the delivery of an individual element is considered not to have occurred if there are undelivered elements that are considered essential to the arrangement. To the extent such arrangements contain refund clauses triggered by non-performance or other adverse circumstances, revenue is not recognized until all contractual obligations are satisfied. Non-refundable up-front fees are deferred and amortized to revenue over the related performance period. We estimate the performance period based on the specific terms of each collaborative agreement. Revenue associated with research and development services is recognized on a proportional performance basis over the period that we perform the related activities under the terms of the agreement. Revenue resulting from the achievement of contingent milestone events stipulated in the agreements is recognized when the milestone is achieved. Milestones are based upon the occurrence of a substantive element specified in the contract. Tysabri ® represented 96% of our fiscal year 2015 royalty revenue. Shipping and handling costs billed to customers are included in net sales. Conversely, shipping and handling expenses we incur are included in cost of sales.
Cash and Cash Equivalents [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents consist primarily of demand deposits and other short-term investments with maturities of three months or less at the date of purchase. The carrying amount of cash and cash equivalents approximates its fair value.
Available for sale [Policy Text Block]	Available for Sale Investments We determine the appropriate classification of securities as held-to-maturity, available-for-sale, or trading. The classification depends on the purpose for which the financial assets were acquired. Marketable equity securities are classified as available-for-sale. These securities are carried at fair value with unrealized gains and losses included in AOCI. The assessment for impairment of marketable securities classified as available-for-sale is based on established financial methodologies, including quoted market prices for publicly traded securities. If we determine that a loss in the value of an investment is other than temporary, the investment is written down to its estimated fair value. Any such losses are recorded in Other expense, net. See Note 6 for more information on our available for sale investments.
Cost Method Investments, Policy [Policy Text Block]	Cost Method Investments Non-marketable equity securities are carried at cost, less any write down for impairments, and are adjusted for impairment based on methodologies, an assessment of the impact of general private equity market conditions, and discounted projected future cash flows. Non-marketable equity securities are recorded in Other non-current assets on the Consolidated Balance Sheets. See Note 6 for more information on our cost method investments.
Equity Method Investments, Policy [Policy Text Block]	Equity Method Investments The equity method of accounting is used for unconsolidated entities over which we have significant influence; generally this represents ownership interests of at least 20% and not more than 50%. Under the equity method of accounting, we record the investments at carrying value and adjust for a proportionate share of the profits and losses of these entities each period. We evaluate our equity method investments for recoverability. If we determine that a loss in the value of an investment is other than temporary, the investment is written down to its estimated fair value. Any such losses are recorded in Other expense, net. Evaluations of recoverability are based primarily on projected cash flows. Due to uncertainties in the estimation process, actual results could differ from such estimates. Equity method investments are recorded in Other non-current assets on the Consolidated Balance Sheets. See Note 6 for more information on our equity method investments.
Derivatives, Policy [Policy Text Block]	Derivative Instruments We record derivative instruments (including certain derivative instruments embedded in other contracts) on the balance sheet on a gross basis as either an asset or liability measured at fair value. See Note 7 for a table indicating where each component is recorded on the Consolidated Balance Sheets. Additionally, changes in a derivative's fair value, which are measured at the end of each period, is recognized in earnings unless specific hedge accounting criteria are met. If hedge accounting criteria are met for cash flow hedges, the changes in a derivative’s fair value are recorded in shareholders’ equity as a component of other comprehensive income ("OCI"), net of tax. These deferred gains and losses are recognized in income in the period in which the hedged item and hedging instrument affect earnings. Any ineffective portion of the change in fair value is immediately recognized in earnings. We are exposed to credit loss in the event of nonperformance by the counterparties on derivative contracts. It is our policy to manage our credit risk on these transactions by dealing only with financial institutions having a long-term credit rating of "A" or better and by distributing the contracts among several financial institutions to diversify credit concentration risk. Should a counterparty default, our maximum exposure to loss is the asset balance of the instrument. The maximum term of the forward currency exchange contracts at June 27, 2015 and June 28, 2014 was 15 months. We enter into certain derivative financial instruments, when available on a cost-effective basis, to mitigate our risk associated with changes in interest rates and foreign currency exchange rates as follows: Interest rate risk management - We are exposed to the impact of interest rate changes through our cash investments and borrowings. We utilize a variety of strategies to manage the impact of changes in interest rates including using a mix of debt maturities along with both fixed-rate and variable-rate debt. In addition, we may enter into treasury-lock agreements and interest rate swap agreements on certain investing and borrowing transactions to manage our exposure to interest rate changes and our overall cost of borrowing. Foreign currency exchange risk management - We conduct business in several major currencies other than the U.S. dollar and are subject to risks associated with changing foreign exchange rates. Our objective is to reduce cash flow volatility associated with foreign exchange rate changes on a consolidated basis to allow management to focus its attention on business operations. Accordingly, we enter into various contracts that change in value as foreign exchange rates change to protect the value of existing foreign currency assets and liabilities, commitments, and anticipated foreign currency sales and expenses. All derivative instruments are managed on a consolidated basis to efficiently net exposures and thus take advantage of any natural offsets. Gains and losses related to the derivative instruments are expected to be offset largely by gains and losses on the original underlying asset or liability. We do not use derivative financial instruments for speculative purposes. All of our designated derivatives were classified as cash flow hedges as of June 27, 2015 and June 28, 2014 . Designated derivatives meet hedge accounting criteria, which means the fair value of the hedge is recorded in shareholders’ equity as a component of OCI, net of tax. The deferred gains and losses are recognized in income in the period in which the hedged item affects earnings. Any ineffective portion of the change in fair value of the derivative is immediately recognized in earnings, recorded in Other expense, net. All of our designated derivatives are assessed for hedge effectiveness quarterly. We also have economic non-designated derivatives that do not meet hedge accounting criteria. These derivative instruments are adjusted to current market value at the end of each period through earnings. Gains or losses on these instruments are offset substantially by the remeasurement adjustment on the hedged item.
Accounts Receivable [Policy Text Block]	Accounts Receivable and Factoring We maintain an allowance for doubtful accounts that reduces our receivables to amounts that are expected to be collected. In estimating the allowance, management considers factors such as current overall and industry-specific economic conditions, statutory requirements, historical and anticipated customer performance, historical experience with write-offs and the level of past-due amounts. Changes in these conditions may result in additional allowances. After all attempts to collect a receivable have failed, the receivable is written off against the allowance.
Transfers and Servicing of Financial Assets, Transfers of Financial Assets, Sales, Policy [Policy Text Block]	As a result of the Omega acquisition, we assumed multiple accounts receivable factoring arrangements with non-related third-party financial institutions (the “Factors”). Pursuant to the terms of the arrangements, we sell to the Factors certain of our accounts receivable balances on a non-recourse basis for credit approved accounts. An administrative fee ranging from 0.14% to 0.15% per diem is charged on the gross amount of accounts receivables assigned to the Factors, plus interest is calculated at the applicable EUR LIBOR rate plus 70 basis points. The total amount factored and excluded from accounts receivable on our Consolidated Balance Sheets was $171.6 million at June 27, 2015 , a $23.9 million increase since we acquired Omega
Inventories [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market. Cost is determined using the first-in first-out ("FIFO") method. Inventory related to research and development is expensed at the point when it is determined the materials have no alternative future use. We maintain reserves for estimated obsolete or unmarketable inventory based on the difference between the cost of the inventory and its estimated net realizable value. In estimating the reserves, management considers factors such as excess or slow-moving inventories, product expiration dating, products on quality hold, current and future customer demand and market conditions. Changes in these conditions may result in additional reserves. See Note 4 for additional information on our inventory.
Fixed Assets [Policy Text Block]	Property, Plant and Equipment, net Property, plant and equipment, net are recorded at cost and are depreciated using the straight-line method. Useful lives for financial reporting range from 2 to 15 years for machinery and equipment and 10 to 45 years for buildings. Maintenance and repair costs are charged to earnings, while expenditures that increase asset lives are capitalized. Depreciation expense was $84.3 million , $77.9 million , and $66.2 million for fiscal years 2015 , 2014 , and 2013 , respectively, and includes amortization of assets recorded under capital leases.
Goodwill and Intangible Assets [Policy Text Block]	Goodwill and Intangible Assets Goodwill represents amounts paid for an acquisition in excess of the fair value of net assets received. Goodwill is tested for impairment annually in our fourth quarter, or more frequently if changes in circumstances or the occurrence of events suggest impairment exists. The test for impairment requires us to make several estimates about fair value, most of which are based on projected future cash flows and market valuation multiples. The estimates associated with the goodwill impairment tests are considered critical due to the judgments required in determining fair value amounts, including projected discounted future cash flows. Changes in these estimates may result in the recognition of an impairment loss. We have intangible assets that we have acquired through various business acquisitions and that include trademarks, trade names and brands, in-process research and development ("IPR&D"), developed product technology/formulation and product rights, distribution and license agreements, customer relationships and distribution networks, and non-compete agreements. The assets are typically initially valued using either the: • Relief from royalty method : This method assumes that if the acquired company did not own the intangible asset or intellectual property, it would be willing to pay a royalty for its use. The benefit of ownership of the intellectual property is valued as the relief from the royalty expense that would otherwise be incurred. We typically use this method for valuing readily transferable intangible assets that have licensing appeal, such as trade names and trademarks and certain technology assets. • Multi-period excess earnings method : This method starts with a forecast of the net cash flows expected to be generated by the asset over its estimated useful life. These cash flows are then adjusted to present value by applying an appropriate discount rate that reflects the risk factors associated with the cash flow streams. We typically use this method for valuing intangible assets such as developed product technology, customer relationships, product formulations and IPR&D. Indefinite-lived intangible assets include IPR&D and certain trademarks, trade names and brands. IPR&D assets are recognized at fair value and are classified as indefinite-lived assets until the successful completion or abandonment of the associated research and development efforts. If the associated research and development is completed, the IPR&D asset becomes a definite-lived intangible asset and is amortized over the asset's assigned useful life. If it is abandoned, an impairment loss is recorded. Indefinite-lived trademarks, trade names and brands are tested for impairment annually during our fourth quarter, or more frequently if changes in circumstances or the occurrence of events suggest impairment exists, by comparing the carrying value of the assets to their estimated fair values. An impairment loss is recognized if the carrying amount of the asset is not recoverable and its carrying amount exceeds its fair value. Definite-lived intangible assets consist of a portfolio of developed product technology/formulation and product rights, distribution and license agreements, customer relationships, non-compete agreements, and certain trademarks and trade names. The assets are amortized on either a straight-line basis or proportionately to the benefits derived from those relationships or agreements. Useful lives vary by asset type and are determined based on the period over which the intangible asset is expected to contribute directly or indirectly to our future cash flows. We also review all other long-lived assets that have finite lives and that are not held for sale for impairment when indicators of impairment are evident by comparing the carrying value of the assets to their estimated future undiscounted cash flows. See Note 3 for further information on our goodwill and intangible assets.
Debt, Policy [Policy Text Block]	Debt We elected to early adopt new accounting guidance related to deferred financing fees (as further described below under "Recent Accounting Standard Pronouncements") as of June 27, 2015. As a result, we changed our accounting policy to record deferred financing fees as a reduction of Long-term debt rather than as a Non-current asset. The balance sheet has been adjusted to reflect this change for all years presented.
Share-Based Awards [Policy Text Block]	Share-Based Awards We measure and record compensation expense for all share-based awards based on estimated grant date fair values, and net of any estimated forfeitures over the vesting period of the awards. Forfeiture rates are estimated at the grant date based on historical experience and adjusted in subsequent periods for any differences in actual forfeitures from those estimates. We estimate the fair value of stock option awards granted based on the Black-Scholes option pricing model, which requires the use of subjective and complex assumptions. These assumptions include estimating the expected term that awards granted are expected to be outstanding, the expected volatility of our stock price for a period commensurate with the expected term of the related options, and the risk-free rate with a maturity closest to the expected term of the related awards. Restricted stock and restricted stock units are valued based on our stock price on the day the awards are granted. See Note 10 for further information on our share-based awards.
Income Taxes [Policy Text Block]	ncome Taxes Deferred income tax assets and liabilities are recorded based upon the difference between the financial reporting and the tax reporting basis of assets and liabilities using the enacted tax rates. To the extent that available evidence raises doubt about the realization of a deferred income tax asset, a valuation allowance is established. We have not made a provision for U.S. or additional non-U.S. taxes on undistributed post-acquisition earnings of non-U.S. subsidiaries because those earnings are considered permanently reinvested in the operations of those subsidiaries. We record reserves for uncertain tax positions to the extent it is more likely than not that the tax position will be sustained on audit, based on the technical merits of the position. Periodic changes in reserves for uncertain tax positions are reflected in the provision for income taxes. We include interest and penalties attributable to uncertain tax positions and income taxes as a component of our income tax provision.
Contingent Liability Reserve Estimate, Policy [Policy Text Block]	Legal Contingencies We are involved in product liability, patent, commercial, regulatory and other legal proceedings that arise in the normal course of business. We record a liability when a loss is considered probable and the amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range and no amount within that range is a better estimate, the minimum amount in the range is accrued. If a loss is not probable or a probable loss cannot be reasonably estimated, no liability is recorded. We have established reserves for certain of our legal matters, as described in Note 14 . We also separately record any insurance recoveries that are probable of occurring.
Research and Development [Policy Text Block]	Research and Development All research and development costs, including payments related to products under development and research consulting agreements, are expensed as incurred. We may continue to make non-refundable payments to third parties for new technologies and for research and development work that has been completed. These payments may be expensed at the time of payment depending on the nature of the payment made. Research and development spending was $187.8 million , $152.5 million , and $115.2 million for fiscal years 2015 , 2014 , and 2013 , respectively. Fiscal year 2015 included incremental research and development expenses related to the collaboration agreement entered into as a result of the Omega acquisition. Fiscal year 2014 included incremental research and development expenses due to the Sergeant's, Velcera, and Aspen acquisitions, as well as research and development expenses related to the novel therapeutic agent for Alzheimer's disease ("ELND005") Phase 2 clinical program in collaboration with Transition Therapeutics Inc. ("Transition") that we acquired in the Elan acquisition. We ended our collaboration with Transition during the third quarter of fiscal 2014 and are no longer responsible for ongoing development activities and costs associated with ELND005. See Note 15 for additional information on collaboration agreements. Fiscal year 2013 included incremental research and development expenses attributable to the acquisitions of Sergeant's, Rosemont, and Velcera acquisitions. We actively collaborate with other pharmaceutical companies to develop, manufacture and market certain products or groups of products. We may choose to enter into these types of agreements to, among other things, leverage our or others’ scientific research and development expertise or utilize our extensive marketing and distribution resources. Our policy on accounting for costs of strategic collaborations determines the timing of the recognition of certain development costs. In addition, this policy determines whether the cost is classified as development expense or capitalized as an asset. Management is required to form judgments with respect to the commercial status of such products in determining whether development costs meet the criteria for immediate expense or capitalization. For example, when we acquire certain products for which there is already an Abbreviated New Drug Application ("ANDA") or New Drug Application ("NDA") approval directly related to the product, and there is net realizable value based on projected sales for these products, we capitalize the amount paid as an intangible asset. If we acquire product rights that are in the development phase and as to which we have no assurance that the third-party will successfully complete its development milestones, we expense the amount paid. See Note 15 for more information on our current collaboration agreements.
Advertising Costs, Policy [Policy Text Block]	Advertising Costs We expense advertising costs as incurred. Advertising costs were $55.7 million , $41.4 million , and $26.1 million in fiscal years 2015 , 2014 , and 2013 , respectively. Advertising costs relate primarily to print advertising, direct mail, on-line advertising and social media communications primarily in our CHC and BCH segments
Earnings per Share (EPS) [Policy Text Block]	Earnings per Share ("EPS") Basic EPS is calculated using the weighted-average number of ordinary shares outstanding during each period. It excludes both the dilutive effects of additional common shares that would have been outstanding if the shares issued under stock incentive plans had been exercised and the dilutive effect of restricted shares and restricted share units, to the extent those shares and units have not vested. Diluted EPS is calculated including the effects of shares and potential shares issued under stock incentive plans, following the treasury stock method.
Postemployment Benefit Plans, Policy [Policy Text Block]	Defined Benefit Plans As part of the Omega acquisition in fiscal year 2015, we assumed the liabilities under a number of defined benefit plans for employees based primarily in the Netherlands, Germany, France and Norway. Omega companies operate various pension plans across each country. As part of the Elan acquisition in fiscal year 2014, we assumed responsibility for the funding of two Irish defined benefit plans, which subsequently have been combined. Two significant assumptions, the discount rate and the expected rate of return on plan assets, are important elements of expense and liability measurement. We evaluate these assumptions annually. Other assumptions involve employee demographic factors, such as retirement patterns, mortality, turnover, and the rate of compensation increase. The liability recognized in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation at the balance sheet date less the fair value of plan assets. The defined benefit obligation is calculated periodically by independent actuaries using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid and that have terms to maturity approximating the terms of the related pension liability. Actuarial gains and losses are recognized using the corridor method. Under the corridor method, to the extent that any cumulative unrecognized net actuarial gain or loss exceeds 10% of the greater of the present value of the defined benefit obligation and the fair value of the plan assets, that portion is recognized over the expected average remaining working lives of the plan participants. Otherwise, the net actuarial gain or loss is recorded in OCI. We recognize the funded status of benefit plans on the Consolidated Balance Sheets. In addition, we recognize the gains or losses and prior service costs or credits that arise during the period but are not recognized as components of net periodic pension cost of the period as a component of OCI. See Note 13 for further information on our defined benefit plans.
Recently adopted accounting standards	Recently Adopted Accounting Standards Accounting Standard Update Description Date of Adoption Effect on the Financial Statements or Other Significant Matters Interest- Imputation of Interest: Simplifying the Presentation of Debt Issuance Costs These amendments require debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the debt liability rather than as an asset. June 27, 2015 As of June 27, 2015 and June 28, 2014 we reclassified $40.5 million and $27.4 million, respectively, of deferred financing fees from Other non-current assets to Long-term debt. Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists These amendments provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. July 1, 2014 In first quarter fiscal year 2015 we presented $90.2 million as a reclassification from Non-current deferred income taxes to Other non-current liabilities upon adoption. Recently Issued Accounting Standards Not Yet Adopted Standard Description Effective Date Effect on the Financial Statements or Other Significant Matters Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity These amendments raise the threshold for a disposal to qualify as a discontinued operation and require new disclosures of both discontinued operations and certain other disposals that do not currently meet the definition of a discontinued operation. Additional disclosures will include an entity's continuing involvement with a discontinued operation following the disposal date and retained equity method investments in a discontinued operation. July 1, 2015 Adoption of this guidance will not have a material effect on our Consolidated Results of Operations or financial condition. Revenue from Contracts with Customers The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: identify the contract(s) with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) the entity satisfies a performance obligation. This guidance allows for two adoption methods, full retrospective approach or modified retrospective approach. January 1, 2018 We are currently evaluating the possible adoption methodologies and the implications of adoption on our consolidated financial statements.
Recently issued accounting standards not yet adopted	Recently Issued Accounting Standards Not Yet Adopted Standard Description Effective Date Effect on the Financial Statements or Other Significant Matters Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity These amendments raise the threshold for a disposal to qualify as a discontinued operation and require new disclosures of both discontinued operations and certain other disposals that do not currently meet the definition of a discontinued operation. Additional disclosures will include an entity's continuing involvement with a discontinued operation following the disposal date and retained equity method investments in a discontinued operation. July 1, 2015 Adoption of this guidance will not have a material effect on our Consolidated Results of Operations or financial condition. Revenue from Contracts with Customers The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, an entity should apply the following steps: identify the contract(s) with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when (or as) the entity satisfies a performance obligation. This guidance allows for two adoption methods, full retrospective approach or modified retrospective approach. January 1, 2018 We are currently evaluating the possible adoption methodologies and the implications of adoption on our consolidated financial statements.

Summary of Signifcant Account29

Summary of Signifcant Accounting Policies (Tables)	12 Months Ended
	Jun. 27, 2015
Summary of Significant Accounting Policies [Abstract]
Property, Plant and Equipment	We held the following property, plant and equipment, net at June 27, 2015 and June 28, 2014 (in millions): June 27, June 28, Land $ 48.7 $ 36.1 Buildings 528.3 430.3 Machinery and equipment 1,094.0 1,001.4 Gross property and equipment 1,671.0 1,467.8 Less accumulated depreciation (738.6 ) (687.9 ) Property and equipment, net $ 932.4 $ 779.9

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014
business acquisition [Line Items]
Business Combination, Segment Allocation	The following table reflects the allocation by reportable segment (in millions): Segment Goodwill CHC $ 1,287.4 Rx Pharmaceuticals 845.1 Specialty Sciences 200.6 Total $ 2,333.1
Business Combination, Separately Recognized Transactions	The below table indicates the final purchase price allocation for fiscal year 2013 acquisitions (in millions): Sergeant's Rosemont Velcera All Other (1) Purchase price paid $ 285.0 $ 282.9 $ 175.1 $ 139.9 Contingent consideration — — — 22.2 Total purchase consideration $ 285.0 $ 282.9 $ 175.1 $ 162.1 Assets acquired: Cash and cash equivalents $ — $ 2.1 $ 18.9 $ — Accounts receivable 19.7 10.6 6.3 — Inventories 37.7 9.6 9.7 1.3 Property and equipment 25.4 13.1 0.6 — Goodwill 80.2 147.0 62.5 18.1 Intangible assets: Developed product technology 66.1 114.6 — 158.1 Distribution and license agreements 1.3 3.6 116.0 — Customer relationships 10.0 — 8.7 — Trademarks, trade names and brands 33.0 17.3 7.6 — Non-competition agreements — 1.5 3.0 — IPR&D — 11.2 — — Favorable supply agreement 25.0 — — — Intangible assets 135.4 148.2 135.3 158.1 Deferred tax assets 1.5 0.2 7.9 3.6 Other non-current assets 3.0 0.8 0.4 0.3 Total assets 302.9 331.6 241.6 181.4 Liabilities assumed: Accounts payable 13.7 2.6 6.5 — Accrued liabilities 4.2 7.6 4.8 0.5 Deferred tax liabilities — 36.0 48.2 18.8 Other non-current liabilities — 2.5 7.0 — Total liabilities 17.9 48.7 66.5 19.3 Net assets acquired $ 285.0 $ 282.9 $ 175.1 $ 162.1	The below table indicates the purchase price allocation for our fiscal year 2014 acquisitions (in millions): Elan All Other (1) Purchase price paid $ 9,451.9 $ 71.0 Contingent consideration — 0.8 Total purchase consideration $ 9,451.9 $ 71.8 Assets acquired: Cash and cash equivalents $ 1,807.3 $ — Investment securities 100.0 — Accounts receivable 44.2 — Inventories — 3.0 Prepaid expenses and other current assets 27.1 — Property and equipment 9.2 — Goodwill 2,333.1 4.6 Intangible assets: Trademarks, trade names and brands — 34.8 Customer relationships — 9.8 Non-competition agreements — 1.8 Distribution and license agreements 5,811.0 17.8 Other intangible assets, net 5,811.0 64.2 Other non-current assets 93.4 — Total assets 10,225.3 71.8 Liabilities assumed: Accounts payable 2.0 — Accrued liabilities 120.8 — Deferred tax liabilities 631.8 — Other non-current liabilities 18.8 — Total liabilities 773.4 — Net assets acquired $ 9,451.9 $ 71.8
Omega, Other [Member]
business acquisition [Line Items]
Business Combination, Separately Recognized Transactions	The below table indicates the purchase price allocation for our fiscal year 2015 acquisitions (in millions): Omega * All Other (1)* Total purchase consideration $ 2,983.2 $ 118.8 Assets acquired: Cash and cash equivalents $ 14.7 $ 4.6 Accounts receivable 264.7 11.4 Inventories 214.4 8.7 Current net deferred tax assets 6.4 0.6 Prepaid expenses and other current assets 39.2 2.7 Property and equipment 121.2 6.1 Goodwill 1,513.1 4.8 Intangible assets: Trademarks, trade names and brands 2,427.2 4.4 Customer relationships and distribution networks 1,342.7 6.6 Formulations — 82.0 Developed product technology 32.7 — Other intangible assets 3,802.6 93.0 Other non-current assets 2.4 0.4 Total assets 5,978.7 132.3 Liabilities assumed: Accounts payable 243.1 4.6 Short-term debt 24.6 — Accrued liabilities 44.5 5.5 Payroll and related taxes 51.3 — Accrued customer programs 39.8 — Long-term debt 1,471.0 — Non-current net deferred income tax liabilities 1,038.7 3.3 Other non-current liabilities 82.5 0.1 Total liabilities 2,995.5 13.5 Net assets acquired $ 2,983.2 $ 118.8
Omega [Member]
business acquisition [Line Items]
Fair value of consideration transferred in business acquisition	The acquisition was a cash and stock transaction made up of the following consideration (in millions except per share data): Perrigo ordinary shares issued 5.4 Perrigo share price at transaction close on March 30, 2015 $ 167.64 Total value of Perrigo ordinary shares issued $ 904.9 Cash consideration 2,078.3 Total consideration $ 2,983.2
Schedule of acquisition-related costs	Fiscal Year Line item 2015 Administration $ 29.7 Interest expense, net 23.7 Other expense, net 324.0 Loss on extinguishment of debt 9.6 Total acquisition-related costs $ 387.0
Elan Corporation [Member]
business acquisition [Line Items]
Fair value of consideration transferred in business acquisition	On December 18, 2013 , we acquired Elan, which led to our new corporate structure headquartered in Dublin, Ireland. We have utilized this new structure to continue to grow in our core markets and further expand outside of the U.S. The acquisition also provided us with our Tysabri ® royalty stream, enhancing our operating cash flows and diversifying our revenues, and recurring annual operational synergies, related cost reductions, and tax savings. Certain of these synergies resulted from the elimination of redundant public company costs while optimizing back-office support. The jurisdictional mix of income and the new corporate structure are expected to provide tax benefits to the worldwide structure. The acquisition was a cash and stock transaction as follows (in millions except per share data): Elan shares outstanding as of December 18, 2013 515.7 Exchange ratio per share 0.07636 Total Perrigo shares issued to Elan shareholders 39.4 Perrigo per share value at transaction close on December 18, 2013 $ 155.34 Total value of Perrigo shares issued to Elan shareholders $ 6,117.2 Cash consideration paid at $6.25 per Elan share 3,223.2 Cash consideration paid for vested Elan stock options and share awards 111.5 Total consideration $ 9,451.9
Schedule of acquisition-related costs	Fiscal Year Line item 2014 Administration expense $ 108.9 Interest, net 10.0 Other expense, net 0.2 Loss on extinguishment of debt 165.8 Total acquisition-related costs $ 284.9
Fiscal 2015 acquisitions [Member]
business acquisition [Line Items]
Business Acquisition, Pro Forma Information	Our Consolidated Financial Statements include operating results from the Omega, Gelcaps, and Elan acquisitions, and the Lumara, Aspen, and Fera (Methazolomide) product acquisitions, from the date of each acquisition through June 27, 2015 . Net sales and operating income attributable to the Omega, Gelcaps, and Lumara acquisitions included in our fiscal year 2015 financial statements totaled $418.2 million and $18.9 million , respectively. Net sales and operating loss attributable to the Elan, Aspen, and Fera (Methazolomide) acquisitions included in our fiscal 2014 financial statements totaled $168.5 million and $53.9 million , respectively. The following unaudited pro forma information gives effect to the Omega, Gelcaps, and Elan acquisitions, and Lumara, Aspen, and Fera (Methazolomide) product acquisitions, as if the acquisitions had occurred on June 30, 2013 and had been included in our Results of Operations for fiscal years 2015 and 2014 (in millions): (Unaudited) Fiscal 2015 Fiscal 2014 Net sales $ 5,671.3 $ 5,816.3 Net income $ 122.5 $ 212.8 The historical consolidated financial information of Perrigo, Omega, Gelcaps, and Elan, and the acquired Lumara, Aspen, and Fera assets, has been adjusted in the pro forma information to give effect to pro forma events that are (1) directly attributable to the transactions, (2) factually supportable and (3) expected to have a continuing impact on combined results. In order to reflect the occurrence of the acquisitions on June 30, 2013 as required, the unaudited pro forma results include adjustments to reflect the incremental amortization expense to be incurred based on the current preliminary values of each acquisition's identifiable intangible and tangible assets, along with the reclassification of acquisition-related costs from the period ended June 27, 2015 to the period ended June 28, 2014. The unaudited pro forma results do not reflect future events that have occurred or may occur after the acquisitions, including but not limited to, the anticipated realization of ongoing savings from operating synergies and tax savings in subsequent periods. The decline in the Euro relative to the U.S. dollar negatively impacted fiscal year 2015 pro forma net sales attributed to Omega. If the Euro to U.S. dollar exchange rate had remained constant from fiscal year 2014 to fiscal year 2015, pro forma net sales attributed to Omega would have increased in fiscal year 2015 by an estimated $189.3 million .

Goodwill and Other Intangible31

Goodwill and Other Intangible Assets (Tables)	12 Months Ended
	Jun. 27, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	Changes in the carrying amount of goodwill, by reportable segment, were as follows (in millions): CHC BCH Rx Pharma- Specialty Sciences Other Total Balance at June 29, 2013 $ 611.6 $ — $ 385.4 $ — $ 92.2 $ 1,089.2 Business acquisitions 1,297.2 — 851.0 201.8 — 2,350.0 Currency translation adjustment 7.6 — 21.9 — 5.4 34.9 Balance at June 28, 2014 1,916.4 — 1,258.3 201.8 97.6 3,474.1 Business acquisitions 4.8 1,513.1 — — — 1,517.9 Impairments (6.8 ) — — — — (6.8 ) Currency translation adjustment (9.7 ) 38.8 (20.0 ) — (9.4 ) (0.3 ) Purchase accounting adjustments (7.2 ) — (4.7 ) (1.1 ) — (13.0 ) Balance at June 27, 2015 $ 1,897.5 $ 1,551.9 $ 1,233.6 $ 200.7 $ 88.2 $ 4,971.9
Schedule of Finite and Indefinite-Lived Intangible Assets	Other intangible assets and the related accumulated amortization consisted of the following (in millions): June 27, 2015 June 28, 2014 Gross Accumulated Amortization Gross Accumulated Amortization Amortizable intangibles : Distribution and license agreements $ 6,029.9 $ 502.3 $ 6,027.3 $ 192.1 Developed product technology/formulation and product rights 1,025.3 383.1 931.7 302.5 Customer relationships and distribution networks 1,749.9 146.2 372.0 97.5 Trademarks, trade names and brands 340.8 11.5 47.8 5.6 Non-compete agreements 14.7 11.9 15.3 9.4 Total amortizable intangibles $ 9,160.6 $ 1,055.0 $ 7,394.1 $ 607.1 Non-amortizable intangibles : Trademarks, trade names and brands $ 2,257.3 $ — $ 59.5 $ — In-process research and development 5.8 — 10.2 — Total non-amortizable intangibles 2,263.1 — 69.7 — Total other intangible assets $ 11,423.7 $ 1,055.0 $ 7,463.8 $ 607.1
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Our estimated future amortization expense is as follows (in millions): Time Period Amount < 1 year $ 589.1 1-2 years 582.7 2-3 years 569.3 3-4 years 551.8 4-5 years 521.6 > 5 years 5,291.1
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	The weighted-average useful life for our amortizable intangible assets by asset class at June 27, 2015 was as follows: Amortizable Intangible Asset Category Weighted-Average Useful Life (Years) Distribution and license agreements 20 Developed product technology/formulation and product rights 12 Customer relationships and distribution networks 20 Trademarks, trade names and brands 19 Non-compete agreements 2

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Jun. 27, 2015
Inventory [Abstract]
Schedule of Inventory, Current [Table Text Block]	Major components of inventory at June 27, 2015 , and June 28, 2014 , were as follows (in millions): June 27, June 28, Finished goods $ 468.9 $ 307.0 Work in process 158.2 146.7 Raw materials 211.8 177.9 Total inventories $ 838.9 $ 631.6

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Jun. 27, 2015
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables summarize the valuation of our financial instruments carried at fair value by the above pricing categories as of June 27, 2015 and June 28, 2014 (in millions): June 27, 2015 Level 1 Level 2 Level 3 Total Assets: Investment securities $ 12.7 $ — $ — $ 12.7 Foreign currency forward contracts — 12.4 — 12.4 Funds associated with Israeli post-employment benefits — 17.3 — 17.3 Total assets $ 12.7 $ 29.7 $ — $ 42.4 Liabilities: Foreign currency forward contracts — 4.6 — 4.6 Total liabilities $ — $ 4.6 $ — $ 4.6 June 28, 2014 Level 1 Level 2 Level 3 Total Assets: Investment securities $ 20.7 $ — $ — $ 20.7 Foreign currency forward contracts — 3.1 — 3.1 Funds associated with Israeli post-employment benefits — 19.3 — 19.3 Total assets $ 20.7 $ 22.4 $ — $ 43.1 Liabilities: Contingent consideration $ — $ — $ 17.4 $ 17.4 Interest rate swap agreements — 8.3 — 8.3 Foreign currency forward contracts — 0.8 — 0.8 Total liabilities $ — $ 9.1 $ 17.4 $ 26.5
Rollforward of the Assets Measured at Fair Value Using Unobservable Inputs	The table below presents a reconciliation for assets and liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) for fiscal years 2015 and 2014 (in millions). Fiscal Year 2015 2014 Contingent Consideration Beginning balance: $ 17.4 $ 22.2 Net realized losses 0.9 1.1 Purchases or additions — 0.8 Settlements (18.3 ) (6.7 ) Ending balance: $ — $ 17.4

Investments (Tables)

Investments (Tables)	12 Months Ended
	Jun. 27, 2015
Investments, Debt and Equity Securities, Equity Method Investments and Joint Ventures [Abstract]
Schedule of Unrealized Gains (Losses) on Available for Sale Securities	Net unrealized investment gains (losses) on available for sale securities were as follows (in millions): Fiscal Year 2015 2014 Net unrealized investment gains (losses): Equity securities, at cost less impairments $ 17.1 $ 17.1 Gross unrealized gains 5.7 3.8 Gross unrealized losses (10.1 ) (0.2 ) Estimated fair value of equity securities $ 12.7 $ 20.7

Indebtedness (Tables)

Indebtedness (Tables)	12 Months Ended
	Jun. 27, 2015
Indebtedness [Abstract]
Schedule of Debt	Debt Total borrowings outstanding at June 27, 2015 and June 28, 2014 are summarized as follows (in millions): June 27, June 28, Short term debt $ 6.4 $ 2.1 Term loans 2013 Term loan due December 18, 2015 — 300.0 2013 Term loan due December 18, 2018 — 630.0 * 2014 Term loan due December 5, 2019 530.5 — Total term loans 530.5 930.0 Public bonds Coupon Due 1.300% November 8, 2016 (2) 500.0 500.0 * 4.500% May 23, 2017 (3) 201.0 — * 5.125% December 12, 2017 (3) 335.0 — 2.300% November 8, 2018 (2) 600.0 600.0 * 5.000% May 23, 2019 (3) 134.1 — 3.500% December 15, 2021 (1) 500.0 — * 5.105% July 19, 2023 (3) 150.8 — 4.000% November 15, 2023 (2) 800.0 800.0 3.900% December 15, 2024 (1) 700.0 — 5.300% November 15, 2043 (2) 400.0 400.0 4.900% December 15, 2044 (1) 400.0 — Total public bonds 4,720.9 2,300.0 Other financing 6.6 8.1 Unamortized premium (discount), net 87.5 (6.0 ) Deferred financing fees (40.5 ) (27.4 ) Total borrowings outstanding 5,311.4 3,206.8 Less short-term debt and current portion of long-term debt (64.6 ) (143.7 ) Total long-term debt less current portion $ 5,246.8 $ 3,063.1 (1) Public bonds issued on December 2, 2014, discussed below collectively as the "2014 Bonds." (2) Private placement unsecured senior notes with registration rights as of June 28, 2014 and public bonds as of October 1, 2014, discussed below collectively as the "2013 Bonds." (3) Debt assumed from Omega. * Debt denominated in euros subject to fluctuations in the euro to U.S. dollar exchange rate.
Schedule of Extinguishment of Debt	As a result of the debt retirements, we recorded a loss of $165.8 million during fiscal year 2014 as follows (in millions): Make-whole payments $ 133.5 Write-off of financing fees on Bridge Credit Agreements 19.0 Write-off of deferred financing fees 10.5 Write-off of unamortized discount 2.8 Total loss on extinguishment of debt $ 165.8
Schedule of Maturities of Short-term and Long-term Debt	The annual future maturities of our short-term and long-term debt, including capitalized leases, are as follows (in millions): Payment Due Amount < 1 year $ 65.0 1-2 years 758.5 2-3 years 399.1 3-4 years 811.3 4-5 years 279.5 > 5 years 2,950.8

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	12 Months Ended
	Jun. 27, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share	A reconciliation of the numerators and denominators used in our basic and diluted EPS calculation is as follows (in millions): Fiscal Year 2015 2014 2013 Numerator: Net income $ 128.0 $ 205.3 $ 441.9 Denominator: Weighted average shares outstanding for basic EPS 139.3 115.1 93.9 Dilutive effect of share-based awards 0.5 0.5 0.6 Weighted average shares outstanding for diluted EPS 139.8 115.6 94.5 Anti-dilutive share-based awards excluded from computation of diluted EPS 0.1 0.1 0.2

Share-based compensation (Table

Share-based compensation (Tables)	12 Months Ended
	Jun. 27, 2015
Share-based Compensation [Abstract]
Schedule of Share-based Compensation, Stock Options, Activiy	A summary of activity related to stock options is presented below (options in thousands): Fiscal Year Ended June 27, 2015 Number of Options Weighted-Average Exercise Price Per Share Weighted- Average Remaining Term in Years Aggregate Intrinsic Value Beginning options outstanding 850 $ 77.26 Granted 181 $ 147.75 Exercised (170 ) $ 49.26 Forfeited or expired (4 ) $ 128.76 Ending options outstanding 857 $ 97.49 6.6 $ 79.8 Options exercisable 515 $ 74.16 5.4 $ 59.9 Options expected to vest 334 $ 132.47 8.4 $ 19.4
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The fair values were estimated using the Black-Scholes option pricing model with the following weighted-average assumptions: Fiscal Year 2015 2014 2013 Dividend yield 0.3 % 0.3 % 0.3 % Volatility, as a percent 27.1 % 32.7 % 34.9 % Risk-free interest rate 1.7 % 1.8 % 0.8 % Expected life in years 5.3 5.3 5.4
Schedule of Nonvested Share Activity	A summary of activity related to nonvested restricted shares is presented below (shares in thousands): Fiscal Year Ended June 27, 2015 Number of Shares Weighted- Average Grant Date Fair Value Per Share Weighted- Average Remaining Term in Years Aggregate Intrinsic Value Beginning non-vested restricted shares outstanding 9 $ 100.84 Granted — $ — Vested (9 ) $ 100.84 Forfeited — $ — Ending non-vested restricted shares outstanding — $ — 0.0 $ —
Schedule of Nonvested Service-based Units Activity	A summary of activity related to non-vested service-based restricted share units is presented below (units in thousands): Fiscal Year Ended June 27, 2015 Number of Non-vested Service- Based Share Units Weighted- Average Grant Date Fair Value Per Share Weighted- Average Remaining Term in Years Aggregate Intrinsic Value Beginning non-vested service-based share units outstanding 247 $ 112.89 Granted 135 $ 153.99 Vested (91 ) $ 99.54 Forfeited (8 ) $ 126.13 Ending non-vested service-based share units outstanding 283 $ 136.48 1.2 $ 53.9
Schedule of Nonvested Performance-based Units Activity	A summary of activity related to non-vested performance-based restricted share units is presented below (units in thousands): Fiscal Year Ended June 27, 2015 Number of Performance- Based Share Units Weighted- Average Grant Date Fair Value Per Share Weighted- Average Remaining Term in Years Aggregate Intrinsic Value Beginning non-vested performance-based share units outstanding 182 $ 109.63 Granted 106 $ 150.14 Vested (56 ) $ 91.14 Forfeited (3 ) $ 126.96 Ending non-vested performance-based share units outstanding 229 $ 129.77 1.38 $ 43.6

Accumulated Other Comprehensi38

Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Jun. 27, 2015
Comprehensive Income [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in our AOCI balances, net of tax, for fiscal years 2015 and 2014 were as follows (in millions): Fair value of derivative financial instruments, net of tax Foreign currency translation adjustments Fair value of investment securities, net of tax Post-retirement and pension liability adjustments, net of tax Total AOCI Balance at June 29, 2013 $ (4.5 ) $ 80.6 $ — $ 0.9 $ 77.0 OCI before reclassifications (18.2 ) 83.8 (4.3 ) (12.0 ) 49.3 Amounts reclassified from AOCI 6.6 — 6.7 — 13.3 Other comprehensive income (loss) (11.6 ) 83.8 2.4 (12.0 ) 62.6 Balance at June 28, 2014 (16.1 ) 164.4 2.4 (11.1 ) 139.6 OCI before reclassifications (15.1 ) (33.5 ) (5.4 ) 1.9 (52.1 ) Amounts reclassified from AOCI 14.9 — — — 14.9 Other comprehensive income (loss) (0.2 ) (33.5 ) (5.4 ) 1.9 (37.2 ) Balance at June 27, 2015 $ (16.3 ) $ 130.9 $ (3.0 ) $ (9.2 ) $ 102.4

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 27, 2015
Income Taxes [Abstract]
Schedule of Income before Income Tax and Components of Income Tax Expense (Benefit)	Pre-tax income and the provision for income taxes from continuing operations are summarized as follows (in millions): Fiscal Year 2015 2014 2013 Pre-tax income (loss): Ireland (821.2 ) (369.3 ) — Other 1,069.2 641.9 607.7 Total 248.0 272.6 607.7 Provision for income taxes: Current: Ireland (2.0 ) 2.2 — United States - Federal 77.0 44.0 125.0 United States - State 6.9 9.3 10.7 Other Foreign 54.1 49.1 24.3 Subtotal 136.0 104.6 160.1 Deferred (credit): Ireland 7.5 (24.2 ) — United States - Federal (17.5 ) 7.8 16.6 United States - State (0.8 ) (5.8 ) — Other Foreign (5.2 ) (15.1 ) (10.9 ) Subtotal (16.0 ) (37.3 ) 5.7 Total 120.0 67.3 165.8
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the provision based on the Federal statutory income tax rate to our effective income tax rate is as follows: Fiscal Year 2015 2014 2013 Provision at statutory rate 12.5 % 12.5 % 35.0 % Ireland tax on non-trading differences (10.3 ) 2.8 — Expenses not deductible for tax purposes/ deductions not expensed for book, net 15.5 12.1 (0.6 ) U.S. Operations: State income taxes, net of federal benefit (1.0 ) (0.2 ) 1.1 Foreign tax credit — 0.2 (0.1 ) Research and development credit (0.8 ) (0.5 ) (0.5 ) Other 5.6 (0.8 ) (1.0 ) Other foreign differences (earnings taxed at other than applicable statutory rate) (16.6 ) (16.0 ) (8.7 ) Worldwide operations: Valuation allowance changes 25.0 2.9 — Audit impacts — — (1.2 ) Change in unrecognized taxes 18.5 15.0 3.3 Rate change impacts — (3.3 ) — Effective income tax rate 48.4 % 24.7 % 27.3 %
Schedule of Deferred Tax Assets and Liabilities	The components of our net deferred income tax asset (liability) was as follows: Fiscal Year 2015 2014 Deferred income tax asset (liability): Depreciation and amortization $ (1,889.0 ) $ (982.6 ) Inventory basis differences 30.2 43.9 Accrued liabilities 67.2 84.3 Allowance for doubtful accounts 0.9 0.9 Research and development 62.8 3.7 Loss carryforwards 502.4 300.4 Share-based compensation 14.3 14.3 Foreign tax credit 10.6 10.6 Federal benefit of unrecognized tax positions 26.3 20.7 Other, net 29.7 59.6 Subtotal (1,144.6 ) (444.2 ) Valuation allowance for loss and credit carryforwards (519.2 ) (198.4 ) Net deferred income tax asset (liability): $ (1,663.8 ) $ (642.6 ) The above amounts are classified on the Consolidated Balance Sheets as follows (in millions): June 27, June 28, Assets $ 161.9 $ 86.4 Liabilities (1,825.7 ) (729.0 ) Net deferred income tax (liability) asset $ (1,663.8 ) $ (642.6 )
Summary of Income Tax Contingencies	The following table summarizes the activity related to amounts recorded for uncertain tax positions, excluding interest and penalties, for the years ended June 27, 2015 and June 28, 2014 (in millions): Unrecognized Tax Benefits Balance at June 29, 2013 $ 110.1 Additions: Positions related to the current year 28.8 Positions related to prior years 22.7 Reductions: Positions related to the current year — Positions related to prior years — Settlements with taxing authorities — Lapse of statutes of limitation (1.5 ) Balance at June 28, 2014 160.1 Additions: Positions related to the current year 38.9 Positions related to prior years 122.7 Reductions: Positions related to the current year — Positions related to prior years — Settlements with taxing authorities (1.4 ) Lapse of statutes of limitation (1.7 ) Balance at June 27, 2015 $ 318.6

Post Employment Plans - (Tables

Post Employment Plans - (Tables)	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014
Defined Benefit Plan Disclosure [Line Items]
Schedule of Defined Benefit Plans Disclosures	The change in the projected benefit obligation and plan assets at June 27, 2015 and June 28, 2014 consisted of the following (in millions): Pension Benefits Other Benefits Fiscal Year 2015 * 2014 ** 2015 * 2014 Projected benefit obligation at beginning of period $ 89.0 $ — $ 4.6 $ 3.9 Acquisitions 70.4 84.4 1.0 — Service costs 0.9 — 0.3 0.5 Interest cost 2.4 1.4 0.2 0.3 Actuarial loss (6.8 ) 12.1 — — Benefits paid (0.9 ) (0.2 ) (0.1 ) (0.1 ) Settlements — (8.0 ) — — Foreign currency translation (14.7 ) (0.7 ) — — Benefit obligation at end of period $ 140.3 $ 89.0 $ 6.0 $ 4.6 Fair value of plan assets at beginning of period 99.6 — — — Acquisitions 49.9 107.3 — — Actual return on plan assets (1.0 ) 5.4 — — Benefits paid (0.1 ) (0.2 ) — — Settlements — (12.1 ) — — Employer contributions 2.4 — — — Foreign currency translation (17.5 ) (0.8 ) — — Fair value of plan assets at end of period $ 133.3 $ 99.6 $ — $ — Funded (unfunded) status recognized in other assets $ (7.0 ) $ 10.6 $ (6.0 ) $ (4.6 )
Schedule of Expected Benefit Payments	At June 27, 2015 , the total estimated future benefit payments to be paid by the plans for the next five years was approximately $6.5 million for pension benefits and $1.0 million for other benefits as follows (in millions): Payment Due Pension Benefits Other Benefits < 1 year $ 0.8 $ 0.1 1 - 2 years 1.1 0.2 3 - 4 years 1.2 0.2 4 - 5 years 1.5 0.2 5 - 6 years 1.9 0.3 > 6 years 13.4 1.8
Schedule of Costs of Retirement Plans	Net periodic pension cost for fiscal years 2015 and 2014 consisted of the following (in millions): Pension Benefits Other Benefits Fiscal Year 2015 * 2014 ** 2015 * 2014 Service cost $ 0.9 $ — $ 0.3 $ 0.5 Interest cost 2.4 1.4 0.2 0.3 Expected return on plan assets (2.7 ) (1.9 ) — 0.6 Net actuarial loss 1.0 0.7 0.1 Net periodic pension cost $ 1.6 $ 0.2 $ 0.6 $ 1.4
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	The weighted-average assumptions used to determine net periodic pension cost and benefit obligation as of June 27, 2015 and June 28, 2014 were: Pension Benefits Other Benefits Fiscal Year 2015 * 2014 ** 2015 * 2014 Discount rate 2.11 % 2.90 % 4.25 % 4.25 % Inflation 1.93 % 2.00 % Expected return on assets 2.85 % 2.92 %
Schedule of Assumptions Used	s of June 27, 2015 , the expected weighted-average long-term rate of return on assets of 2.85% was calculated based on the assumptions of the following returns for each asset class: Equities 5.8 % Bonds 1.2 % Absolute return fund 3.5 % Insurance contracts 2.3 % Property 4.8 %
Schedule of Allocation of Plan Assets	he current long-term asset allocation ranges of the trusts are as follows: Equities 10% - 20% Bonds 30% - 40% Absolute return 20% - 30% Insurance contracts 20% - 30% Property 0% - 10% Other 0% - 10%	he following table sets forth the fair value of the pension plan assets, as of June 28, 2014 (in millions): Quoted Prices in Active Markets Other Observable Inputs Unobservable Inputs (Level 1) (Level 2) (Level 3) Total Equities $ 20.8 $ — $ — $ 20.8 Bonds 48.3 — — 48.3 Property — — 0.8 0.8 Other 0.1 — — 0.1 Absolute return fund 29.6 — — 29.6 Total $ 98.8 $ — $ 0.8 $ 99.6
Schedule of allocation - fair value of the pension plan assets [Table Text Block]	he following table sets forth the fair value of the pension plan assets, as of June 27, 2015 (in millions): Quoted Prices in Active Markets Other Observable Inputs Unobservable Inputs (Level 1) (Level 2) (Level 3) Total Equities $ 16.7 $ — $ — $ 16.7 Bonds 49.7 — — 49.7 Absolute return fund 34.8 — — 34.8 Insurance contracts — — 31.5 31.5 Property — — 0.4 0.4 Other 0.2 — — 0.2 Total $ 101.4 $ — $ 31.9 $ 133.3 The following table sets forth the fair value of the pension plan assets, as of June 28, 2014 (in millions): Quoted Prices in Active Markets Other Observable Inputs Unobservable Inputs (Level 1) (Level 2) (Level 3) Total Equities $ 20.8 $ — $ — $ 20.8 Bonds 48.3 — — 48.3 Property — — 0.8 0.8 Other 0.1 — — 0.1 Absolute return fund 29.6 — — 29.6 Total $ 98.8 $ — $ 0.8 $ 99.6
Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets	he following table sets forth a summary of the changes in the fair value of the Level 3 pension plan assets, which were measured at fair value on a recurring basis for fiscal years 2015 and 2014 (in millions): Fiscal Year 2015 * 2014 ** Level 3 assets held at beginning of year $ 0.8 $ — Acquisitions 31.5 0.7 Unrealized gains (0.4 ) 0.1 Level 3 assets held at end of year $ 31.9 $ 0.8

Commitments and Contingencies O

Commitments and Contingencies Operating Leases, Future Minimum Payments Due (Tables)	12 Months Ended
	Jun. 27, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future non-cancelable minimum operating lease commitments are as follows (in millions): Due Amount < 1 year $ 45.6 1-2 years 37.7 2-3 years 32.3 3-4 years 21.2 5-6 years 15.4 > 6 years 20.3

Restructuring Charges (Tables)

Restructuring Charges (Tables)	12 Months Ended
	Jun. 27, 2015
Restructuring Charges [Abstract]
Schedule of Restructuring Charges	The following reflects our restructuring activity for fiscal years 2015 , 2014 , and 2013 (in millions): Balance at June 30, 2012 $ 1.7 Additional charges 2.9 Payments (1.7 ) Balance at June 29, 2013 2.9 Additional charges 47.0 Payments (28.7 ) Non-cash adjustments (4.8 ) Balance at June 28, 2014 16.4 Additional charges 5.1 Payments (18.5 ) Non-cash adjustments (1.4 ) Balance at June 27, 2015 $ 1.6

Segment and Geographic Inform43

Segment and Geographic Information (Tables)	12 Months Ended
	Jun. 27, 2015
Segments and Geographic Information [Abstract]
Schedule of Revenue by Geographic Location	We generated third-party net sales in the following geographic locations (1) during each of the fiscal years presented (in millions): 2015 2014 2013 Ireland $ 344.0 $ 146.7 $ — U.S. 3,303.6 3,291.6 2,978.1 Europe 613.6 217.2 164.0 All other countries (2) 342.7 405.3 397.7 $ 4,603.9 $ 4,060.8 $ 3,539.8 (1) We attribute net sales to countries based on sales location. (2) Includes sales generated primarily in Israel, Mexico, Australia, and Canada.
Schedule of Property and Equipment by Geographic Location	The net book value of property and equipment at June 27, 2015 and June 28, 2014 was as follows (in millions): June 27, June 28, Ireland $ 1.4 $ 2.0 U.S. 558.6 530.7 Europe 153.8 31.7 Israel 119.8 119.6 All other countries 98.8 95.9 $ 932.4 $ 779.9
Schedule of Segment Reporting Information, by Segment	CHC BCH (1) Rx Pharmaceut-icals Specialty Sciences (2) Other Unallocated expenses Total (3) Fiscal Year 2015 Net sales $ 2,750.0 $ 401.1 $ 1,001.1 $ 344.0 $ 107.7 $ — $ 4,603.9 Operating income (loss) $ 405.6 $ 26.6 $ 373.9 $ 36.3 $ 26.8 $ (121.5 ) $ 747.7 Operating income % 14.7 % 6.6 % 37.3 % 10.6 % 24.9 % — % 16.2 % Total assets $ 4,381.6 $ 6,441.1 $ 2,667.9 $ 5,979.0 $ 251.0 $ — $ 19,720.6 Capital expenditures $ 80.5 $ 3.6 $ 42.9 $ 0.5 $ 6.4 $ 3.1 $ 137.0 Property and equip, net $ 600.0 $ 122.5 $ 124.1 $ — $ 85.8 $ — $ 932.4 Depreciation/amortization $ 123.2 $ 38.3 $ 85.1 $ 291.6 $ 10.6 $ — $ 548.8 Fiscal Year 2014 Net sales $ 2,849.4 $ — $ 927.1 $ 146.7 $ 137.6 $ — $ 4,060.8 Operating income (loss) $ 413.1 $ — $ 349.8 $ (68.6 ) $ 46.1 $ (173.4 ) $ 567.0 Operating income (loss) % 14.5 % — % 37.7 % (46.7 )% 33.5 % — % 14.0 % Total assets $ 4,931.0 $ — $ 2,537.2 $ 6,096.6 $ 288.0 $ — $ 13,852.8 Capital expenditures $ 128.3 $ — $ 32.9 $ — $ 10.4 $ — $ 171.6 Property and equip, net $ 577.3 $ — $ 104.8 $ 2.1 $ 95.7 $ — $ 779.9 Depreciation/amortization $ 106.6 $ — $ 86.5 154.4 $ 11.4 $ — $ 358.9 Fiscal Year 2013 Net sales $ 2,671.0 $ — $ 709.5 — $ 159.3 $ — $ 3,539.8 Operating income (loss) $ 401.8 $ — $ 263.2 — $ 48.9 $ (34.7 ) $ 679.1 Operating income % 15.0 % — % 37.1 % — % 30.7 % — % 19.2 % Total assets $ 3,447.5 $ — $ 1,604.9 — $ 284.5 $ — $ 5,336.9 Capital expenditures $ 97.1 $ — $ 17.7 — $ 17.3 $ — $ 132.2 Property and equip, net $ 508.0 $ — $ 80.8 — $ 92.7 $ — $ 681.4 Depreciation/amortization $ 96.1 $ — $ 54.9 — $ 9.1 $ — $ 160.2 (1) BCH only includes activity from March 30, 2015 to June 27, 2015. (2) Specialty Sciences only includes activity from December 18, 2013 to June 28, 2014 for fiscal year 2014. (3) Amounts may not cross-foot due to rounding.
Schedule of Sales by Major Product Category	The following is a summary of our net sales by category by fiscal year (in millions): 2015 2014 2013 CHC Cough/Cold/Allergy/Sinus (1) $ 486.2 $ 510.1 $ 500.6 Analgesics (1) 441.7 504.0 536.0 Gastrointestinal (1) 395.3 400.1 388.8 Infant nutritionals 383.9 374.8 350.1 Smoking cessation 299.4 236.8 193.2 Vitamins, minerals and dietary supplements 185.6 176.9 158.3 Animal health 156.9 178.0 123.2 Other CHC (1) , (2) 335.9 468.7 420.9 Total CHC 2,684.9 2,849.4 2,671.1 BCH branded OTC products 401.2 — — Generic prescription drugs 1,066.1 927.1 709.5 Tysabri ® royalties 344.0 146.7 — Active pharmaceutical ingredients 107.7 137.6 159.3 Total net sales $ 4,603.9 $ 4,060.8 $ 3,539.8 (1) Includes sales from our OTC contract manufacturing business. (2) Consists primarily of feminine hygiene, diabetes care, dermatological care, diagnostic products, and other miscellaneous or otherwise uncategorized product lines and markets none of which is greater than 10% of the CHC segment.

Quarterly Financial Data (Table

Quarterly Financial Data (Tables)	12 Months Ended
	Jun. 27, 2015
Quarterly Financial Data [Abstract]
Schedule of Quarterly Financial Information [Table Text Block]	The following table presents unaudited quarterly consolidated operating results for each of our last eight fiscal quarters. The information below has been prepared on a basis consistent with our audited consolidated financial statements (in millions, except per share amounts). Fiscal Year 2015 First Quarter (2) Second Quarter (3) Third Quarter (4) Fourth Quarter (5) Net sales $ 951.5 $ 1,071.7 $ 1,049.1 $ 1,531.6 Gross profit $ 321.8 $ 383.8 $ 378.8 $ 628.1 Net income (loss) $ 96.3 $ 70.2 $ (94.9 ) $ 56.4 Earnings (loss) per share (1) : Basic $ 0.72 $ 0.52 $ (0.67 ) $ 0.39 Diluted $ 0.72 $ 0.51 $ (0.67 ) $ 0.38 Weighted average shares outstanding Basic 133.9 136.3 140.8 146.3 Diluted 134.4 136.8 140.8 146.8 (1) The sum of individual per share amounts may not equal due to rounding. (2) Includes acquisition costs of $1.1 million , restructuring charges of $1.7 million , equity method investment losses of $3.1 million , and a $1.2 million investment distribution . (3) Includes restructuring charges of $2.4 million , an R&D payment made in connection with a collaborative agreement of $10.0 million , Omega transaction expenses of $17.8 million , losses on derivatives associated with the Omega acquisition of $64.7 million , equity method investment losses of $3.0 million , income from transfer of rights agreement of $12.5 million , and $9.6 million loss on extinguishment of debt. (4) Includes acquisition costs totaling $2.0 million , an increase in litigation accrual of $2.0 million , restructuring charges of $1.1 million , Omega financing fees of $18.6 million , and losses on derivatives associated with the Omega acquisition of $258.2 million . (5) Includes legal and consulting fees related to our defense against Mylan N.V. of $13.4 million , acquisition costs of $18.5 million , goodwill impairment of $6.8 million , losses on derivatives terminated with extinguishment of associated debt and associated with hedging the pending GSK acquisition of $5.5 million , losses on equity method investments of $3.5 million , an inventory step up related to the Omega acquisition totaling $15.6 million , and an initial payment made in connection with an R&D agreement of $18.0 million . Fiscal Year 2014 First Quarter (2) Second Quarter (3) Third Quarter (4) Fourth Quarter (5) Net sales $ 933.4 $ 979.0 $ 1,004.2 $ 1,144.2 Gross profit $ 356.3 $ 360.7 $ 315.0 $ 415.7 Net income (loss) $ 111.4 $ (86.0 ) $ 48.1 $ 131.7 Earnings (loss) per share (1) : Basic $ 1.18 $ (0.87 ) $ 0.36 $ 0.98 Diluted $ 1.18 $ (0.87 ) $ 0.36 $ 0.98 Weighted average shares outstanding Basic 94.2 98.7 133.7 133.8 Diluted 94.7 98.7 134.3 134.3 (1) The sum of individual per share amounts may not equal due to rounding. (2) Includes Elan transactions costs of $12.0 million , litigation settlement of $2.5 million , and acquisition costs of $1.9 million . (3) Includes loss on extinguishment of debt of $165.8 million , Elan transaction costs of $103.2 million , restructuring charges totaling $14.9 million , write-off of contingent consideration of $4.9 million related to Fera, and write-off of IPR&D totaling $6.0 million related to Paddock and Rosemont. (4) Includes restructuring charges totaling $19.5 million , write-up of contingent consideration of $5.8 million related to Fera, and $3.2 million of Elan transaction costs . (5) Includes restructuring charges totaling $10.5 million and a loss contingency of $15.0 million related to Texas Medicaid.

Derivative Instruments and He45

Derivative Instruments and Hedging Activities (Tables)	12 Months Ended
	Jun. 27, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The balance sheet location and gross fair value of our outstanding derivative instruments were as follows: Asset Derivatives Fair Value Balance Sheet Location June 27, June 28, Designated derivatives: Foreign currency forward contracts Other current assets $ 3.3 $ 2.8 Total designated derivatives $ 3.3 $ 2.8 Non-designated derivatives: Foreign currency forward contracts Other current assets $ 9.1 $ 0.3 Total non-designated derivatives $ 9.1 $ 0.3 Liability Derivatives Fair Value Balance Sheet Location June 27, June 28, Designated derivatives: Foreign currency forward contracts Accrued liabilities $ 2.0 $ 0.7 Interest rate swap agreements Other non-current liabilities — 8.3 Total designated derivatives $ 2.0 $ 9.0 Non-designated derivatives: Foreign currency forward contracts Accrued liabilities $ 2.6 $ 0.1 Total non-designated derivatives $ 2.6 $ 0.1
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]	The gains (losses) recognized in OCI for the effective portion of our designated cash flow hedges were as follows: Amount of Gain/(Loss) Recorded in OCI Designated Cash Flow Hedges June 27, June 28, Treasury locks $ (2.7 ) $ — Interest rate swap agreements (10.1 ) 7.2 Foreign currency forward contracts (7.7 ) 15.1 $ (20.5 ) $ 22.3
Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]	The gains (losses) reclassified from AOCI into earnings for the effective portion of our designated cash flow hedges were as follows: Amount of Gain/(Loss) Reclassified from AOCI to Income Designated Cash Flow Hedges Income Statement Location June 27, June 28, Treasury locks Interest expense, net $ (0.1 ) $ 0.2 Interest rate swap agreements Interest expense, net (16.4 ) 3.9 Foreign currency forward contracts Net sales 2.0 (2.5 ) Cost of sales (4.2 ) (6.3 ) Interest expense, net — (0.2 ) Other expense, net (4.5 ) (2.2 ) $ (23.2 ) $ (7.1 )
Schedule of hedge ineffectiveness [Table Text Block]	The gains (losses) recognized against earnings for the ineffective portion of our designated cash flow hedges were as follows: Amount of Gain/(Loss) Recognized in Income Designated Cash Flow Hedges Income Statement Location June 27, June 28, Treasury locks Other expense, net $ (0.4 ) $ 2.3 Interest rate swap agreements Other expense, net (0.7 ) (5.4 ) Foreign currency forward contracts Net sales (0.1 ) (0.1 ) Cost of sales 0.2 0.3 Total $ (1.0 ) $ (2.9 )
Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]	The effects of our fair value hedges on the Consolidated Statements of Operations were as follows: Amount of Gain/(Loss) Recognized in Income Designated Fair Value Hedges Income Statement Location June 27, June 28, Interest rate swap agreements Other expense, net $ — $ 0.9 Fixed-rate debt Other expense, net — (4.1 ) Net hedge $ — $ (3.2 )
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]	The effects of our non-designated derivatives on the Consolidated Statements of Operations were as follows: Amount of Gain/(Loss) Recognized in Income Non-Designated Derivatives Income Statement Location June 27, June 28, Foreign currency forward contracts Other expense, net $ (295.4 ) $ (0.1 ) Interest expense, net (3.4 ) — Foreign exchange option contracts Other expense, net (26.4 ) — Total $ (325.2 ) $ (0.1 )

Summary of Signifcant Account46

Summary of Signifcant Accounting Policies Policy (Details) $ in Millions		12 Months Ended
		Jun. 27, 2015USD ($)segments	Jun. 28, 2014USD ($)	Jun. 29, 2013USD ($)
Summary of Significant Accounting Policies [Line Items]
Deferred Finance Costs, Net		$ 40.5	$ 27.4
Current year fiscal period (in weeks)
Number of Reportable Segments | segments		4
Customer Related Accruals and Allowances		$ 434.9	$ 318
Percent of royalty revenues generated by specific agreement		96.00%
Maximum Remaining Maturity of Foreign Currency Derivatives			15 months
Balance of non recourse receivables sold		$ 171.6
non recourse receivable activity		23.9
Depreciation		84.3	$ 77.9	$ 66.2
Land		48.7	36.1
Buildings and Improvements, Gross		528.3	430.3
Machinery and Equipment, Gross		1,094	1,001.4
Property, Plant and Equipment, Gross		1,671	1,467.8
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment		(738.6)	(687.9)
Property, Plant and Equipment, Net	[1]	932.4	779.9	681.4
Research and development spending		187.8	152.5	115.2
Advertising Expense		$ 55.7	$ 41.4	$ 26.1
Debt Instrument, Fee		90.2
Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Financial asset servicing fees percentage		0.14%
Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Financial asset servicing fees percentage		0.15%
Machinery and Equipment [Member] | Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Property and equipment, useful life, minimum (in years)		2 years
Machinery and Equipment [Member] | Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Property and equipment, useful life, minimum (in years)		15 years
Building [Member] | Minimum [Member]
Summary of Significant Accounting Policies [Line Items]
Property and equipment, useful life, minimum (in years)		10 years
Building [Member] | Maximum [Member]
Summary of Significant Accounting Policies [Line Items]
Property and equipment, useful life, minimum (in years)		45 years
Foreign Exchange Forward [Member]
Summary of Significant Accounting Policies [Line Items]
Maximum Remaining Maturity of Foreign Currency Derivatives		15 months
[1]	Amounts may not cross-foot due to rounding.

Acquisitions Business Combinati

Acquisitions Business Combination (Details) - Fair Value by Liability Class [Domain] $ / shares in Units, € in Millions, $ in Millions

May. 12, 2015USD ($)

Apr. 08, 2015USD ($)

Mar. 30, 2015EUR (€)shares

Mar. 30, 2015USD ($)$ / sharesshares

Dec. 05, 2014USD ($)

Oct. 31, 2014USD ($)products

Feb. 28, 2014

Feb. 18, 2014USD ($)

Dec. 18, 2013USD ($)shares$ / shares

Feb. 11, 2013USD ($)

Feb. 01, 2013USD ($)

Oct. 01, 2012USD ($)

Jun. 27, 2015USD ($)shares

Mar. 28, 2015USD ($)

Dec. 27, 2014USD ($)

Sep. 27, 2014USD ($)

Jun. 28, 2014USD ($)shares

Mar. 29, 2014USD ($)

Dec. 28, 2013USD ($)

Dec. 29, 2012USD ($)

Mar. 28, 2015USD ($)

Jun. 27, 2015EUR (€)shares

Jun. 27, 2015USD ($)shares

Jun. 28, 2014USD ($)shares

May. 01, 2014

Jun. 29, 2013USD ($)shares

Jun. 27, 2009USD ($)

Nov. 08, 2013USD ($)

Apr. 01, 2013

Dec. 28, 2012USD ($)

Jun. 30, 2012shares

Aug. 06, 2009

May. 29, 2008USD ($)

Business Acquisition [Line Items]

Proceeds from Issuance or Sale of Equity

$ 999.3

Senior notes

$ 4,720.9

$ 2,300

4,720.9

$ 2,300

$ 2,300

Business Acquisition, Pro Forma Revenue

5,671.3

5,816.3

Business Acquisition, Percentage of Voting Interests Acquired

100.00%

Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests

7.2

Payment for Business Combination, Cash Payment

€ 200

$ 223.4

Contingent consideration

17.4

17.4

Percent of royalty revenues generated by specific agreement

96.00%

96.00%

Business Acquisition, Effective Date of Acquisition

May 12, 2015

Purchase Accounting Adjustments

$ (13)

Goodwill

4,971.9

3,474.1

4,971.9

3,474.1

$ 1,089.2

Restructuring

$ 1.1

$ 2.4

$ 1.7

10.5

$ 19.5

$ 14.9

5.1

47

$ 2.9

Business Combination, Acquisition Related Costs

18.5

$ 2

$ 17.8

$ 1.1

Business Acquisition, Pro Forma Net Income (Loss)

$ 122.5

212.8

Extinguishment of Debt, Amount

$ 895

Developed Technology Rights [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

12 years

12 years

Developed Technology Rights [Member] | Minimum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

4 years

4 years

Developed Technology Rights [Member] | Maximum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

13 years

13 years

Trademarks and Trade Names [Member] | Minimum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

8 years

8 years

Trademarks and Trade Names [Member] | Maximum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

20 years

20 years

Tysabri [Member]

Business Acquisition [Line Items]

Percent of royalty revenues generated by specific agreement

12.00%

Tysabri [Member] | Minimum [Member]

Business Acquisition [Line Items]

Percent of royalty revenues generated by specific agreement

18.00%

18.00%

Tysabri [Member] | Maximum [Member]

Business Acquisition [Line Items]

Percent of royalty revenues generated by specific agreement

25.00%

25.00%

Prialt [Member] | Minimum [Member]

Business Acquisition [Line Items]

Percent of royalty revenues generated by specific agreement

7.00%

7.00%

Prialt [Member] | Maximum [Member]

Business Acquisition [Line Items]

Percent of royalty revenues generated by specific agreement

17.50%

17.50%

Customer Relationships [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

20 years

20 years

Customer Relationships [Member] | Minimum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

7 years

7 years

Customer Relationships [Member] | Maximum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

21 years

21 years

Noncompete Agreements [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

2 years

2 years

Distribution And License Agreements [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

20 years

20 years

Naturwohl Pharma [Member]

Business Acquisition [Line Items]

Payment for Business Combination, Cash Payment

€ 130

$ 145.2

Patheon [Member]

Business Acquisition [Line Items]

Payment for Business Combination, Cash Payment

35.8

Omega [Member]

Business Acquisition [Line Items]

Foreign exchange impact on pro forma net sales

189.3

Shares, Issued | shares

5,400,000

Business Acquisition, Share Price | $ / shares

$ 167.64

Treasury Stock, Shares, Acquired | shares

30,243,983

30,243,983

Shares, Outstanding | shares

685,300,000

Business Acquisition, Percentage of Voting Interests Acquired

95.77%

Payment for Business Combination, Cash Payment

[1]

$ 2,983.2

Business Acquisition, Effective Date of Acquisition

Mar. 30, 2015

Mar. 30, 2015

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

[1]

$ 14.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

[1]

264.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

[1]

214.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets, Current

[1]

6.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets

[1]

39.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

[1]

121.2

Goodwill

[1]

1,513.1

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[1]

3,802.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets

[1]

2.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

[1]

5,978.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable

[1]

243.1

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, short term debt

[1]

24.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

[1]

44.5

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, accrued payroll

[1]

51.3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, accrued customer programs

[1]

39.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

[1]

1,038.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

[1]

82.5

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

[1]

2,995.5

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

[1]

2,983.2

Business Combination, Acquisition Related Costs

387

Business Acquisition, Equity Interest Issued or Issuable, Value Assigned

904.9

Business Acquisition, Cash Exchange

2,078.3

Business acquisition, cash consideration paid for vested stock options and awards

[1]

$ 1,471

Debt Instrument, Maturity Date

Jan. 1, 2016

Jan. 1, 2016

Extinguishment of Debt, Amount

$ 539.1

Omega [Member] | Maximum [Member]

Business Acquisition [Line Items]

Indemnification available from acquired company's sellers

€ 277

$ 248

Omega [Member] | Developed Technology Rights [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[1]

32.7

Omega [Member] | Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[1]

2,427.2

Omega [Member] | Customer Relationships [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[1]

1,342.7

Omega [Member] | formulations [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[1]

$ 0

Omega [Member] | Noncompete Agreements [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

3 years

3 years

Omega [Member] | Non-solicit agreement [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

2 years

2 years

Lumara [Member]

Business Acquisition [Line Items]

Payment for Business Combination, Cash Payment

$ 83

Business Acquisition, Effective Date of Acquisition

Oct. 31, 2014

Number of formulations | products

3

Smaller FY15 acquisitions [Member]

Business Acquisition [Line Items]

Payment for Business Combination, Cash Payment

[1],[2]

118.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

[1],[2]

4.6

4.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

[1],[2]

11.4

11.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

[1],[2]

8.7

8.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets, Current

[1],[2]

0.6

0.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets

[1],[2]

2.7

2.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

[1],[2]

6.1

6.1

Goodwill

[1],[2]

4.8

4.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[1],[2]

93

93

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets

[1],[2]

0.4

0.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

[1],[2]

132.3

132.3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable

[1],[2]

4.6

4.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, short term debt

[1],[2]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

[1],[2]

5.5

5.5

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, accrued payroll

[1],[2]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, accrued customer programs

[1],[2]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

[1],[2]

3.3

3.3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

[1],[2]

0.1

0.1

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

[1],[2]

13.5

13.5

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

[1],[2]

118.8

118.8

Business acquisition, cash consideration paid for vested stock options and awards

[1],[2]

0

0

Smaller FY15 acquisitions [Member] | Developed Technology Rights [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[1],[2]

0

0

Smaller FY15 acquisitions [Member] | Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[1],[2]

$ 4.4

Smaller FY15 acquisitions [Member] | Customer Relationships [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[1],[2]

6.6

Smaller FY15 acquisitions [Member] | formulations [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[1],[2]

82

82

Aspen Global [Member]

Business Acquisition [Line Items]

Business Acquisition, Effective Date of Acquisition

Feb. 28, 2014

Fera (methazolomide) [Member]

Business Acquisition [Line Items]

Contingent consideration

$ 0.8

Business Acquisition, Effective Date of Acquisition

Feb. 18, 2014

Elan Corporation [Member]

Business Acquisition [Line Items]

Business Acquisition, Share Price | $ / shares

$ 155.34

Shares, Outstanding | shares

515,700,000

Business Acquisition, Percentage of Voting Interests Acquired

29.00%

Payment for Business Combination, Cash Payment

$ 9,451.9

Contingent consideration

$ 0

Business Acquisition, Effective Date of Acquisition

Dec. 18, 2013

Business Combination, Consideration Transferred

$ 9,451.9

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

1,807.3

business combination, recognized identifiable assets acquired and liabilities assumed, investments

100

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

44.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets

27.1

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

9.2

Goodwill

2,333.1

$ 2,333.1

2,300

$ 2,333.1

2,300

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

5,811

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets

93.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

10,225.3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable

2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

120.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

631.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

18.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

773.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

$ 9,451.9

Business Combination, Acquisition Related Costs

284.9

Business Acquisition, Share Exchange Ratio | shares

0.07636

Total Company shares issued to acquired company shareholders | shares

39,400,000

Business Acquisition, Equity Interest Issued or Issuable, Value Assigned

$ 6,117.2

Business Acquisition, Cash Exchange

3,223.2

Elan Corporation [Member] | Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

0

Elan Corporation [Member] | Customer Relationships [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

0

Elan Corporation [Member] | Noncompete Agreements [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

0

Elan Corporation [Member] | Distribution And License Agreements [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 5,811

Smaller FY14 acquisitions [Member]

Business Acquisition [Line Items]

Payment for Business Combination, Cash Payment

[3]

71

Contingent consideration

[3]

0.8

0.8

Business Combination, Consideration Transferred

[3]

71.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

[3]

0

0

business combination, recognized identifiable assets acquired and liabilities assumed, investments

[3]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

[3]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

[3]

3

3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets

[3]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

[3]

0

0

Goodwill

[3]

4.6

4.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[3]

64.2

64.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets

[3]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

[3]

71.8

71.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable

[3]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

[3]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

[3]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

[3]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

[3]

0

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

[3]

71.8

71.8

Smaller FY14 acquisitions [Member] | Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[3]

34.8

34.8

Smaller FY14 acquisitions [Member] | Customer Relationships [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[3]

9.8

9.8

Smaller FY14 acquisitions [Member] | Noncompete Agreements [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[3]

1.8

1.8

Smaller FY14 acquisitions [Member] | Distribution And License Agreements [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[3]

$ 17.8

$ 17.8

Vedants Drug and Fine Chemicals Private Ltd [Member]

Business Acquisition [Line Items]

Business Acquisition, Percentage of Voting Interests Acquired

15.00%

85.00%

Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests

$ 7.2

$ 11.5

Perrigo Company [Member]

Business Acquisition [Line Items]

Business Acquisition, Percentage of Voting Interests Acquired

71.00%

Vedants Drug & Fine Chemicals [Domain]

Business Acquisition [Line Items]

Business Acquisition, Effective Date of Acquisition

Aug. 6, 2009

Fera Pharmaceuticals, LLC [Domain]

Business Acquisition [Line Items]

Business Acquisition, Effective Date of Acquisition

Jun. 17, 2013

Fera Pharmaceuticals, LLC [Domain] | Developed Technology Rights [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

15 years

Velcera, Inc. [Domain]

Business Acquisition [Line Items]

Business Acquisition, Percentage of Voting Interests Acquired

100.00%

Payment for Business Combination, Cash Payment

$ 175.1

Contingent consideration

0

Business Acquisition, Effective Date of Acquisition

Apr. 1, 2013

Business Combination, Consideration Transferred

$ 175.1

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

18.9

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

6.3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

9.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

0.6

Goodwill

62.5

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

135.3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Noncurrent

7.9

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets

0.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

241.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable

6.5

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

4.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

48.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

66.5

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

175.1

Velcera, Inc. [Domain] | Developed Technology Rights [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

0

Velcera, Inc. [Domain] | Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

25 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

7.6

Velcera, Inc. [Domain] | Customer Relationships [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

20 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

8.7

Velcera, Inc. [Domain] | Noncompete Agreements [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

3 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

3

Velcera, Inc. [Domain] | Distribution And License Agreements [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

10 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

116

Velcera, Inc. [Domain] | In Process Research and Development [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

0

Velcera, Inc. [Domain] | favorable supply agreement [Domain]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 0

Smaller FY13 acquisitions [Member]

Business Acquisition [Line Items]

Payment for Business Combination, Cash Payment

[4]

139.9

Contingent consideration

[4]

22.2

Business Combination, Consideration Transferred

[4]

162.1

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

[4]

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

[4]

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

[4]

1.3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

[4]

0

Goodwill

[4]

18.1

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[4]

158.1

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Noncurrent

[4]

3.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets

[4]

0.3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

[4]

181.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable

[4]

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

[4]

0.5

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

[4]

18.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

[4]

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

[4]

19.3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

[4]

162.1

Smaller FY13 acquisitions [Member] | Developed Technology Rights [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[4]

158.1

Smaller FY13 acquisitions [Member] | Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[4]

0

Smaller FY13 acquisitions [Member] | Customer Relationships [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[4]

0

Smaller FY13 acquisitions [Member] | Noncompete Agreements [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[4]

0

Smaller FY13 acquisitions [Member] | Distribution And License Agreements [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[4]

0

Smaller FY13 acquisitions [Member] | In Process Research and Development [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[4]

0

Smaller FY13 acquisitions [Member] | favorable supply agreement [Domain]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

[4]

$ 0

Rosemont Pharmaceuticals Ltd. [Domain]

Business Acquisition [Line Items]

Business Acquisition, Percentage of Voting Interests Acquired

100.00%

Payment for Business Combination, Cash Payment

$ 282.9

Contingent consideration

0

Business Acquisition, Effective Date of Acquisition

Dec. 28, 2012

Business Combination, Consideration Transferred

$ 282.9

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

2.1

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

10.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

9.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

13.1

Goodwill

147

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

148.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Noncurrent

0.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets

0.8

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

331.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable

2.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

7.6

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

36

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

2.5

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

48.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

282.9

Rosemont Pharmaceuticals Ltd. [Domain] | Developed Technology Rights [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

14 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

114.6

Rosemont Pharmaceuticals Ltd. [Domain] | Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

17.3

Rosemont Pharmaceuticals Ltd. [Domain] | Customer Relationships [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

0

Rosemont Pharmaceuticals Ltd. [Domain] | Noncompete Agreements [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

3 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

1.5

Rosemont Pharmaceuticals Ltd. [Domain] | Distribution And License Agreements [Member]

Business Acquisition [Line Items]

Acquired Finite-lived Intangible Assets, Weighted Average Useful Life

7 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

3.6

Rosemont Pharmaceuticals Ltd. [Domain] | In Process Research and Development [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

11.2

Rosemont Pharmaceuticals Ltd. [Domain] | favorable supply agreement [Domain]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 0

Cobrek Pharmaceuticals, Inc. [Domain]

Business Acquisition [Line Items]

Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage

81.50%

18.50%

Payment for Business Combination, Cash Payment

$ 42

$ 12.6

Business Acquisition, Effective Date of Acquisition

Feb. 11, 2013

Cobrek Pharmaceuticals, Inc. [Domain] | Developed Technology Rights [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

12 years

Sergeant's Pet Care Products, Inc. [Domain]

Business Acquisition [Line Items]

Payment for Business Combination, Cash Payment

$ 285

Contingent consideration

0

Business Acquisition, Effective Date of Acquisition

Oct. 1, 2012

Business Combination, Consideration Transferred

$ 285

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables

19.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory

37.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment

25.4

Goodwill

80.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

135.4

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Noncurrent

1.5

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets

3

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets

302.9

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable

13.7

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities

4.2

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Noncurrent

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities

0

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities

17.9

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net

285

Sergeant's Pet Care Products, Inc. [Domain] | Developed Technology Rights [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

10 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

66.1

Sergeant's Pet Care Products, Inc. [Domain] | Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

33

Sergeant's Pet Care Products, Inc. [Domain] | Customer Relationships [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

20 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

10

Sergeant's Pet Care Products, Inc. [Domain] | Noncompete Agreements [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

0

Sergeant's Pet Care Products, Inc. [Domain] | Noncompete Agreements [Member] | Minimum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

1 year

Sergeant's Pet Care Products, Inc. [Domain] | Noncompete Agreements [Member] | Maximum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

3 years

Sergeant's Pet Care Products, Inc. [Domain] | Distribution And License Agreements [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

1.3

Inventory step-up charges

$ 7.7

Fixed Assets Fair Value Adjustment

$ 6.1

Sergeant's Pet Care Products, Inc. [Domain] | In Process Research and Development [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

0

Sergeant's Pet Care Products, Inc. [Domain] | favorable supply agreement [Domain]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

7 years

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles

$ 25

Gelcaps [Member] | Customer-Related Intangible Assets [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

20 years

Gelcaps [Member] | Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

25 years

Aspen Global [Member] | Customer-Related Intangible Assets [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

15 years

15 years

Aspen Global [Member] | Trademarks and Trade Names [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

25 years

25 years

Aspen Global [Member] | Noncompete Agreements [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

5 years

5 years

Lumara [Member] | Minimum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

8 years

8 years

Lumara [Member] | Maximum [Member]

Business Acquisition [Line Items]

Finite-Lived Intangible Asset, Useful Life

12 years

12 years

Interest Net [Member] | Omega [Member]

Business Acquisition [Line Items]

Business Combination, Acquisition Related Costs

$ 23.7

Interest Net [Member] | Elan Corporation [Member]

Business Acquisition [Line Items]

Business Combination, Acquisition Related Costs

$ 10

Other Expense [Member] | Omega [Member]

Business Acquisition [Line Items]

Business Combination, Acquisition Related Costs

324

Other Expense [Member] | Elan Corporation [Member]

Business Acquisition [Line Items]

Business Combination, Acquisition Related Costs

0.2

Discharge of Debt [Member] | Omega [Member]

Business Acquisition [Line Items]

Business Combination, Acquisition Related Costs

9.6

Discharge of Debt [Member] | Elan Corporation [Member]

Business Acquisition [Line Items]

Business Combination, Acquisition Related Costs

165.8

General and Administrative Expense [Member] | Omega [Member]

Business Acquisition [Line Items]

Business Combination, Acquisition Related Costs

$ 29.7

General and Administrative Expense [Member] | Elan Corporation [Member]

Business Acquisition [Line Items]

Business Combination, Acquisition Related Costs

$ 108.9

5.1045% Senior Note [Member] | Omega [Member]

Business Acquisition [Line Items]

Business acquisition, cash consideration paid for vested stock options and awards

$ 147

Debt Instrument, Interest Rate, Stated Percentage

5.1045%

Debt Instrument, Maturity Date

Jan. 1, 2023

Jan. 1, 2023

6.19% Senior Note [Member] | Omega [Member]

Business Acquisition [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

6.19%

5.125% Retail Bond [Member] | Omega [Member]

Business Acquisition [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.125%

Debt Instrument, Maturity Date

Jan. 1, 2017

Jan. 1, 2017

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 326.7

4.5% Retail Bond [Member] | Omega [Member]

Business Acquisition [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.50%

Debt Instrument, Maturity Date

Jan. 1, 2017

Jan. 1, 2017

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 196

5.0% Retail Bond [Member] | Omega [Member]

Business Acquisition [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Maturity Date

Jan. 1, 2019

Jan. 1, 2019

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 130.7

Credit facility indebtedness [Member] | Omega [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

544.5

Over Draft [Member] | Omega [Member]

Business Acquisition [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

56

Inventories [Member] | Gelcaps [Member]

Business Acquisition [Line Items]

Inventory Adjustments

$ 0.6

Inventories [Member] | Omega [Member]

Business Acquisition [Line Items]

Inventory Adjustments

15.1

Property, Plant and Equipment [Member] | Gelcaps [Member]

Business Acquisition [Line Items]

Inventory Adjustments

$ 0.9

Property, Plant and Equipment [Member] | Omega [Member]

Business Acquisition [Line Items]

Inventory Adjustments

41.5

Long-term Debt [Member] | Omega [Member]

Business Acquisition [Line Items]

Inventory Adjustments

$ 101.9

Common Stock Issued [Member]

Business Acquisition [Line Items]

Treasury Stock, Shares, Acquired | shares

100,000

100,000

60,000

112,000

Stock Issued During Period, Shares, New Issues | shares

6,800,000

6,800,000

Shares, Outstanding | shares

146,300,000

133,800,000

146,300,000

133,800,000

94,100,000

93,500,000

Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests

$ 7.2

[1]

Omega and Gelcaps opening balance sheets are preliminary.

[2]

Includes opening balance sheets for the Gelcaps acquisition and Lumara product acquisition.

[3]

Includes opening balance sheet of the Aspen and Fera (Methazolomide) product acquisitions.

[4]

Includes opening balance sheet of the Cobrek acquisition and Fera product acquisition.

Acquisitions Asset Acquisitions

Acquisitions Asset Acquisitions (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014	May. 01, 2014	Jun. 29, 2013
Acquired Finite-Lived Intangible Assets [Line Items]
Percent of royalty revenues generated by specific agreement	96.00%
Net sales for royalties	$ 4,603.9	$ 4,060.8		$ 3,539.8
Tysabri [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Percent of royalty revenues generated by specific agreement			12.00%
Finite-lived Intangible Assets Acquired	$ 5,800
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	2 years
Prialt [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets Acquired	$ 11
Distribution And License Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Fera Pharmaceuticals, LLC [Domain] | Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		15 years
Velcera, Inc. [Domain] | Trademarks and Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		25 years
Velcera, Inc. [Domain] | Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		3 years
Velcera, Inc. [Domain] | Distribution And License Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		10 years
Velcera, Inc. [Domain] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		20 years
Rosemont Pharmaceuticals Ltd. [Domain] | Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		3 years
Rosemont Pharmaceuticals Ltd. [Domain] | Distribution And License Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		7 years
Rosemont Pharmaceuticals Ltd. [Domain] | Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		14 years
Cobrek Pharmaceuticals, Inc. [Domain] | Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		12 years
Sergeant's Pet Care Products, Inc. [Domain] | Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life				10 years
Sergeant's Pet Care Products, Inc. [Domain] | favorable supply agreement [Domain]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life				7 years
Sergeant's Pet Care Products, Inc. [Domain] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		20 years
Fera (methazolomide) [Member] | Customer-Related Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	15 years
Elan Corporation [Member] | Tysabri [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Elan Corporation [Member] | Prialt [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years
Minimum [Member] | Tysabri [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Percent of royalty revenues generated by specific agreement	18.00%
Net sales for royalties	$ 2,000
Minimum [Member] | Trademarks and Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	8 years
Minimum [Member] | Prialt [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Percent of royalty revenues generated by specific agreement	7.00%
Minimum [Member] | Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	4 years
Minimum [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	7 years
Minimum [Member] | Sergeant's Pet Care Products, Inc. [Domain] | Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		1 year
Maximum [Member] | Tysabri [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Percent of royalty revenues generated by specific agreement	25.00%
Net sales for royalties	$ 2,000
Maximum [Member] | Trademarks and Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	20 years
Maximum [Member] | Prialt [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Percent of royalty revenues generated by specific agreement	17.50%
Maximum [Member] | Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	13 years
Maximum [Member] | Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	21 years
Maximum [Member] | Sergeant's Pet Care Products, Inc. [Domain] | Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life		3 years

Fair value of consideration pai

Fair value of consideration paid (Details) $ / shares in Units, € in Millions, $ in Millions	Dec. 18, 2013USD ($)shares$ / shares	Jun. 27, 2015EUR (€)	Jun. 27, 2015USD ($)	Jun. 28, 2014USD ($)	May. 12, 2015
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Business Acquisition, Cash Exchange per share | $ / shares	$ 6.25
Business Acquisition, Percentage of Voting Interests Acquired					100.00%
Payment for Business Combination, Cash Payment		€ 200	$ 223.4
Elan Corporation [Member]
Business Acquisition, Equity Interests Issued or Issuable [Line Items]
Business acquisition, cash consideration paid on unvested stock options and awards				$ 16.1
Shares, Outstanding | shares	515,700,000
Business Acquisition, Share Exchange Ratio | shares	0.07636
Total Company shares issued to acquired company shareholders | shares	39,400,000
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 6,117.2
Business Acquisition, Cash Exchange	3,223.2
Business acquisition, cash consideration paid for vested stock options and awards	111.5
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	$ 9,451.9
Business Acquisition, Percentage of Voting Interests Acquired	29.00%
Business Combination, Consideration Transferred	$ 9,451.9
Payment for Business Combination, Cash Payment	$ 9,451.9

Acquisitions Schedule of acquis

Acquisitions Schedule of acquisition costs (Details) - USD ($) $ in Millions	3 Months Ended				12 Months Ended
	Jun. 27, 2015	Mar. 28, 2015	Dec. 27, 2014	Sep. 27, 2014	Jun. 28, 2014
schedule of acquisition expenses [Line Items]
Business Combination, Acquisition Related Costs	$ 18.5	$ 2	$ 17.8	$ 1.1
Elan Corporation [Member]
schedule of acquisition expenses [Line Items]
Business Combination, Acquisition Related Costs					$ 284.9
Elan Corporation [Member] | General and Administrative Expense [Member]
schedule of acquisition expenses [Line Items]
Business Combination, Acquisition Related Costs					108.9
Elan Corporation [Member] | Interest Net [Member]
schedule of acquisition expenses [Line Items]
Business Combination, Acquisition Related Costs					10
Elan Corporation [Member] | Other Expense [Member]
schedule of acquisition expenses [Line Items]
Business Combination, Acquisition Related Costs					0.2
Elan Corporation [Member] | Discharge of Debt [Member]
schedule of acquisition expenses [Line Items]
Business Combination, Acquisition Related Costs					$ 165.8

Acquisitions Goodwill allocatio

Acquisitions Goodwill allocation (Details) - USD ($) $ in Millions	Jun. 27, 2015	Jun. 28, 2014	Dec. 18, 2013	Jun. 29, 2013
Business Combination Segment Allocation [Line Items]
Goodwill	$ 4,971.9	$ 3,474.1		$ 1,089.2
CHC [Member]
Business Combination Segment Allocation [Line Items]
Goodwill	1,897.5	1,916.4		611.6
Rx Pharmaceuticals [Member]
Business Combination Segment Allocation [Line Items]
Goodwill	1,233.6	1,258.3		385.4
Specialty Sciences [Member]
Business Combination Segment Allocation [Line Items]
Goodwill	200.7	201.8		$ 0
Elan Corporation [Member]
Business Combination Segment Allocation [Line Items]
Goodwill	2,333.1	$ 2,300	$ 2,333.1
Elan Corporation [Member] | CHC [Member]
Business Combination Segment Allocation [Line Items]
Goodwill	1,287.4
Elan Corporation [Member] | Rx Pharmaceuticals [Member]
Business Combination Segment Allocation [Line Items]
Goodwill	845.1
Elan Corporation [Member] | Specialty Sciences [Member]
Business Combination Segment Allocation [Line Items]
Goodwill	$ 200.6

Acquisitions Pro forma (Details

Acquisitions Pro forma (Details) - USD ($) $ in Millions		3 Months Ended								12 Months Ended
		Jun. 27, 2015	Mar. 28, 2015	Dec. 27, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 28, 2013	Sep. 28, 2013	Jun. 27, 2015		Jun. 28, 2014		Jun. 29, 2013
Business Combination, Separately Recognized Transactions [Line Items]
Net sales										$ 4,603.9		$ 4,060.8		$ 3,539.8
Business Acquisition, Pro Forma Net Income (Loss)										122.5		212.8
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles										(13)
Net sales		$ 1,531.6	$ 1,049.1	$ 1,071.7	$ 951.5	$ 1,144.2	$ 1,004.2	$ 979	$ 933.4	4,603.9	[1]	4,060.8	[1]	3,539.8	[1]
Operating income	[1]									747.7		567		679.1
Amortization of Intangible Assets										464.5		281		94
Restructuring			$ 1.1	$ 2.4	$ 1.7	$ 10.5	$ 19.5	$ 14.9		5.1		47		$ 2.9
Fiscal 2015 acquisitions [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Net sales										418.2
Operating income										$ 18.9
Fiscal 2014 acquisitions [Member]
Business Combination, Separately Recognized Transactions [Line Items]
Net sales												168.5
Operating income												$ (53.9)
[1]	Amounts may not cross-foot due to rounding.

Goodwill and Other Intangible53

Goodwill and Other Intangible Assets Goodwill (Details) - USD ($)	3 Months Ended	12 Months Ended
	Jun. 27, 2015	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Goodwill [Line Items]
Research and Development Asset Acquired, Written-off		$ 0	$ 6,000,000	$ 9,000,000
Impairment of Intangible Assets, Finite-lived		0	0
Goodwill [Roll Forward]
Beginning balance		3,474,100,000	1,089,200,000
Business acquisitions		1,517,900,000	2,350,000,000
Goodwill impairment charge	$ (6,800,000)	(6,800,000)	0	0
Currency translation adjustment		(300,000)	34,900,000
Purchase Accounting Adjustments		(13,000,000)
Ending balance	4,971,900,000	4,971,900,000	3,474,100,000	1,089,200,000
CHC [Member]
Goodwill [Roll Forward]
Beginning balance		1,916,400,000	611,600,000
Business acquisitions		4,800,000	1,297,200,000
Goodwill impairment charge		(6,800,000)
Currency translation adjustment		(9,700,000)	7,600,000
Purchase Accounting Adjustments		(7,200,000)
Ending balance	1,897,500,000	1,897,500,000	1,916,400,000	611,600,000
BCH [Member]
Goodwill [Roll Forward]
Beginning balance		0	0
Business acquisitions		1,513,100,000	0
Goodwill impairment charge		0
Currency translation adjustment		38,800,000	0
Purchase Accounting Adjustments		0
Ending balance	1,551,900,000	1,551,900,000	0	0
Rx Pharmaceuticals [Member]
Goodwill [Roll Forward]
Beginning balance		1,258,300,000	385,400,000
Business acquisitions		0	851,000,000
Goodwill impairment charge		0
Currency translation adjustment		(20,000,000)	21,900,000
Purchase Accounting Adjustments		(4,700,000)
Ending balance	1,233,600,000	1,233,600,000	1,258,300,000	385,400,000
Specialty Sciences [Member]
Goodwill [Roll Forward]
Beginning balance		201,800,000	0
Business acquisitions		0	201,800,000
Goodwill impairment charge		0
Currency translation adjustment		0	0
Purchase Accounting Adjustments		(1,100,000)
Ending balance	200,700,000	200,700,000	201,800,000	0
Other [Member]
Goodwill [Roll Forward]
Beginning balance		97,600,000	92,200,000
Business acquisitions		0	0
Goodwill impairment charge		0
Currency translation adjustment		(9,400,000)	5,400,000
Purchase Accounting Adjustments		0
Ending balance	88,200,000	88,200,000	97,600,000	$ 92,200,000
Elan Corporation [Member]
Goodwill [Line Items]
Amount of goodwill allocated to other business segments			2,100,000,000
Goodwill [Roll Forward]
Beginning balance		2,300,000,000
Ending balance	2,333,100,000	2,333,100,000	2,300,000,000
Elan Corporation [Member] | CHC [Member]
Goodwill [Roll Forward]
Ending balance	1,287,400,000	1,287,400,000
Elan Corporation [Member] | Rx Pharmaceuticals [Member]
Goodwill [Roll Forward]
Ending balance	845,100,000	845,100,000
Elan Corporation [Member] | Specialty Sciences [Member]
Goodwill [Roll Forward]
Ending balance	$ 200,600,000	200,600,000
Aspen Global [Member] | CHC [Member]
Goodwill [Roll Forward]
Beginning balance		4,600,000
Ending balance			$ 4,600,000
MEXICO | CHC [Member]
Goodwill [Roll Forward]
Goodwill impairment charge		$ (6,800,000)

Goodwill and Other Intangible54

Goodwill and Other Intangible Assets Intangible Assets (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Finite And Indefinite Lived Assets By Major Class [Line Items]
Goodwill, Acquired During Period	$ 1,517.9	$ 2,350
Intangible assets subject to amortization, Gross	9,160.6	7,394.1
Intangible assets subject to amortization, Accumulated Amortization	1,055	607.1
Intangible assets not subject to amortization	2,263.1	69.7
Total other intangible assets	11,423.7	7,463.8
Research and Development Asset Acquired, Written-off	0	(6)	$ (9)
Amortization of Intangible Assets	464.5	281	$ 94
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
2,016	589.1
2,017	582.7
2,018	569.3
2,019	551.8
2,020	521.6
Thereafter	5,291.1
Trade names and trademarks [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets not subject to amortization	2,257.3	59.5
In Process Research and Development [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets not subject to amortization	5.8	10.2
Distribution And License Agreements [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets subject to amortization, Gross	6,029.9	6,027.3
Intangible assets subject to amortization, Accumulated Amortization	$ 502.3	192.1
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Developed Technology Rights [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets subject to amortization, Gross	$ 1,025.3	931.7
Intangible assets subject to amortization, Accumulated Amortization	$ 383.1	302.5
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years
Customer Relationships [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets subject to amortization, Gross	$ 1,749.9	372
Intangible assets subject to amortization, Accumulated Amortization	$ 146.2	97.5
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Trade names and trademarks [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets subject to amortization, Gross	$ 340.8	47.8
Intangible assets subject to amortization, Accumulated Amortization	$ 11.5	5.6
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	19 years
Noncompete Agreements [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Intangible assets subject to amortization, Gross	$ 14.7	15.3
Intangible assets subject to amortization, Accumulated Amortization	$ 11.9	9.4
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	2 years
Paddock Laboratories Inc [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Reclass of IPR&D to Developed Product Technology		$ 13
Paddock Laboratories Inc [Member] | Developed Technology Rights [Member]
Finite And Indefinite Lived Assets By Major Class [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life		12 years

Goodwill and Other Intangible55

Goodwill and Other Intangible Assets Intangible asset useful lives (Details)	12 Months Ended
	Jun. 27, 2015
Distribution And License Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	12 years
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	20 years
Trade names and trademarks [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	19 years
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	2 years

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jun. 27, 2015	Jun. 28, 2014
Inventory [Abstract]
Finished Goods	$ 468.9	$ 307
Work in Process	158.2	146.7
Raw Materials	211.8	177.9
Total Inventory	$ 838.9	$ 631.6

Fair Value Measurements Fair va

Fair Value Measurements Fair value on recurring and nonrecurring basis (Details) - USD ($) $ in Millions	Jun. 27, 2015	Jun. 28, 2014
Assets:
Investments	$ 12.7	$ 20.7
Foreign currency forward contracts (asset)	12.4	3.1
Funds associated with Israeli post employment benefits	17.3	19.3
Total Fair Value Assets	42.4	43.1
Liabilities:
Contingent consideration		17.4
Interest rate swap agreements		8.3
Foreign Currency Forward Contracts	4.6	0.8
Total Fair Value Liabilities	4.6	26.5
Fair Value, Inputs, Level 1 [Member]
Assets:
Investments	12.7	20.7
Foreign currency forward contracts (asset)	0	0
Funds associated with Israeli post employment benefits	0	0
Total Fair Value Assets	12.7	20.7
Liabilities:
Contingent consideration		0
Interest rate swap agreements		0
Foreign Currency Forward Contracts	0	0
Total Fair Value Liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Assets:
Investments	0	0
Foreign currency forward contracts (asset)	12.4	3.1
Funds associated with Israeli post employment benefits	17.3	19.3
Total Fair Value Assets	29.7	22.4
Liabilities:
Contingent consideration		0
Interest rate swap agreements		8.3
Foreign Currency Forward Contracts	4.6	0.8
Total Fair Value Liabilities	4.6	9.1
Level 3 [Member]
Assets:
Investments	0	0
Foreign currency forward contracts (asset)	0	0
Funds associated with Israeli post employment benefits	0	0
Total Fair Value Assets	0	0
Liabilities:
Contingent consideration		17.4
Interest rate swap agreements		0
Foreign Currency Forward Contracts	0	0
Total Fair Value Liabilities	$ 0	$ 17.4

Fair Value Measurements Level 3

Fair Value Measurements Level 3 recurring basis (Details 2) - Contingent Consideration Classified as Equity [Member] - Level 3 [Member] - USD ($) $ in Millions	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value	$ 0	$ 17.4	$ 22.2
Investment Securities, Unobservable Inputs, Gain (Loss) Included in Earnings	0.9	1.1
Investment Securities, Unobservable Inputs, Purchases	0	0.8
Investment Securities, Unobservable Inputs, Settlements	$ (18.3)	$ (6.7)

Fair Value Measurements Narrati

Fair Value Measurements Narrative (Details 3) - USD ($)	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014	Nov. 08, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed-rate long-term debt	$ 4,720,900,000	$ 2,300,000,000	$ 2,300,000,000
Long-term Debt	820,900,000
Fair value of fixed-rate long-term debt		900,000,000
Fair Value, Assets, Level 1, Level 2, Level 3 Transfers, Amount	0	0
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed-rate long-term debt	3,900,000,000
Fair value of fixed-rate long-term debt	$ 3,900,000,000
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fixed-rate long-term debt		2,300,000,000
Fair value of fixed-rate long-term debt		$ 2,400,000,000

Fair Value Measurements Fair 60

Fair Value Measurements Fair value (Details) $ in Billions	Jun. 28, 2014USD ($)
Fair Value Disclosures [Abstract]
Debt Instrument, Fair Value Disclosure	$ 0.9

Investments - Available for Sal

Investments - Available for Sale Securities (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 28, 2014	Jun. 27, 2015
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities	$ 20.7
Net unrealized investment gains (losses):
Equity securities, at cost less impairments	17.1	$ 17.1
Gross unrealized gains	3.8	5.7
Gross unrealized losses	(0.2)	(10.1)
Estimated fair value of equity securities	20.7	12.7
Available-for-sale Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities	5.9	$ 12.7
Available-for-sale Securities, Gross Realized Losses	(9.9)
Other Noncurrent Assets [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale Securities	$ 14.8

Investments - Equity Method Inv

Investments - Equity Method Investments (Details) - USD ($) $ in Millions	3 Months Ended			12 Months Ended
	Jun. 27, 2015	Dec. 27, 2014	Sep. 27, 2014	Jun. 27, 2015	Jun. 28, 2014
Schedule of Equity Method Investments [Line Items]
Net loss from equity method investment	$ 3.5	$ 3	$ 3.1	$ (9.9)	$ (8.7)
Realized loss on sale of equity method investment					(2.8)
Other Noncurrent Assets [Member]
Schedule of Equity Method Investments [Line Items]
Cost Method Investments	6.8			6.8	9
Equity method investments	$ 48.9			$ 48.9	$ 57.4

Indebtedness (Details)

Indebtedness (Details) € in Millions

Apr. 08, 2015EUR (€)

Apr. 08, 2015USD ($)

Mar. 30, 2015EUR (€)

Mar. 30, 2015USD ($)

Dec. 05, 2014USD ($)

Dec. 02, 2014USD ($)

Nov. 06, 2014EUR (€)

Jul. 28, 2014

Dec. 27, 2013USD ($)

Dec. 23, 2013USD ($)

Dec. 18, 2013USD ($)

Sep. 06, 2013USD ($)

Nov. 30, 2013USD ($)

Dec. 27, 2014USD ($)

Dec. 28, 2013USD ($)

Jun. 27, 2015USD ($)

Jun. 28, 2014USD ($)

Jun. 29, 2013USD ($)

Mar. 30, 2015USD ($)

Dec. 05, 2014EUR (€)

Dec. 05, 2014USD ($)

Nov. 08, 2013USD ($)

Jul. 28, 2013USD ($)

Debt Instrument [Line Items]

Maximum Borrowings Under Securitization Program

$ 200,000,000

Short term debt

6,400,000

$ 2,100,000

Term loans

$ 1,000,000,000

530,500,000

930,000,000

Senior notes

4,720,900,000

2,300,000,000

$ 2,300,000,000

Other financing

6,600,000

8,100,000

Unamortized premium, net

87,500,000

(6,000,000)

Deferred financing fees

(40,500,000)

(27,400,000)

Total borrowings outstanding

5,311,400,000

3,206,800,000

Debt, Short Term and Current Portion of Long Term

(64,600,000)

(143,700,000)

Total long-term debt, less current portion

5,246,900,000

3,063,100,000

Payments for Deposits Applied to Debt Retirements

$ 133,500,000

Write off of financing fees on bridge credit agreements

19,000,000

Line of Credit Facility, Collateral

364 days

Debt Instrument, Issuance Date

Dec. 5, 2014

Nov. 6, 2014

Jul. 28, 2013

Sep. 6, 2013

Line of Credit Facility, Maximum Borrowing Capacity | €

€ 1,000

Line of Credit Facility, Fair Value of Amount Outstanding

0

0

Borrowings Outstanding Under Securitization Program

0

0

Gains (Losses) on Extinguishment of Debt [Abstract]

Extinguishment of Debt, Amount

$ 895,000,000

Write off of financing fees

10,500,000

Write-off of unamortized discount

2,800,000

Total loss on extinguishment of debt

$ (9,600,000)

$ 165,800,000

10,500,000

$ 165,800,000

$ 0

Long-term Debt, Fiscal Year Maturity [Abstract]

Annual maturities of debt: 2015

65,000,000

Annual maturities of debt: 2016

758,500,000

Annual maturities of debt: 2017

399,100,000

Annual maturities of debt: 2018

811,300,000

Annual maturities of debt: 2019

279,500,000

Annual maturities of debt: Thereafter

$ 2,950,800,000

2014 Euro-Denominated Term Loan due December 5, 2019 additional draw [Domain]

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount | €

368.6

2014 term loan due December 18, 2015 [Member]

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount

$ 300,000,000

2014 Euro-Denominated Term Loan due December 5, 2019 [Member]

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount | €

614.3

3.5% Senior note due 2021 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

3.50%

3.50%

Debt Instrument, Maturity Date

Dec. 15, 2021

Debt Instrument, Issuance Date

Dec. 2, 2014

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount

$ 500,000,000

3.9% senior note due 2024 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

3.90%

3.90%

Debt Instrument, Maturity Date

Dec. 15, 2024

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount

$ 700,000,000

4.9% Senior Loan due 2044 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.90%

4.90%

Debt Instrument, Maturity Date

Dec. 15, 2044

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount

$ 400,000,000

1.30% Unsecured Senior Notes due November 8, 2016 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

1.30%

1.30%

Debt Instrument, Maturity Date

Nov. 8, 2016

Nov. 8, 2016

2.30% Unsecured Senior notes November 8, 2018 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

2.30%

2.30%

Debt Instrument, Maturity Date

Nov. 8, 2018

Nov. 8, 2018

4.00% Unsecured Senior Notes due November 15, 2023 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.00%

4.00%

Debt Instrument, Maturity Date

Nov. 15, 2023

Nov. 15, 2023

5.30% Unsecured Senior Notes due November 15, 2043 [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.30%

5.30%

Debt Instrument, Maturity Date

Nov. 15, 2043

Nov. 15, 2043

Bridge Credit Agreements [Member]

Debt Instrument [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity | €

€ 2,170

2014 bonds [Member]

Debt Instrument [Line Items]

Senior notes

$ 1,600,000,000

Revolving Credit Facility [Member]

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount

$ 600,000,000

Debt Bridge Credit Agreement [Member]

Debt Instrument [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$ 2,650,000,000

Cash Bridge Credit Agreement [Member]

Debt Instrument [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

$ 1,700,000,000

5.105% Senior note due July 19, 2023 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.105%

Debt Instrument, Maturity Date

Jul. 19, 2023

Senior notes

[1]

$ 150,800,000

[2]

$ 0

5.000% Unsecured Senior notes due May 23, 2019 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

Debt Instrument, Maturity Date

May 23, 2019

Senior notes

[1]

$ 134,100,000

[2]

0

4.500% Unsecured Senior Notes due May 23, 2017 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.50%

Debt Instrument, Maturity Date

May 23, 2017

Senior notes

[1]

$ 201,000,000

[2]

$ 0

2014 Euro-Denominated Term Loan due December 5, 2019 [Member]

Debt Instrument [Line Items]

Debt Instrument, Maturity Date

Dec. 5, 2019

Dec. 5, 2019

Term loans

$ 530,500,000

$ 0

2013 Term Loan due December 18, 2015 [Member]

Debt Instrument [Line Items]

Debt Instrument, Maturity Date

Dec. 18, 2015

Dec. 18, 2015

Term loans

$ 300,000,000

$ 0

$ 300,000,000

2013 Term Loan due December 18, 2018 [Member]

Debt Instrument [Line Items]

Debt Instrument, Maturity Date

Dec. 18, 2018

Dec. 18, 2018

Term loans

$ 700,000,000

$ 0

$ 630,000,000

3.5% Senior note due 2021 [Member]

Debt Instrument [Line Items]

Senior notes

[3]

500,000,000

0

3.9% senior note due 2024 [Member]

Debt Instrument [Line Items]

Senior notes

[3]

700,000,000

0

4.9% Senior Loan due 2044 [Member]

Debt Instrument [Line Items]

Senior notes

[3]

400,000,000

0

1.30% Unsecured Senior Notes due November 8, 2016 [Member]

Debt Instrument [Line Items]

Senior notes

[4]

500,000,000

500,000,000

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount

500,000,000

2.30% Unsecured Senior notes November 8, 2018 [Member]

Debt Instrument [Line Items]

Senior notes

[4]

600,000,000

600,000,000

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount

600,000,000

4.00% Unsecured Senior Notes due November 15, 2023 [Member]

Debt Instrument [Line Items]

Senior notes

[4]

800,000,000

800,000,000

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount

800,000,000

5.30% Unsecured Senior Notes due November 15, 2043 [Member]

Debt Instrument [Line Items]

Senior notes

[4]

$ 400,000,000

400,000,000

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount

$ 400,000,000

2011 Term Loan due October 26, 2016 [Member]

Gains (Losses) on Extinguishment of Debt [Abstract]

Extinguishment of Debt, Amount

$ 360,000,000

2.95% Unsecured Senior Notes due May 15, 2023 [Member] | Tender Offer [Member]

Gains (Losses) on Extinguishment of Debt [Abstract]

Repayments of Debt

$ 578,300,000

2.95% Unsecured Senior Notes due May 15, 2023 [Member] | Redemption [Member]

Gains (Losses) on Extinguishment of Debt [Abstract]

Repayments of Debt

$ 28,500,000

Senior notes [Member]

Gains (Losses) on Extinguishment of Debt [Abstract]

Repayments of Debt

$ 1,100,000,000

5.125% Unsecured Senior Notes due December 12, 2017 [Domain]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.125%

Debt Instrument, Maturity Date

Dec. 12, 2017

Senior notes

[1]

$ 335,000,000

[2]

$ 0

Omega [Member]

Debt Instrument [Line Items]

Debt Instrument, Maturity Date

Jan. 1, 2016

Jan. 1, 2016

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt

[5]

$ 1,471,000,000

Gains (Losses) on Extinguishment of Debt [Abstract]

Extinguishment of Debt, Amount

$ 539,100,000

Omega [Member] | 5.125% Retail Bond [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.125%

5.125%

Debt Instrument, Maturity Date

Jan. 1, 2017

Jan. 1, 2017

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 326,700,000

Omega [Member] | Over Draft [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 56,000,000

Omega [Member] | 4.5% Retail Bond [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

4.50%

4.50%

Debt Instrument, Maturity Date

Jan. 1, 2017

Jan. 1, 2017

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 196,000,000

Omega [Member] | 5.0% Retail Bond [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.00%

5.00%

Debt Instrument, Maturity Date

Jan. 1, 2019

Jan. 1, 2019

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 130,700,000

Omega [Member] | Credit facility indebtedness [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 544,500,000

Omega [Member] | 6.19% Senior Note [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

6.19%

6.19%

Omega [Member] | 5.1045% Senior Note [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

5.1045%

5.1045%

Debt Instrument, Maturity Date

Jan. 1, 2023

Jan. 1, 2023

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt

$ 147,000,000

Perrigo Co PLC [Member]

Debt Instrument [Line Items]

Total long-term debt, less current portion

$ 5,246,800,000

Omega [Member]

Debt Instrument [Line Items]

Amount debt exceeded par value

$ 101,900,000

Omega [Member] | Omega [Member] | 6.19% Senior Note [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt

$ 20,000,000

Euro Member Countries, Euro | 2014 Euro-Denominated Term Loan due December 5, 2019 additional draw [Domain]

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount | €

300

Euro Member Countries, Euro | 2014 Euro-Denominated Term Loan due December 5, 2019 [Member]

Gains (Losses) on Extinguishment of Debt [Abstract]

Debt Instrument, Face Amount | €

€ 500

Euro Member Countries, Euro | Bridge Credit Agreements [Member]

Debt Instrument [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity | €

€ 1,750

Euro Member Countries, Euro | Omega [Member]

Gains (Losses) on Extinguishment of Debt [Abstract]

Extinguishment of Debt, Amount | €

€ 500

Euro Member Countries, Euro | Omega [Member] | 5.125% Retail Bond [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt | €

€ 300

Euro Member Countries, Euro | Omega [Member] | Over Draft [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt | €

51.4

Euro Member Countries, Euro | Omega [Member] | 4.5% Retail Bond [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt | €

180

Euro Member Countries, Euro | Omega [Member] | 5.0% Retail Bond [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt | €

120

Euro Member Countries, Euro | Omega [Member] | Credit facility indebtedness [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt | €

500

Euro Member Countries, Euro | Omega [Member] | 5.1045% Senior Note [Member]

Debt Instrument [Line Items]

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt | €

135

Euro Member Countries, Euro | Omega [Member]

Debt Instrument [Line Items]

Amount debt exceeded par value | €

€ 93.6

[1]

Debt assumed from Omega.

[2]

Debt denominated in euros subject to fluctuations in the euro to U.S. dollar exchange rate.

[3]

(1) Public bonds issued on December 2, 2014, discussed below collectively as the "2014 Bonds."

[4]

(2) Private placement unsecured senior notes with registration rights as of June 28, 2014 and public bonds as of October 1, 2014, discussed below collectively as the "2013 Bonds."

[5]

Omega and Gelcaps opening balance sheets are preliminary.

Earnings (Loss) Per Share (Deta

Earnings (Loss) Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended																12 Months Ended
	Jun. 27, 2015		Mar. 28, 2015		Dec. 27, 2014		Sep. 27, 2014		Jun. 28, 2014		Mar. 29, 2014		Dec. 28, 2013		Sep. 28, 2013		Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Numerator:
Net income	$ 56.4	[1]	$ (94.9)	[2]	$ 70.2	[3]	$ 96.3	[4]	$ 131.7	[5]	$ 48.1	[6]	$ (86)	[7]	$ 111.4	[8]	$ 128	$ 205.3	$ 441.9
Denominator:
Weighted average shares outstanding for basic EPS	146.3		140.8		136.3		133.9		133.8		133.7		98.7		94.2		139.3	115.1	93.9
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements																	0.5	0.5	0.6
Weighted average shares outstanding for diluted EPS	146.8		140.8		136.8		134.4		134.3		134.3		98.7		94.7		139.8	115.6	94.5
Antidilutive share-based awards oustanding																	0.1	0.1	0.2
Payments of Dividends																	$ 64.8	$ 46.1	$ 33
Common Stock, Dividends, Per Share, Declared																	$ 0.4600	$ 0.3900	$ 0.3500
[1]	Includes legal and consulting fees related to our defense against Mylan N.V. of $13.4 million, acquisition costs of $18.5 million, goodwill impairment of $6.8 million, losses on derivatives terminated with extinguishment of associated debt and associated with hedging the pending GSK acquisition of $5.5 million, losses on equity method investments of $3.5 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and an initial payment made in connection with an R&D agreement of $18.0 million.
[2]	Includes acquisition costs totaling $2.0 million, an increase in litigation accrual of $2.0 million, restructuring charges of $1.1 million, Omega financing fees of $18.6 million, and losses on derivatives associated with the Omega acquisition of $258.2 million.
[3]	Includes restructuring charges of $2.4 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, Omega transaction expenses of $17.8 million, losses on derivatives associated with the Omega acquisition of $64.7 million, equity method investment losses of $3.0 million, income from transfer of rights agreement of $12.5 million, and $9.6 million loss on extinguishment of debt.
[4]	Includes acquisition costs of $1.1 million, restructuring charges of $1.7 million, equity method investment losses of $3.1 million, and a $1.2 million investment distribution.
[5]	Includes restructuring charges totaling $10.5 million and a loss contingency of $15.0 million related to Texas Medicaid.
[6]	Includes restructuring charges totaling $19.5 million, write-up of contingent consideration of $5.8 million related to Fera, and $3.2 million of Elan transaction costs.
[7]	Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, restructuring charges totaling $14.9 million, write-off of contingent consideration of $4.9 million related to Fera, and write-off of IPR&D totaling $6.0 million related to Paddock and Rosemont.
[8]	Includes Elan transactions costs of $12.0 million, litigation settlement of $2.5 million, and acquisition costs of $1.9 million.

Share-based compensation (Detai

Share-based compensation (Details) - Equity Component [Domain] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available to be granted	5,100
Share-based compensation	$ 31,600	$ 24,600	$ 18,400
Unrecognized share-based compensation expense	$ 35,300
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Beginning options outstanding, number of options	850
Granted, number of options	181
Exercised, number of options	(170)
Forfeited or expired, number of options	(4)
Ending options outstanding, number of options	857	850
Beginning options outstanding, weighted average exercise price	$ 77.26
Granted, weighted average exercise price	147.75
Exercised, weighted average exercise price	49.26
Forfeited or expired, weighted average exercise price	128.76
Ending options outstanding, weighted average exercise price	$ 97.49	$ 77.26
Options exercisable, number of options	515
Options expected to vest, number of options	334
Options exercisable, weighted average exercise price	$ 74.16
Options expected to vest, weighted average exercise price	$ 132.47
Options expected to vest, weighted average remaining term in years	8 years 4 months 24 days
Options outstanding, aggregate intrinsic value	$ 79,760
Options exercisable, aggregate intrinsic value	59,900
Options expected to vest, aggregate intrinsic value	19,400
Options exercised, aggregate intrinsic value	$ 20,700	$ 17,800	$ 29,500
Options granted, weighted average grant date fair value	$ 39.96	$ 38.28	$ 34.24
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Dividend yield	0.30%	0.30%	0.30%
Volatility, as a percent	27.10%	32.70%	34.90%
Risk-free interest rate	1.70%	1.80%	0.80%
Expected life in years after vest date	5 years 3 months 18 days	5 years 3 months 18 days	5 years 4 months 24 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	1 year 8 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 7 months 6 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 4 months 24 days
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning non-vested shares/units outstanding, number of shares/units	9
Granted, number of shares/units	0
Vested, number of shares/units	(9)
Cancelled, number of shares/units	0
Ending non-vested shares/units outstanding, number of shares/units	0	9
Beginning non-vested shares/units, weighted average grant date fair value	$ 100.84
Granted, weighted average grant date fair value	0	$ 145.19	$ 100.84
Vested, weighted average grant date fair value	100.84
Cancelled, weighted average grant date fair value	0
Ending non-vested shares/units, weighted average grant date fair value	$ 0	$ 100.84
Non-vested shares/units, weighted average remaining term in years
Non-vested shares/units, aggregate intrinsic value	$ 0
Vested, total fair value	$ 900	$ 2,300	$ 600
Service-based Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning non-vested shares/units outstanding, number of shares/units	247
Granted, number of shares/units	135
Vested, number of shares/units	(91)
Cancelled, number of shares/units	(8)
Ending non-vested shares/units outstanding, number of shares/units	283	247
Beginning non-vested shares/units, weighted average grant date fair value	$ 112.89
Granted, weighted average grant date fair value	153.99	$ 133.08	$ 109.20
Vested, weighted average grant date fair value	99.54
Cancelled, weighted average grant date fair value	126.13
Ending non-vested shares/units, weighted average grant date fair value	$ 136.48	$ 112.89
Non-vested shares/units, weighted average remaining term in years	1 year 2 months 12 days
Non-vested shares/units, aggregate intrinsic value	$ 53,900
Vested, total fair value	$ 9,100	$ 6,800	$ 5,700
Performance-based Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning non-vested shares/units outstanding, number of shares/units	182
Granted, number of shares/units	106
Vested, number of shares/units	(56)
Cancelled, number of shares/units	(3)
Ending non-vested shares/units outstanding, number of shares/units	229	182
Beginning non-vested shares/units, weighted average grant date fair value	$ 109.63
Granted, weighted average grant date fair value	150.14	$ 119.85	$ 108.6
Vested, weighted average grant date fair value	91.14
Cancelled, weighted average grant date fair value	126.96
Ending non-vested shares/units, weighted average grant date fair value	$ 129.77	$ 109.63
Non-vested shares/units, weighted average remaining term in years	1 year 4 months 17 days
Non-vested shares/units, aggregate intrinsic value	$ 43,625
Vested, total fair value	$ 5,100	$ 4,600	$ 5,000

Accumulated Other Comprehensi66

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	$ 139.6	$ 77
OCI before reclassifications	(52.1)	49.3
Amounts reclassified from AOCI	14.9	13.3
Other comprehensive income (loss)	(37.2)	62.6	$ 37.6
Balance,ending	102.4	139.6	77
Fair value of derivative financial instruments, net of tax [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	(16.1)	(4.5)
OCI before reclassifications	(15.1)	(18.2)
Amounts reclassified from AOCI	14.9	6.6
Other comprehensive income (loss)	(0.2)	(11.6)
Balance,ending	(16.3)	(16.1)	(4.5)
Foreign currency translation adjustments [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	164.4	80.6
OCI before reclassifications	(33.5)	83.8
Amounts reclassified from AOCI	0	0
Other comprehensive income (loss)	(33.5)	83.8
Balance,ending	130.9	164.4	80.6
Fair value of investment securities, net of tax [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	2.4	0
OCI before reclassifications	(5.4)	(4.3)
Amounts reclassified from AOCI	0	6.7
Other comprehensive income (loss)	(5.4)	2.4
Balance,ending	(3)	2.4	0
Post- retirement and pension liability adjustments, net of tax [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Balance, beginning	(11.1)	0.9
OCI before reclassifications	1.9	(12)
Amounts reclassified from AOCI	0	0
Other comprehensive income (loss)	1.9	(12)
Balance,ending	$ (9.2)	$ (11.1)	$ 0.9

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Pre-tax income:
Foreign	$ 1,069.2	$ 641.9	$ 607.7
Income from continuing operations before income taxes	248	272.6	607.7
Current:
Federal	77	44	125
State	6.9	9.3	10.7
Foreign	54.1	49.1	24.3
Subtotal	136	104.6	160.1
Deferred:
Federal	(17.5)	7.8	16.6
State	(0.8)	(5.8)	0
Foreign	(5.2)	(15.1)	(10.9)
Subtotal	(16)	(37.3)	5.7
Total	$ 120	$ 67.3	$ 165.8
Effective Income Tax Rate Reconciliation
Provision at statutory rate	12.50%	12.50%	35.00%
Ireland tax on non-trading differences	(10.30%)	2.80%	0.00%
Expenses not deductible for tax purposes/ deductions not expensed for book, net	15.50%	12.10%	(0.60%)
State income taxes, net of Federal benefit	(1.00%)	(0.20%)	1.10%
Foreign tax credit	0.00%	0.20%	(0.10%)
Research and development credit	(0.80%)	(0.50%)	(0.50%)
Other	5.60%	(0.80%)	(1.00%)
Foreign tax rate differences	(16.60%)	(16.00%)	(8.70%)
Valuation allowance changes	25.00%	2.90%	0.00%
Audit impacts	0.00%	0.00%	(1.20%)
Change in unrecognized taxes	18.50%	15.00%	3.30%
Rate change impacts	0.00%	(3.30%)	0.00%
Effective income tax rate	48.40%	24.70%	27.30%
Undistributed earnings of foreign subsidiaries reinvested indefinitely for which no provision have been provided	$ 3,400
Deferred income tax asset (liability):
Depreciation and amortization	(1,889)	$ (982.6)
Inventory basis differences	30.2	43.9
Accrued liabilities	67.2	84.3
Allowance for doubtful accounts	0.9	0.9
Research and development	62.8	3.7
Loss carryforwards	502.4	300.4
Share-based compensation	14.3	14.3
Foreign Tax Credit	10.6	10.6
Federal benefit of unrecognized tax positions	26.3	20.7
Other, net	29.7	59.6
Subtotal	(1,144.6)	(444.2)
Valuation allowance for loss and credit carry forwards	(519.2)	(198.4)
Net deferred income tax asset (liability):	(1,663.8)	(642.6)
Assets	161.9	86.4
Liabilities	(1,825.7)	(729)
Tax credit carryforwards	167.8
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Unrecognized tax benefits, beginning balance	160.1	110.1
Additions: Positions related to the current year	38.9	28.8
Additions: Positions of prior years	122.7	22.7
Reductions: Positions related to the current year	0	0
Reductions: Positions of prior years	0	0
Reductions: Settlements with taxing authorities	(1.4)	0
Reductions: Lapse of statutes of limitation	(1.7)	(1.5)
Unrecognized tax benefits, ending balance	318.6	160.1	$ 110.1
Unrecognized tax benefits liability, interest and penalties accrued	65.7	45.3
Unrecognized tax benefits, including income tax penalties and interest accrued	384.3	205.4
Unrecognized tax benefits that would impact effective tax rate	217.6	170.2
Income Tax Examination, Penalties and Interest Expense	8
Incremental tax obligation	$ 68.9
Israeli Holding Company Subsidiary [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Estimated tax rate on dividends distribution if distributed out of tax exempt income, minimum	10.00%
Estimated tax rate on dividends distribution if distributed out of tax exempt income, maximum	25.00%
Foreign Statutory Corporate Tax Rate, Prior To Change, Prior Two Years	10.00%
Foreign Statutory Corporate Tax Rate, Prior To Change, Prior Year	7.00%
Israel statutory corporate tax rate under new law: 2013	6.00%
Israel statutory corporate tax rate under new law: 2014	9.00%
All Other Entities [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Israel statutory corporate tax rate under new law: 2013	25.00%
Israel statutory corporate tax rate under new law: 2014	26.50%
Revenue Commissioners, Ireland [Member]
Pre-tax income:
Foreign	$ (821.2)	(369.3)	0
Current:
Foreign	(2)	2.2	0
Deferred:
Foreign	7.5	$ (24.2)	$ 0
Domestic Tax Authority [Member]
Deferred income tax asset (liability):
Tax credit carryforwards	269.1
Domestic Tax Authority [Member] | Capital Loss Carryforward [Member]
Deferred income tax asset (liability):
Tax credit carryforwards, valuation allowance	29.4
Foreign Tax Authority [Member]
Deferred income tax asset (liability):
Net operating loss carryforwards	459
Operating loss carryforwards, valuation allowance	416
Foreign Tax Authority [Member] | Capital Loss Carryforward [Member]
Deferred income tax asset (liability):
Tax credit carryforwards	29.4
State and Local Jurisdiction [Member]
Deferred income tax asset (liability):
Net operating loss carryforwards	2,910.6
Tax credit carryforwards	1,458.8
Operating loss carryforwards, valuation allowance	2,385.2
Tax credit carryforwards, valuation allowance	1,458.8
Federal Jurisdiction [Member]
Deferred income tax asset (liability):
Tax credit carryforwards	37.2
Tax credit carryforwards, valuation allowance	198.2
Minimum [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Estimated Range of Change, Upper Bound	2
Maximum [Member]
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Estimated Range of Change, Upper Bound	15
2017 [Member] | State and Local Jurisdiction [Member]
Deferred income tax asset (liability):
Tax credit carryforwards	4.4
2020 [Member] | State and Local Jurisdiction [Member]
Deferred income tax asset (liability):
Tax credit carryforwards	32
2022 [Member] | State and Local Jurisdiction [Member]
Deferred income tax asset (liability):
Tax credit carryforwards	0.1
2023 [Member] | State and Local Jurisdiction [Member]
Deferred income tax asset (liability):
Tax credit carryforwards	1.2
2025 [Member] | State and Local Jurisdiction [Member]
Deferred income tax asset (liability):
Tax credit carryforwards	$ 4.5

Post Employment Plans - Additio

Post Employment Plans - Additional Information (Details) - Defined Contribution Plan Type [Domain] $ in Millions		6 Months Ended		12 Months Ended
		Jun. 28, 2014USD ($)		Jun. 27, 2015USD ($)years		Jun. 28, 2014USD ($)		Jun. 29, 2013USD ($)	Dec. 18, 2013USD ($)	[2]
Postemployment Benefits [Abstract]
Expected Return on Assets, percent				2.85%	[1]	2.92%	[2]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined Benefit Plan, Expected Future Benefit Payments, Next Twelve Months				$ 0.8
Defined Benefit Plan, Service Cost				$ 0.9	[1]	$ 0	[2]
Employer Nondiscretionary Contribution to Plan				3.00%
Defined Benefit Plan, Current Assets				$ 12.8
Company's contributions to the plan	[1]			2.4
Defined Contribution Plan, Employer Discretionary Contribution Amount	[1]			0.9
Post employment benefits, non-current liabilities	[1]	$ 89		140.3		89
Post employment benefits, non-current assets	[1]	99.6		133.3		99.6
Unfunded accumulated projected benefit obligation		89		136.6		89
Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax		11.9		9.2		11.9
Net periodic benefit gain				(1.6)	[1]	(0.2)	[2]
Amount to be amortized from accumulated other comprehensive income (loss) next fiscal year				0.8
Defined Benefit Plan, Expected Future Benefit Payments, Year One Through Five				6.5
Estimated future employer contributions in next fiscal year				2
Interest cost				2.4	[1]	1.4	[2]
Defined Benefit Plan, Expected Return on Plan Assets				(2.7)	[1]	(1.9)	[2]
Defined Benefit Plan, Actuarial Gain (Loss)				(1)	[1]	(0.7)	[2]
Defined Benefit Plan, Expected Future Benefit Payments, Year Two				1.1
Estimated future benefit payments, June 30, 2018				1.2
Defined Benefit Plan, Expected Future Benefit Payments, Year Four				1.5
Defined Benefit Plan, Expected Future Benefit Payments, Year Five				1.9
Defined Benefit Plan, Expected Future Benefit Payments, Five Fiscal Years Thereafter				13.4
IRELAND
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined Benefit Plan, Service Cost	[2]	0
Company's contributions to the plan	[2]			0
Defined Contribution Plan, Employer Discretionary Contribution Amount	[2]	0.2
Post employment benefits, non-current liabilities	[2]	89				89		$ 0
Post employment benefits, non-current assets		99.6		$ 99.6	[2]	99.6			$ 0
Employer matching contribution, percent of employees' gross pay				18.00%
Interest cost	[2]	1.4
Qualified Profit-Sharing and Investment Plans under 401(k) [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company's contributions to the plan				$ 24.6		25.6		23
Foreign Post Employment Benefits [Member] | ISRAEL [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Company's contributions to the plan				1		0.4		0.9
Post employment benefits, non-current liabilities		24		21.3		24
Post employment benefits, non-current assets		19.3		17.3		19.3
Foreign Post Employment Benefits [Member] | IRELAND
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined Contribution Plan, Employer Discretionary Contribution Amount		0.5		0.7
Foreign Post Employment Benefits [Member] | Europe [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined Contribution Plan, Employer Discretionary Contribution Amount				0.6
Deferred Compensation Arrangement with Individual, by Type of Compensation, Pension and Other Postretirement Benefits [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Cash surrender value of insurance policies		28		32.7		28
Deferred compensation liability, non-current		28.1		32.3		28.1
Postretirement Medical Benefits [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined Benefit Plan, Expected Future Benefit Payments, Next Twelve Months				0.1
Defined Benefit Plan, Service Cost				0.3	[1]	0.5
Pension and Other Postretirement Defined Benefit Plans, Liabilities				6
Company's contributions to the plan				0	[1]	0
Defined Contribution Plan, Employer Discretionary Contribution Amount				0.1	[1]	0.1
Post employment benefits, non-current liabilities		4.6	[1]	6	[1]	4.6	[1]	3.9
Post employment benefits, non-current assets				$ 0	[1]			$ 0
Retiree eligible age | years				65
Unfunded accumulated projected benefit obligation		$ 4.6		$ 6		4.6
Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax				(0.1)
Net periodic benefit gain				(0.6)	[1]	(1.4)
Interest cost				0.2	[1]	0.3
Defined Benefit Plan, Expected Return on Plan Assets				0	[1]	$ 0.6
Defined Benefit Plan, Actuarial Gain (Loss)	[1]			(0.1)
Defined Benefit Plan, Expected Future Benefit Payments, Year Two				0.2
Estimated future benefit payments, June 30, 2018				0.2
Defined Benefit Plan, Expected Future Benefit Payments, Year Four				0.2
Defined Benefit Plan, Expected Future Benefit Payments, Year Five				0.3
Defined Benefit Plan, Expected Future Benefit Payments, Five Fiscal Years Thereafter				1.8
Other Assets [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Post employment benefits, non-current liabilities				$ 19.8
[1]	*Includes Omega activity from March 30, 2015 to June 27, 2015
[2]	**Includes Elan activity from December 18, 2013 to June 28, 2014.

Post Employment Plans - Project

Post Employment Plans - Projected Benefit Obligation (Details) - USD ($) $ in Millions		12 Months Ended
		Jun. 27, 2015		Jun. 28, 2014
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Plan, Employer Discretionary Contribution Amount	[1]	$ 0.9
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
Projected benefit obligation, beginning	[1]	89
Interest cost		2.4	[1]	$ 1.4	[2]
Actuarial loss	[1]	6.8
Defined Benefit Plan, Benefits Paid	[1]	(0.1)
Defined Benefit Plan, Settlements, Benefit Obligation	[1]	0
Foreign currency translation	[1]	14.7
Projected benefit obligation, ending	[1]	140.3		89
Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, beginning	[1]	99.6
Actual return on plan assets	[1]	(1)
Defined Benefit Plan, Benefits Paid	[1]	(0.1)
Settlements	[1]	0
Fair value of plan assets, ending	[1]	133.3		$ 99.6
Funded status recognized in Other Assets	[1]	$ (7)
[1]	*Includes Omega activity from March 30, 2015 to June 27, 2015
[2]	**Includes Elan activity from December 18, 2013 to June 28, 2014.

Post Employment Plans - Expecte

Post Employment Plans - Expected Future Minimum Benefit Payment (Details) $ in Millions	Jun. 27, 2015USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payments, Year One Through Five	$ 6.5
Estimated future benefit payments, June 25, 2016	0.8
Defined Benefit Plan, Expected Future Benefit Payments, Year Two	1.1
Estimated future benefit payments, June 30, 2018	1.2
Defined Benefit Plan, Expected Future Benefit Payments, Year Four	1.5
Defined Benefit Plan, Expected Future Benefit Payments, Year Five	1.9
Defined Benefit Plan, Expected Future Benefit Payments, Five Fiscal Years Thereafter	13.4
Postretirement Medical Benefits [Member]
Defined Benefit Plan Disclosure [Line Items]
Estimated future benefit payments, June 25, 2016	0.1
Defined Benefit Plan, Expected Future Benefit Payments, Year Two	0.2
Estimated future benefit payments, June 30, 2018	0.2
Defined Benefit Plan, Expected Future Benefit Payments, Year Four	0.2
Defined Benefit Plan, Expected Future Benefit Payments, Year Five	0.3
Defined Benefit Plan, Expected Future Benefit Payments, Five Fiscal Years Thereafter	1.8
Postretirement Medical Benefits [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payments, Year One Through Five	$ 1

Post Employment Plans - Net Per

Post Employment Plans - Net Periodic Pension Cost (Details) - USD ($) $ in Millions		12 Months Ended
		Jun. 27, 2015		Jun. 28, 2014
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined Benefit Plan, Service Cost		$ 0.9	[1]	$ 0	[2]
Interest cost		2.4	[1]	1.4	[2]
Defined Benefit Plan, Expected Return on Plan Assets		(2.7)	[1]	(1.9)	[2]
Net actuarial (gain)/loss		1	[1]	0.7	[2]
Net periodic pension cost		1.6	[1]	0.2	[2]
Postretirement Medical Benefits [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Defined Benefit Plan, Service Cost		0.3	[1]	0.5
Interest cost		0.2	[1]	0.3
Defined Benefit Plan, Expected Return on Plan Assets		0	[1]	0.6
Net actuarial (gain)/loss	[1]	0.1
Net periodic pension cost		$ 0.6	[1]	$ 1.4
[1]	*Includes Omega activity from March 30, 2015 to June 27, 2015
[2]	**Includes Elan activity from December 18, 2013 to June 28, 2014.

Post Employment Plans - Weighte

Post Employment Plans - Weighted Average Assumptions (Details)	12 Months Ended
	Jun. 27, 2015	[1]	Jun. 28, 2014
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount Rate, percent	2.11%		2.90%	[2]
Inflation, percent	1.93%		2.00%	[2]
Expected Return on Assets, percent	2.85%		2.92%	[2]
Postretirement Medical Benefits [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount Rate, percent	4.25%		4.25%
[1]	*Includes Omega activity from March 30, 2015 to June 27, 2015
[2]	**Includes Elan activity from December 18, 2013 to June 28, 2014.

Post Employment Plans - Expec73

Post Employment Plans - Expected Long-term Rate of Return (Details)	12 Months Ended
	Jun. 27, 2015		Jun. 28, 2014	[2]
Defined Benefit Plan Disclosure [Line Items]
Expected Return on Assets, percent	2.85%	[1]	2.92%
Equities [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected Return on Assets, percent	5.80%
Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected Return on Assets, percent	1.20%
Property [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected Return on Assets, percent	4.80%
Absolute return fund [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected Return on Assets, percent	3.50%
Insurance Contract, Rights and Obligations [Member]
Defined Benefit Plan Disclosure [Line Items]
Expected Return on Assets, percent	2.30%
[1]	*Includes Omega activity from March 30, 2015 to June 27, 2015
[2]	**Includes Elan activity from December 18, 2013 to June 28, 2014.

Post Employment Plans - Target

Post Employment Plans - Target Asset Allocation Ranges (Details)	12 Months Ended
	Jun. 27, 2015
Equities [Member]
Defined Benefit Plan Disclosure [Line Items]
Long-term asset allocation range, minimum	10.00%
Long-term asset allocation range, maximum	20.00%
Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Long-term asset allocation range, minimum	30.00%
Long-term asset allocation range, maximum	40.00%
Property [Member]
Defined Benefit Plan Disclosure [Line Items]
Long-term asset allocation range, minimum	0.00%
Long-term asset allocation range, maximum	10.00%
Absolute return fund [Member]
Defined Benefit Plan Disclosure [Line Items]
Long-term asset allocation range, minimum	20.00%
Long-term asset allocation range, maximum	30.00%
Insurance Contract, Rights and Obligations [Member]
Defined Benefit Plan Disclosure [Line Items]
Long-term asset allocation range, minimum	20.00%
Long-term asset allocation range, maximum	30.00%
Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Long-term asset allocation range, minimum	0.00%
Long-term asset allocation range, maximum	10.00%

Post Employment Plans - Fair Va

Post Employment Plans - Fair Value of Pension Plan Assets (Details) - USD ($) $ in Millions		6 Months Ended		12 Months Ended
		Jun. 28, 2014		Jun. 27, 2015		Jun. 28, 2014		Sep. 27, 2014	Dec. 18, 2013	[2]	Jun. 29, 2013
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Interest Cost				$ 2.4	[1]	$ 1.4	[2]
Fair value of pension plan assets	[1]	$ 99.6		133.3		99.6
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets	[1]			49.9
Defined Benefit Plan, Funded Status of Plan	[1]			(7)
Defined Benefit Plan, Actual Return on Plan Assets	[1]			(1)
Actuarial loss	[1]			(6.8)
Defined Benefit Plan, Benefits Paid	[1]			(0.1)
Defined Contribution Plan, Employer Discretionary Contribution Amount	[1]			0.9
Defined Benefit Plan, Purchases, Sales, and Settlements	[1]			0
Defined Benefit Plan, Contributions by Employer	[1]			2.4
Defined Benefit Plan, Settlements, Benefit Obligation	[1]			0
Defined Benefit Plan, Foreign Currency Exchange Rate Gain (Loss)	[1]			14.7
Defined Benefit Plan, Benefit Obligation	[1]	89		140.3		89
Defined Benefit Plan, Business Combinations and Acquisitions, Benefit Obligation	[1]			70.4
Defined Benefit Plan, Service Cost				0.9	[1]	0	[2]
Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0.8	[2]	31.9	[1]	0.8	[2]		$ 0
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets				31.5	[1]	0.7	[2]
IRELAND
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Interest Cost	[2]	1.4
Fair value of pension plan assets		99.6		99.6	[2]	99.6			$ 0
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets	[2]					107.3
Defined Benefit Plan, Funded Status of Plan	[2]			10.6
Defined Benefit Plan, Actual Return on Plan Assets	[2]			5.4
Actuarial loss	[2]	(12.1)
Defined Benefit Plan, Benefits Paid	[2]			(0.2)
Defined Contribution Plan, Employer Discretionary Contribution Amount	[2]	0.2
Defined Benefit Plan, Purchases, Sales, and Settlements	[2]	(12.1)
Defined Benefit Plan, Contributions by Employer	[2]			0
Defined Benefit Plan, Settlements, Benefit Obligation	[2]	(8)
Defined Benefit Plan, Foreign Currency Exchange Rate Gain (Loss)	[2]	0.7		(0.8)
Defined Benefit Plan, Benefit Obligation	[2]	89				89					$ 0
Defined Benefit Plan, Business Combinations and Acquisitions, Benefit Obligation	[2]	84.4
Defined Benefit Plan, Service Cost	[2]	0
IRELAND | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		98.8				98.8
IRELAND | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0				0
IRELAND | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0.8				0.8
IRELAND | Equities [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets								$ 0
IRELAND | Equities [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets								0
IRELAND | Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		48.3				48.3
IRELAND | Bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0				0
IRELAND | Bonds [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0				0
IRELAND | Property [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0.8				0.8
IRELAND | Property [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0				0
IRELAND | Property [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0				0
IRELAND | Property [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0.8				0.8
IRELAND | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0.1				0.1
IRELAND | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0.1				0.1
IRELAND | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0				0
IRELAND | Cash and Cash Equivalents [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0				0
IRELAND | Absolute return fund [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		29.6				29.6
IRELAND | Absolute return fund [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		29.6				29.6
IRELAND | Absolute return fund [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0				0
IRELAND | Absolute return fund [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0				0
Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				133.3
Assets [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				101.4
Assets [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		0.8	[1]	31.9		0.8	[1]
Assets [Member] | Equities [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				16.7				$ 20.8
Assets [Member] | Equities [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		20.8		16.7		20.8
Assets [Member] | Equities [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Equities [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Bonds [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				49.7
Assets [Member] | Bonds [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets		48.3		49.7		48.3
Assets [Member] | Bonds [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Bonds [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Property [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0.4
Assets [Member] | Property [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Property [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Property [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0.4
Assets [Member] | Cash and Cash Equivalents [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0.2
Assets [Member] | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0.2
Assets [Member] | Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Cash and Cash Equivalents [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Absolute return fund [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				34.8
Assets [Member] | Absolute return fund [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				34.8
Assets [Member] | Absolute return fund [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Absolute return fund [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Insurance Contract, Rights and Obligations [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				31.5
Assets [Member] | Insurance Contract, Rights and Obligations [Member] | Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Insurance Contract, Rights and Obligations [Member] | Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				0
Assets [Member] | Insurance Contract, Rights and Obligations [Member] | Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value of pension plan assets				31.5
Postretirement Medical Benefits [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Interest Cost				0.2	[1]	0.3
Fair value of pension plan assets				0	[1]						0
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets				0	[1]	0
Defined Benefit Plan, Funded Status of Plan		(4.6)		(6)	[1]	(4.6)
Defined Benefit Plan, Actual Return on Plan Assets				0	[1]	0
Actuarial loss				0	[1]	0
Defined Benefit Plan, Benefits Paid				0	[1]	0
Defined Contribution Plan, Employer Discretionary Contribution Amount				0.1	[1]	0.1
Defined Benefit Plan, Purchases, Sales, and Settlements				0	[1]	0
Defined Benefit Plan, Contributions by Employer				0	[1]	0
Defined Benefit Plan, Settlements, Benefit Obligation				0	[1]	0
Defined Benefit Plan, Foreign Currency Exchange Rate Gain (Loss)				0	[1]	0
Defined Benefit Plan, Benefit Obligation		$ 4.6	[1]	6	[1]	4.6	[1]				$ 3.9
Defined Benefit Plan, Business Combinations and Acquisitions, Benefit Obligation				1	[1]	0
Defined Benefit Plan, Service Cost				0.3	[1]	$ 0.5
Defined Contribution Plan Type [Domain]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Foreign Currency Exchange Rate Gain (Loss)	[1]			$ (17.5)
[1]	*Includes Omega activity from March 30, 2015 to June 27, 2015
[2]	**Includes Elan activity from December 18, 2013 to June 28, 2014.

Post Employment Plans - Changes

Post Employment Plans - Changes in Fair Value of Level 3 Pension Plan Assets (Details) - USD ($) $ in Millions		12 Months Ended
		Jun. 27, 2015		Jun. 28, 2014
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets	[1]	$ 49.9
Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, beginning	[1]	99.6
Fair value of plan assets, ending	[1]	133.3		$ 99.6
Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Business Combinations and Acquisitions, Plan Assets		31.5	[1]	0.7	[2]
Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, beginning	[2]	0.8
Unrealized gains		(0.4)	[1]	0.1	[2]
Fair value of plan assets, ending		31.9	[1]	0.8	[2]
Assets [Member]
Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, ending		133.3
Assets [Member] | Level 3 [Member]
Change in Fair Value of Plan Assets [Roll Forward]
Fair value of plan assets, beginning	[1]	0.8
Fair value of plan assets, ending		$ 31.9		$ 0.8	[1]
[1]	*Includes Omega activity from March 30, 2015 to June 27, 2015
[2]	**Includes Elan activity from December 18, 2013 to June 28, 2014.

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
2,016	$ 45.6
2,017	37.7
2,018	32.3
2,019	21.2
2,020	15.4
Thereafter	20.3
Rent expense under all leases	39.2	$ 34.5	$ 27.6
Purchase Obligation	$ 429.9

Commitments and Contingencies78

Commitments and Contingencies (Details 2) - USD ($) $ in Millions	12 Months Ended
	Jun. 27, 2015	Mar. 28, 2015	Jun. 28, 2014
Loss Contingencies [Line Items]
Loss Contingency, Damages Sought, Value	$ 72.5
Texas Medicaid [Member]
Loss Contingencies [Line Items]
Loss Contingency Accrual	$ 15	$ 9	$ 15
Loss Contingency, Receivable			$ 7

Collaboration Agreements (Detai

Collaboration Agreements (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Mar. 29, 2014	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		$ (187.8)	$ (152.5)	$ (115.2)
Potential contingent milestone payments		30
Royalty revenue, percent of net sales	6.50%
Revenues				0.8
Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments	$ 10			0.5
Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments	$ 15			2
Gelcaps [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		(78)
Biotech [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		(10)
Potential contingent milestone payments		50
Phase three [Member] | Biotech [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		(5)
Final phase [Member] | Minimum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments				3.8
Final phase [Member] | Maximum [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments				$ 5.5
Final phase [Member] | Gelcaps [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		(105)
Final phase [Member] | Biotech [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		(10)
Topical product [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential contingent milestone payments		17.5
contractual arrangement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development expense		$ (18)

Restructuring Charges (Details)

Restructuring Charges (Details) - USD ($)	3 Months Ended						12 Months Ended
	Mar. 28, 2015	Dec. 27, 2014	Sep. 27, 2014	Jun. 28, 2014	Mar. 29, 2014	Dec. 28, 2013	Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Restructuring Reserve [Roll Forward]
Beginning balance									$ 1,700,000
Restructuring	$ 1,100,000	$ 2,400,000	$ 1,700,000	$ 10,500,000	$ 19,500,000	$ 14,900,000	$ 5,100,000	$ 47,000,000	2,900,000
Payments							(18,500,000)	(28,700,000)	(1,700,000)
Non-cash adjustments							(1,400,000)	(4,800,000)
Severance [Member]
Restructuring Reserve [Roll Forward]
Beginning balance			$ 16,400,000				$ 16,400,000	2,900,000
Ending balance				$ 16,400,000				$ 16,400,000	$ 2,900,000

Segment and Geographic Inform81

Segment and Geographic Information (Details) $ in Millions		3 Months Ended								12 Months Ended
		Jun. 27, 2015USD ($)	Mar. 28, 2015USD ($)	Dec. 27, 2014USD ($)	Sep. 27, 2014USD ($)	Jun. 28, 2014USD ($)	Mar. 29, 2014USD ($)	Dec. 28, 2013USD ($)	Sep. 28, 2013USD ($)	Jun. 27, 2015USD ($)segments		Jun. 28, 2014USD ($)customers		Jun. 29, 2013USD ($)customers
Segment Reporting Information [Line Items]
Number of Reportable Segments | segments										4
Net sales		$ 1,531.6	$ 1,049.1	$ 1,071.7	$ 951.5	$ 1,144.2	$ 1,004.2	$ 979	$ 933.4	$ 4,603.9	[1]	$ 4,060.8	[1]	$ 3,539.8	[1]
Operating income	[1]									$ 747.7		$ 567		$ 679.1
Operating income %	[1]									16.20%		14.00%		19.20%
Assets	[1]	19,720.6				13,852.8				$ 19,720.6		$ 13,852.8		$ 5,336.9
Capital expenditures	[1]									137		171.6		132.2
Property and equip, net	[1]	932.4				779.9				932.4		779.9		681.4
Depreciation/amortization	[1]									548.8		358.9		160.2
All Countries [Domain]
Segment Reporting Information [Line Items]
Net sales										4,603.9
CHC [Member]
Segment Reporting Information [Line Items]
Net sales										2,750		2,849.4		2,671
Operating income										$ 405.6		$ 413.1		$ 401.8
Operating income %										14.70%		14.50%		15.00%
Assets		4,381.6				4,931				$ 4,381.6		$ 4,931		$ 3,447.5
Capital expenditures										80.5		128.3		97.1
Property and equip, net		600				577.3				600		577.3		508
Depreciation/amortization										123.2		106.6		96.1
CHC [Member] | Cough/Cold [Member]
Segment Reporting Information [Line Items]
Net sales	[2]									486.2		510.1		500.6
CHC [Member] | Analgesics [Member]
Segment Reporting Information [Line Items]
Net sales	[2]									441.7		504		536
CHC [Member] | Gastrointestinal [Member]
Segment Reporting Information [Line Items]
Net sales	[2]									395.3		400.1		388.8
CHC [Member] | Smoking Cessation [Member]
Segment Reporting Information [Line Items]
Net sales										299.4		236.8		193.2
CHC [Member] | Animal Health [Member]
Segment Reporting Information [Line Items]
Net sales										156.9		178		123.2
CHC [Member] | Other CHC [Member]
Segment Reporting Information [Line Items]
Net sales	[2]									335.9		468.7		420.9
CHC [Member] | Infant Nutritionals [Member]
Segment Reporting Information [Line Items]
Net sales										383.9		374.8		350.1
CHC [Member] | Vitamins, Minerals, and Dietary Supplements [Member]
Segment Reporting Information [Line Items]
Net sales										185.6		176.9		158.3
CHC [Member] | CHC [Member]
Segment Reporting Information [Line Items]
Net sales										2,684.9		2,849.4		2,671.1
BCH [Member]
Segment Reporting Information [Line Items]
Net sales	[3]									401.1		0		0
Operating income	[3]									$ 26.6		$ 0		$ 0
Operating income %	[3]									6.60%		0.00%		0.00%
Assets	[3]	6,441.1				0				$ 6,441.1		$ 0		$ 0
Capital expenditures	[3]									3.6		0		0
Property and equip, net	[3]	122.5				0				122.5		0		0
Depreciation/amortization	[3]									38.3		0		0
BCH [Member] | BCH [Member]
Segment Reporting Information [Line Items]
Net sales										401.2		0		0
Rx Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Net sales										1,001.1		927.1		709.5
Operating income										$ 373.9		$ 349.8		$ 263.2
Operating income %										37.30%		37.70%		37.10%
Assets		2,667.9				2,537.2				$ 2,667.9		$ 2,537.2		$ 1,604.9
Capital expenditures										42.9		32.9		17.7
Property and equip, net		124.1				104.8				124.1		104.8		80.8
Depreciation/amortization										85.1		86.5		54.9
Rx Pharmaceuticals [Member] | Rx Pharmaceuticals [Member]
Segment Reporting Information [Line Items]
Net sales										1,066.1		927.1		709.5
Specialty Sciences [Member]
Segment Reporting Information [Line Items]
Net sales										344	[4]	$ 146.7		0	[4]
Operating income	[4]									$ 36.3				$ 0
Operating income %	[4]									10.60%		(47.00%)		0.00%
Assets	[4]	5,979				6,096.6				$ 5,979		$ 6,096.6		$ 0
Capital expenditures	[4]									0.5				0
Property and equip, net	[4]	0				2.1				0		2.1		0
Depreciation/amortization	[4]									291.6				0
All Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales										107.7		137.6		159.3
Operating income										$ 26.8		$ 46.1		$ 48.9
Operating income %										24.90%		33.50%		30.70%
Assets		251				288				$ 251		$ 288		$ 284.5
Capital expenditures										6.4		10.4		17.3
Property and equip, net		85.8				95.7				85.8		95.7		92.7
Depreciation/amortization										10.6		11.4		9.1
Significant Reconciling Items [Member]
Segment Reporting Information [Line Items]
Net sales										0		0		0
Operating income										$ (121.5)		$ (173.4)		$ (34.7)
Operating income %										0.00%		0.00%		0.00%
Assets		0				0				$ 0		$ 0		$ 0
Capital expenditures										3.1		0		0
Property and equip, net		0				0				0		0		0
Depreciation/amortization										$ 0		$ 0		$ 0
Net Sales [Member] | Customer Concentration Risk [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Number of Major Customers | customers												1		1
Concentration risk percentage										15.00%		19.00%		19.00%
Net Sales [Member] | Customer Concentration Risk [Member] | CHC [Member]
Segment Reporting Information [Line Items]
Segment Reporting, Number of Major Customers | customers												1		1
IRELAND
Segment Reporting Information [Line Items]
Net sales										$ 344		$ 146.7		$ 0
Property and equip, net		1.4				2				1.4		2
UNITED STATES
Segment Reporting Information [Line Items]
Net sales										3,303.6		3,291.6		2,978.1
Property and equip, net		558.6				530.7				558.6		530.7
Europe [Member]
Segment Reporting Information [Line Items]
Net sales										613.6		217.2		164
Property and equip, net		153.8				31.7				153.8		31.7
ISRAEL [Member]
Segment Reporting Information [Line Items]
Property and equip, net		119.8				119.6				119.8		119.6
Outside United States [Member]
Segment Reporting Information [Line Items]
Net sales	[5]									342.7		405.3		$ 397.7
Property and equip, net		$ 98.8				$ 95.9				$ 98.8		$ 95.9
[1]	Amounts may not cross-foot due to rounding.
[2]	Includes sales from our OTC contract manufacturing business.
[3]	(1) BCH only includes activity from March 30, 2015 to June 27, 2015.
[4]	Specialty Sciences only includes activity from December 18, 2013 to June 28, 2014
[5]	(2) Includes sales generated primarily in Israel, Mexico, Australia, and Canada.

Quarterly Financial Data (Detai

Quarterly Financial Data (Details) - USD ($) $ / shares in Units, shares in Millions	3 Months Ended																12 Months Ended
	Jun. 27, 2015		Mar. 28, 2015		Dec. 27, 2014		Sep. 27, 2014		Jun. 28, 2014		Mar. 29, 2014		Dec. 28, 2013		Sep. 28, 2013		Jun. 27, 2015		Jun. 28, 2014		Jun. 29, 2013
Net sales	$ 1,531,600,000		$ 1,049,100,000		$ 1,071,700,000		$ 951,500,000		$ 1,144,200,000		$ 1,004,200,000		$ 979,000,000		$ 933,400,000		$ 4,603,900,000	[1]	$ 4,060,800,000	[1]	$ 3,539,800,000	[1]
Gross profit	628,100,000		378,800,000		383,800,000		321,800,000		415,700,000		315,000,000		360,700,000		356,300,000		1,712,500,000		1,447,700,000		1,280,000,000
Net income	$ 56,400,000	[2]	$ (94,900,000)	[3]	$ 70,200,000	[4]	$ 96,300,000	[5]	$ 131,700,000	[6]	$ 48,100,000	[7]	$ (86,000,000)	[8]	$ 111,400,000	[9]	$ 128,000,000		$ 205,300,000		$ 441,900,000
Earnings (loss) per share:
Earnings Per Share, Basic	$ 0.39	[2],[10]	$ (0.67)	[3],[10]	$ 0.52	[4],[10]	$ 0.72	[5],[10]	$ 0.98	[6],[10]	$ 0.36	[7],[10]	$ (0.87)	[8],[10]	$ 1.18	[9],[10]	$ 0.92		$ 1.78		$ 4.71
Earnings Per Share, Diluted	$ 0.38	[2],[10]	$ (0.67)	[3],[10]	$ 0.51	[4],[10]	$ 0.72	[5],[10]	$ 0.98	[6],[10]	$ 0.36	[7],[10]	$ (0.87)	[8],[10]	$ 1.18	[9],[10]	$ 0.92		$ 1.77		$ 4.68
Weighted average shares outstanding
Basic	146.3		140.8		136.3		133.9		133.8		133.7		98.7		94.2		139.3		115.1		93.9
Diluted	146.8		140.8		136.8		134.4		134.3		134.3		98.7		94.7		139.8		115.6		94.5
Selected Quarterly Financial Information [Abstract]
Business Acquisition, Transaction Costs											$ 3,200,000		$ 103,200,000		$ 12,000,000
Litigation Settlement, Expense			$ 2,000,000												2,500,000
Acquisition Costs, Period Cost															$ 1,900,000
Goodwill impairment charge	$ 6,800,000																$ 6,800,000		$ 0		$ 0
Derivative, Loss on Derivative	5,500,000		258,200,000		$ 64,700,000												326,400,000		0		0
Net loss from equity method investment	3,500,000				3,000,000		$ 3,100,000										(9,900,000)		(8,700,000)
Investment distribution							1,200,000
Proceeds from Collaborators					12,500,000
Inventory Step-up	15,600,000
Cost of Services, Licenses and Maintenance Agreements	18,000,000				10,000,000
Restructuring			1,100,000		2,400,000		1,700,000		$ 10,500,000		19,500,000		14,900,000				5,100,000		47,000,000		2,900,000
Legal Fees	13,400,000
Business Combination, Acquisition Related Costs	18,500,000		2,000,000		17,800,000		$ 1,100,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability											$ 5,800,000		4,900,000
Total loss on extinguishment of debt					$ 9,600,000								(165,800,000)				(10,500,000)		(165,800,000)		$ 0
Write-off of in-process research and development													6,000,000
Texas Medicaid [Member]
Selected Quarterly Financial Information [Abstract]
Loss Contingency Accrual	$ 15,000,000		9,000,000						$ 15,000,000								$ 15,000,000		$ 15,000,000
Omega [Member]
Selected Quarterly Financial Information [Abstract]
Business Combination, Acquisition Related Costs			$ 18,600,000
Extinguishment of Debt, Type [Domain]
Selected Quarterly Financial Information [Abstract]
Total loss on extinguishment of debt													$ 165,800,000
[1]	Amounts may not cross-foot due to rounding.
[2]	Includes legal and consulting fees related to our defense against Mylan N.V. of $13.4 million, acquisition costs of $18.5 million, goodwill impairment of $6.8 million, losses on derivatives terminated with extinguishment of associated debt and associated with hedging the pending GSK acquisition of $5.5 million, losses on equity method investments of $3.5 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and an initial payment made in connection with an R&D agreement of $18.0 million.
[3]	Includes acquisition costs totaling $2.0 million, an increase in litigation accrual of $2.0 million, restructuring charges of $1.1 million, Omega financing fees of $18.6 million, and losses on derivatives associated with the Omega acquisition of $258.2 million.
[4]	Includes restructuring charges of $2.4 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, Omega transaction expenses of $17.8 million, losses on derivatives associated with the Omega acquisition of $64.7 million, equity method investment losses of $3.0 million, income from transfer of rights agreement of $12.5 million, and $9.6 million loss on extinguishment of debt.
[5]	Includes acquisition costs of $1.1 million, restructuring charges of $1.7 million, equity method investment losses of $3.1 million, and a $1.2 million investment distribution.
[6]	Includes restructuring charges totaling $10.5 million and a loss contingency of $15.0 million related to Texas Medicaid.
[7]	Includes restructuring charges totaling $19.5 million, write-up of contingent consideration of $5.8 million related to Fera, and $3.2 million of Elan transaction costs.
[8]	Includes loss on extinguishment of debt of $165.8 million, Elan transaction costs of $103.2 million, restructuring charges totaling $14.9 million, write-off of contingent consideration of $4.9 million related to Fera, and write-off of IPR&D totaling $6.0 million related to Paddock and Rosemont.
[9]	Includes Elan transactions costs of $12.0 million, litigation settlement of $2.5 million, and acquisition costs of $1.9 million.
[10]	The sum of individual per share amounts may not equal due to rounding.

Schedule II - Valuation and Q83

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Millions		12 Months Ended
		Jun. 27, 2015	Jun. 28, 2014	Jun. 29, 2013
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation Allowances and Reserves, Balance at Beginning of Period		$ 2.7	$ 2.1
Valuation Allowances and Reserves, Balance at End of Period		2.4	2.7	$ 2.1
Allowance for Doubtful Accounts [Member]
Movement in Valuation Allowances and Reserves [Roll Forward]
Valuation Allowances and Reserves, Balance at Beginning of Period		2.7	2.1	2.6
Valuation Allowances and Reserves, Net Bad Debt Expenses		(0.6)	(0.5)	0
Valuation Allowances and Reserves, Deductions	[1]	$ (0.9)	(1.1)	(0.4)
Valuation Allowances and Reserves, Balance at End of Period			$ 2.7	$ 2.1
[1]	(1) Uncollectible accounts written off, net of recoveries. Also includes effects of changes in foreign exchange rates

Accounts Receivable Securitizat

Accounts Receivable Securitization (Details) $ in Millions	Jun. 27, 2015USD ($)
Accounts Receivable Securitization [Line Items]
Maximum Borrowings Under Securitization Program	$ 200

Derivative Instruments and He85

Derivative Instruments and Hedging Activities (Details) € in Millions, $ in Millions	Dec. 02, 2014USD ($)	Dec. 23, 2013USD ($)	Dec. 18, 2013USD ($)	Jun. 27, 2015USD ($)	Mar. 28, 2015USD ($)	Dec. 27, 2014USD ($)	Mar. 28, 2015USD ($)	Jun. 27, 2015USD ($)	Jun. 28, 2014USD ($)	Jun. 29, 2013USD ($)	Mar. 30, 2015EUR (€)	Mar. 30, 2015USD ($)	Dec. 05, 2014EUR (€)	Dec. 02, 2014EUR (€)	Dec. 02, 2014USD ($)	Sep. 28, 2013USD ($)	Sep. 06, 2013USD ($)
Derivatives, Fair Value [Line Items]
Loans Payable				$ 530.5				$ 530.5	$ 930								$ 1,000
Derivative, Loss on Derivative				5.5	$ 258.2	$ 64.7		326.4	0	$ 0
Investment Owned, Balance, Principal Amount	$ 1,600		$ 2,300
Derivative, Gain (Loss) on Derivative, Net	(5.8)
Gain (loss) on ineffective portion, net								(1)	$ (2.9)
Maximum Remaining Maturity of Foreign Currency Derivatives									15 months
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months				1.2				1.2
Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net	$ 1.1
Other Expense [Member]
Derivatives, Fair Value [Line Items]
Derivative, Loss on Derivative								3.6
Treasury Lock [Member] | Other Nonoperating Income (Expense) [Member]
Derivatives, Fair Value [Line Items]
Gain (loss) on ineffective portion, net								(0.4)	$ 2.3
Foreign Exchange Contract [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount				452.3				$ 452.3	228.5
Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Maximum Remaining Maturity of Foreign Currency Derivatives								15 months
Foreign Exchange Forward [Member] | Sales Revenue, Goods, Net [Member]
Derivatives, Fair Value [Line Items]
Gain (loss) on ineffective portion, net								$ (0.1)	(0.1)
Foreign Exchange Forward [Member] | Cost of Sales [Member]
Derivatives, Fair Value [Line Items]
Gain (loss) on ineffective portion, net								0.2	0.3
Interest Rate Swap [Member] | Other Nonoperating Income (Expense) [Member]
Derivatives, Fair Value [Line Items]
Gain (loss) on ineffective portion, net								(0.7)	(5.4)
Interest Rate Swap [Member] | Other Nonoperating Income (Expense) [Member] | Fair Value Hedging [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								0	0.9
Fixed-rate Debt [Member] | Other Nonoperating Income (Expense) [Member] | Fair Value Hedging [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								0	(4.1)
Fair Value Hedging [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount																$ 425
Fair Value Hedging [Member] | Fair Value Hedging [Member]
Derivatives, Fair Value [Line Items]
Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net								0	(3.2)
Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Amount Not Offset Against Collateral				3.3				3.3	2.8
Derivative Liability, Fair Value, Amount Not Offset Against Collateral				2				2	9
Derivative, Gain (Loss) on Derivative, Net								(23.2)	(7.1)
Unrealized Gain (Loss) on Price Risk Cash Flow Derivatives, before Tax								(20.5)	22.3
Designated as Hedging Instrument [Member] | Foreign Exchange Option [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net							$ (26.4)	(1.9)
Designated as Hedging Instrument [Member] | Treasury Lock [Member]
Derivatives, Fair Value [Line Items]
Unrealized Gain (Loss) on Price Risk Cash Flow Derivatives, before Tax								(2.7)	0
Designated as Hedging Instrument [Member] | Treasury Lock [Member] | Interest Expense [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								(0.1)	0.2
Designated as Hedging Instrument [Member] | Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Unrealized Gain (Loss) on Price Risk Cash Flow Derivatives, before Tax								(7.7)	15.1
Designated as Hedging Instrument [Member] | Foreign Exchange Forward [Member] | Interest Expense [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								0	(0.2)
Designated as Hedging Instrument [Member] | Foreign Exchange Forward [Member] | Other Nonoperating Income (Expense) [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								(4.5)	(2.2)
Designated as Hedging Instrument [Member] | Foreign Exchange Forward [Member] | Sales Revenue, Goods, Net [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								2	(2.5)
Designated as Hedging Instrument [Member] | Foreign Exchange Forward [Member] | Cost of Sales [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								(4.2)	(6.3)
Designated as Hedging Instrument [Member] | Interest Rate Swap [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount			725	240				240			€ 135				$ 750
Derivative, Gain (Loss) on Derivative, Net			12.8
Unrealized Gain (Loss) on Price Risk Cash Flow Derivatives, before Tax								(10.1)	7.2
Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net			$ 0.5
Designated as Hedging Instrument [Member] | Interest Rate Swap [Member] | Interest Expense [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								(16.4)	3.9
Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member]
Derivatives, Fair Value [Line Items]
Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net		$ 2.6
Designated as Hedging Instrument [Member] | Other Liabilities [Member] | Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Amount Not Offset Against Collateral				2				2	0.7
Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member] | Interest Rate Swap [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Amount Not Offset Against Collateral				0				0	8.3
Designated as Hedging Instrument [Member] | Other Current Assets [Member] | Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Amount Not Offset Against Collateral				3.3				3.3	2.8
Not Designated as Hedging Instrument [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Amount Not Offset Against Collateral				2.6				2.6	0.1
Derivative, Gain (Loss) on Derivative, Net								(325.2)	(0.1)
Not Designated as Hedging Instrument [Member] | Foreign Exchange Option [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount | €														€ 2,000
Not Designated as Hedging Instrument [Member] | Foreign Exchange Option [Member] | Other Nonoperating Income (Expense) [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								(26.4)	0
Not Designated as Hedging Instrument [Member] | Foreign Exchange Forward [Member] | Interest Expense [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								(3.4)	0
Not Designated as Hedging Instrument [Member] | Foreign Exchange Forward [Member] | Other Nonoperating Income (Expense) [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								(295.4)	(0.1)
Not Designated as Hedging Instrument [Member] | Other Liabilities [Member] | Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Derivative Liability, Fair Value, Amount Not Offset Against Collateral				2.6				2.6	0.1
Not Designated as Hedging Instrument [Member] | Other Current Assets [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Amount Not Offset Against Collateral				9.1				9.1	0.3
Not Designated as Hedging Instrument [Member] | Other Current Assets [Member] | Foreign Exchange Forward [Member]
Derivatives, Fair Value [Line Items]
Derivative Asset, Fair Value, Amount Not Offset Against Collateral				9.1				9.1	0.3
Omega [Member] | Designated as Hedging Instrument [Member] | Interest Rate Swap [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount												$ 20
Perrigo Co PLC [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Option [Member]
Derivatives, Fair Value [Line Items]
Derivative, Gain (Loss) on Derivative, Net								298.1
Omega [Member] | Designated as Hedging Instrument [Member] | Interest Rate Swap [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount												147
2013 Term Loan due December 18, 2015 [Member]
Derivatives, Fair Value [Line Items]
Loans Payable				$ 0				$ 0	$ 300								$ 300
6.19% Senior Note [Member] | Omega [Member] | Omega [Member]
Derivatives, Fair Value [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt												20
Credit facility indebtedness [Member] | Omega [Member]
Derivatives, Fair Value [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt												$ 544.5
2014 Euro-Denominated Term Loan due December 5, 2019 [Member]
Derivatives, Fair Value [Line Items]
Debt Instrument, Face Amount | €													€ 614.3